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Abstract Purpose:The newly identified bone marrow ^ derived cell population, called lymphatic/vascular
endothelial progenitor cells (LVEPC), has been shown to contribute to lymph capillary growth in
experimental tumor systems.The clinical significance of these cells has not yet been investigated
in ahumanmalignancy. Our aimwas to study whether peripheral blood circulating LVEPCspartic-
ipate in the progression of human small cell lung cancer (SCLC).
Experimental Design:A total of 88 patientswith limited-stage SCLC and 32 tumor-free control
subjects were included. Peripheral blood circulating LVEPC labeled with CD34 and vascular en-
dothelial growth factor receptor-3 (VEGFR3) antibodies and the serum levels of the key lymphan-
giogenic moleculeVEGF-C were measured by flow cytometry and ELISA, respectively.
Results: CD34-positive/VEGFR3-positive LVEPC levels were significantly increased in patients
(versus controls; P < 0.01), and there was also a significant relationship between LVEPC counts
and lymph node metastasis (P < 0.01). High pretreatment circulating LVEPC numbers correlated
with poor overall survival (P < 0.01). Although we observed significantly elevated VEGF-C con-
centrations in patients (versus controls; P < 0.01), there was no significant correlation between
VEGF-C and LVEPC levels. Moreover, no significant differences in peripheral bloodVEGF-C levels
were seen between patients subgrouped by clinicopathologic variables including tumor and
lymph node stages and survival.
Conclusions: Peripheral blood levels of bone marrow ^ derived LVEPCs are significantly in-
creased in patients with SCLC and correlate with lymphatic involvement and prognosis. This is
the first study that shows evidence of increased numbers of circulating LVEPC in patients with a
malignant tumor.
Small cell lung cancer (SCLC) is an aggressive pulmonary
malignancy that constitutes approximately 13% of lung cancers
(1). Despite its sensitivity to chemotherapy and radiotherapy,
SCLC is rarely curable with these treatment strategies (2).
Consequently, new biological targets are needed to develop
more effective therapies. Among the potential targets are
hemangiogenesis and lymphangiogenesis, which are thought
to be fundamental to the progression of different solid tumors
(3, 4). However, because no specific markers for lymphatic
endothelium were available until recently, our knowledge of
the lymphatic system of malignant tumors lags far behind that
of the vascular system (5), and the role of lymphangiogenesis in
the growth and dissemination of SCLC remains unexplored.
Nevertheless, based on recent observations, lymphangiogenesis
seems to be a critical mechanism for the progression in a variety
of human cancers (6). As part of the lymphangiogenic
machinery, the newly identified bone marrow–derived cell
population, called lymphatic/vascular endothelial progenitor
cells (LVEPC; ref. 7), has been shown to contribute to de novo
lymphangiogenesis in human renal transplants (8), and more
importantly, in experimental tumor systems (9). It is still
unclear, however, whether LVEPC participate in SCLC-induced
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lymph vessel growth. Nevertheless, because an analogous cell
population [vascular endothelial growth factor receptor 2
(VEGFR2)-positive hemangiogenic endothelial progenitor cells
(EPC)] has been shown recently to have clinical significance in
the hemangiogenic process of a wide range of human
malignancies (10–14), including non-SCLC (15, 16), we
hypothesized that LVEPC could be involved in the progression
of human SCLC. Hence, using peripheral blood samples
obtained from SCLC patients, we assessed the numbers of
circulating LVEPCs by flow cytometry and investigated whether
these numbers might be related to the levels of the key
lymphangiogenic molecule VEGF-C and/or to the risk of lymph
node metastasis and to patient survival.
Materials andMethods
Clinical data. To measure the number of circulating LVEPC,
peripheral blood samples were collected in EDTA tubes through 21G
needles from 88 patients with limited-disease SCLC before therapy.
According to the consensus report of the International Association for
the Study of Lung Cancer, limited disease was defined as disease that is
limited to one hemithorax with regional lymph node metastases,
including hilar, ipsilateral and/or contralateral mediastinal and/or
ipsilateral and/or contralateral supraclavicular nodes (17). However,
patients with limited disease with the presence of malignant pericardial
and/or pleural effusions were not included in the current study. SCLC
patients were free of additional malignant or inflammatory diseases,
pulmonary fibrosis, wounds or ulcers, and cardiovascular risk states
including diabetes mellitus, chronic renal failure, untreated hyperten-
sion, and rheumatoid arthritis that, as described in the case of the
analogous bone marrow–derived cell population (VEGFR2-positive
hemangiogenic EPC; ref. 28), might influence the number of LVEPC.
Moreover, because Fadini et al. have found the depletion of VEGFR2-
positive hemangiogenic progenitors in the peripheral blood of patients
with chronic lung disease and long-lasting hypoxia recently (18), SCLC
patients with GOLD (Global Initiative for Chronic Obstructive Lung
Disease; ref. 19) stage III-IV (severe or very severe) and exacerbating
stage I-II chronic obstructive pulmonary disease (COPD) were also
excluded from the study. There were 54 male and 34 female patients
with a median age of 63 y (range, 44-77 y; Table 1). Patients underwent
staging work-ups consisting of physical examination, complete blood
counts, spirometry tests, comprehensive chemistry panels, chest radio-
graphs, computed tomography scans of the chest and abdomen, bone
scintigraphy, and magnetic resonance image or computed tomography
scans of the brain. All limited-stage SCLC patients received chemother-
apy (cisplatin and etoposide) plus thoracic irradiation. In case of
disease progression, patients with chemosensitive tumors (progression
>3 mo after the last cycle of first-line therapy) were retreated with the
cisplatin and etoposide regimen. Patients who progressed during or
within 3 mo after first-line therapy received a cyclophosphamide,
epirubicin, and vincristine combination as a second-line treatment.
Survival was defined as the time between the date of diagnosis and the
date of death. The actual median follow-up was 15 mo (range, 4-27
mo). Potential median follow-up calculated by the "reverse Kaplan-
Meier" analysis (20) was 26 mo (range, 25-27 mo). By the end of the
study 77 patients (87%) had died of their SCLC. The control group
included 32 individuals matched for age, gender, smoking status, and
spirometry test result (Table 1). Informed consent was obtained from
all patients and control volunteers, and the study was done with the
approval of the ethics committees of the host institutions and in
accordance with the ethical standards prescribed by the Helsinki
Declaration of the World Medical Association.
Enumeration of LVEPC by flow cytometry from the peripheral blood of
SCLC patients. To quantify the content of circulating LVEPC by flow
cytometric analysis, following erythrocyte lysis, the remaining periph-
eral blood mononuclear cell fraction was resuspended in 90 AL
of a fluorescence-activated cell-sorting buffer containing PBS and
0.1% bovine albumin and incubated for 30 min at 4jC with
phycoerythrin-Cy5-conjugated antihuman CD34 (BD Biosciences)
and phycoerythrin-conjugated antihuman VEGFR3 (R&D Systems).
Fluorochrom-conjugated isotype controls were used for each staining
procedure. After appropriate gating, the number of CD34-positive/
VEGFR3-positive double-positive cells were quantified and expressed as
the number of cells per milliliter of blood using the CyFlow SL flow
cytometer and the FlowMax software (both from Partec).
Measuring the levels of VEGF-C in the peripheral blood of controls and
patients with SCLC. For VEGF-C measurements, serum samples from
all patients and controls were prepared and stored at -80jC until further
analysis. Levels of VEGF-C were quantified with the use of a commercial
ELISA kit (R&D Systems) according to the manufacturer’s instructions.
Results were compared with standard curves, and the lower detection
limit was 4 pg/mL. Measurements were done in duplicate.
Statistical analysis. Continuous variables were compared with
Student’s t test if the sample distribution was normal or with Mann-
Whitney U test if the sample distribution was asymmetrical. Categorical
data were compared using Fisher’s exact probability and m2 tests.
Correlations of LVEPC and VEGF-C levels were determined using
Spearman’s rank correlation test. Overall survival analyses were done
using the Kaplan-Meier method. Overall survival intervals were
determined as the time period from initial diagnosis to the time of
death. The comparison between survival functions for different strata
was assessed with the log-rank statistic. Multivariate analysis of
prognostic factors was done using Cox’s regression model. Differences
were considered significant when P < 0.05. All statistical analyses were
done using Statistica 7.0 (StatSoft Inc.) software program.
Results
Characterization and levels of LVEPC in peripheral blood
samples of SCLC patients. Endothelial progenitor cells (both
blood and lymphatic) are thought to derive from CD34-
positive hematopoietic progenitor cells (7, 21, 22). Whereas
hemangiogenic progenitors can be identified by the expression
of the cell surface markers CD34, CD133, and VEGFR2 (3),
LVEPC are characterized by the expression of CD34, CD133,
and VEGFR3 (7). However, because both types of endothelial
progenitor cells rapidly lose their CD133 expression after the
migration into the circulation from the bone marrow and
Translational Relevance
According to recent results, lymphatic vessels in tumors
do not necessarily derive from capillary sprouting; instead,
similar to the mechanism of vasculogenesis, they can also
arise through ‘‘lymphvasculogenesis,’’ a process by which
bonemarrow ^ derived lymphatic/vascular endothelial pro-
genitor cells (LVEPC) are recruited and differentiate in situ
intomature endothelial cells to formnew lymphatic capillar-
ies.The current study shows for the first time that small cell
lung cancer patients have peripheral blood circulating
CD34-positive/VEGFR3-positive LVEPC numbers signifi-
cantly higher than those in tumor-free control subjects.
Moreover, this is the first study that shows the clinical sig-
nificance of these cells in a human cancer.
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CD133-positive LVEPC correspond to a subfraction of the total
CD34-positive LVEPC population, we determined the numbers
of CD34-positive/VEGFR3-positive double-positive LVEPC in
the peripheral blood of 32 control subjects and 88 SCLC
patients by flow cytometry (Fig. 1A). In the control group, the
median value of CD34-positive/VEGFR3-positive circulating
LVEPC was 455/mL (interquartile range, 370-530/mL) of
peripheral blood (n = 32; Fig. 1B). In patients with SCLC, this
level was significantly higher, with a median value of 1,625
(interquartile range, 600-2,750/mL; n = 88; P < 0.01; Fig. 1B).
Correlations between LVEPC levels and clinicopathologic
parameters. LVEPC numbers were also evaluated according
to the clinicopathologic factors of our patients. There was a
statistically significant relationship between LVEPC levels and
lymph node involvement (P < 0.01; Table 2). However, no
significant associations with age, smoking history, gender,or
tumor (T) stage were detected (Table 2).
LVEPC levels as prognostic markers in patients with
SCLC. Because lymphatic involvement of SCLCs was associ-
ated with increased LVEPC counts, we next used Kaplan-Meier
analysis to calculate the overall survival rates for patients with
low and high peripheral blood LVEPC levels (Fig. 2). We
found that patients whose peripheral blood samples were
categorized by low pretreatment CD34-positive/VEGFR3-pos-
itive LVEPC levels (based on median value, <1,625/mL of
peripheral blood) had significantly longer survival times than
those with high levels of circulating LVEPC (median survival
time was 20 versus 11.5 months; P < 0.01; Fig. 2). The
median overall survival for all patients was 14 months.
Multivariate analysis (including standard prognostic variables,
such as age, gender, and tumor and lymph node stage) also
indicated that pretreatment circulating LVEPC levels predicted
outcome independent of other variables (P < 0.01; Table 3).
In accordance with the latest International Association for
the Study of Lung Cancer analysis of clinical staging for
SCLC (23), a further independent prognostic factor related to
poor survival was N2-3 disease (versus N0-1 stage; P = 0.014;
Table 3).
Peripheral blood levels of VEGF-C in SCLC patients. Although
VEGF-C serum levels of patients were significantly elevated as
compared with those of control subjects (4931 F 881 versus
3992 F 462 pg/mL, respectively; P < 0.01; Table 1), we were
unable to detect a significant relationship between the concen-
trations of the key lymphangiogenic molecule, VEGF-C, and
circulating CD34-positive/VEGFR3-positive LVEPC counts
(P = 0.74; data not shown). Moreover, when VEGF-C levels
were evaluated according to the clinicopathologic factors of our
patients, no significant associations with age, smoking history,
Table 1. Characteristics and VEGF-C levels of patient and control groups
Patients (n = 88) Controls (n = 32) P
Gender (male/female) 54/34 (61.4% vs. 38.6%) 19/13 (59.4% vs. 40.6%) 0.5*
Age (y) 63 (range, 44-77) 61 (range, 48-70) 0.62c
Smoking status (current or ex-smoker/non-smoker) 75/13 (85.2% vs. 14.8%) 26/6 (81.2% vs. 18.8%) 0.39*
Lung function, spirometry (normal/mild or moderate COPD)b 74/14 (84% vs. 16%) 27/5 (84.4% vs. 15.6%) 0.61*
VEGF-C (pg/mL) 4,931 F 881x 3,992 F 462x <0.01k,{
*Fischer’s exact test.
cMann-Whitney test.
bAccording to the GOLD (Global Initiative for Chronic Obstructive Lung Diseases) classification of COPD severity (ref. 19).
xMean F SD.
kStudent’s t-test.
{Significant difference between patient and control groups.
Fig. 1. Quantitative evaluation of circulating LVEPC by flow cytometric analysis
(A to B). A, representative flow cytometric analysis for determining the number of
CD34-positive/VEGFR3-positive LVEPC (Q1, CD34-negative/VEGFR3-positive;
Q2, CD34-positive/VEGFR3-positive; Q3, CD34-negative/VEGFR3-negative;
Q4, CD34-positive/VEGFR3-negative cells). B, box plots showing median (central
dots), 25%-75% quartile ranges (boxes), and minimum/maximum levels (whiskers)
of circulating CD34-positive/VEGFR3-positive LVEPC levels in control subjects
(n = 32) and patients with SCLC (n = 88).
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gender, or more interestingly, with lymph node status, tumor
stage, or survival were detected (data not shown).
Discussion
This study presents the novel finding that patients with SCLC
have peripheral blood circulating CD34-positive/VEGFR3-
positive LVEPC numbers significantly higher than those in
tumor-free control subjects, and that the levels of these cells
correlated to lymphatic progression and to clinical behavior.
Although increased levels of bone marrow–derived circulating
VEGFR2-positive hemangiogenic EPC have been reported in
various malignant diseases (10–16), to the best of our
knowledge, this is the first study that shows evidence of high
numbers of circulating lymphatic/vascular EPC in the periph-
eral blood of patients with a malignancy.
There is a growing body of evidence that tumor blood vessel
growth not only depends on cells formerly residing within the
vascular walls (i.e. endothelial sprouting) but also is consider-
ably supported by vasculogenesis, the mechanism by which a
subset of bone marrow–derived cells, EPC, enhance ongoing
vascularization by providing a circulating cell population that
home to the blood capillary walls and incorporate into the
endothelial tube (3, 14). It is also well established now that
lymphangiogenesis (i.e. in situ lymph vessel sprouting), facili-
tated by VEGFR3 signaling, contributes to tumor progression
(24, 25). However, more recent evidence suggests that tumor
lymphatics do not necessarily derive from endothelial sprouting;
instead, similar to the mechanism of vasculogenesis, tumor
lymph vessels can also arise through ‘‘lymphvasculogenesis,’’
a process by which bone marrow–derived LVEPC are recruited
and differentiate in situ into mature endothelial cells to form
new lymphatic capillaries (9). These VEGFR3-positive LVEPC are
functionally a unique population of progenitor cells expressing
CD34 but not CD105, CD11b, CD14, or VEGFR1 (7). Because
they have been shown to have an in vitro capacity to differentiate
into lymphatic and/or vascular endothelial cells (7), LVEPC
could contribute to both lymph and blood capillary growth of
human SCLCs. The data from this current study do not allow us
to measure the vasculogenic activity of LVEPC or determine the
Table 2. Correlation of clinicopathologic features and circulating LVEPC numbers in 88 SCLC patients
No. of patients (%) CD34+/VEGFR3+ LVEPC P
Low* (%) High* (%)
Age (y)*
63< 43 (48.9%) 22 (50%) 21 (47.7%)
63> 45 (51.1%) 22 (50%) 23 (52.3%) 0.83
Smoking history
Nonsmoker 13 (14.8%) 6 (13.7%) 7 (15.9%)
Current or ex-smoker 75 (85.2%) 38 (86.3%) 37 (84.1%) 0.77
Gender
Male 54 (61.4%) 25 (56.8%) 29 (65.9%)
Female 34 (38.6%) 19 (43.2%) 15 (34.1%) 0.38
N stage
N0-1 24 (27.3%) 21 (47.3%) 3 (6.8%)
N2-3 64 (72.7%) 23 (52.7%) 41 (93.2%) <0.01
T stage
T1 8 (9.1%) 6 (13.6%) 2 (4.5%)
T2-T4 80 (90.9%) 38 (86.4%) 42 (95.5%) 0.14
VEGF-C levelc
High 44 (50%) 22 (50%) 22 (50%)
Low 44 (50%) 22 (50%) 22 (50%) 1
Chemotherapy regimens
EP 68 (77.3%) 37 (84.1%) 31 (70.5%)
EP+CEV 20 (22.7%) 7 (15.9%) 13 (29.5%) 0.13
Abbreviations: EP, cisplatin and etoposide; CEV, cyclophosphamide, epirubicin and vincristine.
*Cutoff value is median value.
cCut-off value is mean value. Data shown in parentheses are column percentages.
Fig. 2. Kaplan-Meier curves for the overall survival of the patient population with
SCLC, according to peripheral blood circulating CD34-positive/VEGFR3-positive
LVEPC numbers as determined with flow cytometry. Cutoff value between low and
high pretreatment CD34-positive/VEGFR3-positive LVEPC levels was1,625
LVEPC/mL of peripheral blood.
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ratio of LVEPC contributions between vasculogenesis and
lymphvasculogenesis. However, given the observation that
LVEPC numbers were related to the extent of lymph node
metastases, one can hypothesize a potential role for these cells
in the lymphangiogenic machinery, or at least the possibility
that the driving force behind the lymphatic progression of
SCLC and the mobilization of LVEPC from the bone marrow is
similar.
Based on the above theory, one can assume that our
observation on increased LVEPC numbers is the result of
elevated levels of the VEGFR3 ligand VEGF-C. Recent studies
in experimental animal models have shown direct evidence
that this key lymphaniogenic cytokine plays a critical role in
cancer progression by inducing lymphangiogenesis and
enhancing metastatic spread via the lymphatics, and that
these effects can be suppressed by blocking VEGFR3 signaling
(reviewed in ref. 26). In a human non-SCLC xenograft model,
for example, tumors overexpressing VEGF-C had higher lymph
vessel densities than control tumors, and inhibition of
VEGFR3 signaling suppressed tumor lymphangiogenesis and
metastasis to regional lymph nodes (27). Thus, we assayed the
peripheral blood levels of VEGF-C and found that although its
concentrations were significantly higher in SCLC patients than
in control subjects, no statistically significant relationship
existed between VEGF-C levels and numbers of circulating
LVEPCs. However, although the possibility of VEGF-C–
induced LVEPC release from the bone marrow in SCLC is
not supported by the current results, chances are that as in
other (for example cardiovascular, malignant, or inflammato-
ry) disorders in which the interaction of several inflammatory
and noninflammatory cytokines controls vasculogenic EPC
(reviewed in refs. 28, 29), the dynamic balance of multiple
growth factors is also likely to determine the number and
function of LVEPC in cancer.
In addition to the observation of significantly higher
pretreatment circulating LVEPC counts in SCLC patients as
compared with control subjects, this prospective study
presents the novel finding that a single flow cytometric
measurement of CD34-positive/VEGFR3-positive LVEPC is a
useful tool to predict outcomes in patients with SCLC.
During the follow-up period of 25 months, a significantly
higher incidence of death from SCLC was observed in
patients with high pretreatment LVEPC levels as compared
with patients with low LVEPC levels, suggesting that the
pretreatment levels of LVEPC, detectable by flow cytometry in
the peripheral blood, correlate with the clinical behavior of
human SCLC.
Besides the previous experimental findings mentioned above,
several studies in various human cancers have suggested that
VEGF-C expression, as assessed by immunohistochemistry in
tumor tissue and/or by ELISA in peripheral blood samples,
correlates with lymph node metastasis and/or patient survival
(5, 30–35). Hence, we also evaluated the potential of
measuring peripheral blood levels of VEGF-C as a tool for
determining lymph node metastasis and/or prognosis in SCLC.
However, although we showed elevated VEGF-C concentrations
in SCLC patients over tumor-free controls, we failed to detect
an association between VEGF-C levels and patients’ survival,
and analysis of the cancer patient cohort showed no differences
between clinicopathologic subgroups. In particular, no differ-
ence in VEGF-C levels was seen between patients with N0-1 and
with N2-3 stages. This accords with the results obtained in the
only previous study on peripheral blood VEGF-C measure-
ments in SCLC (36). In contrast, peripheral blood VEGF-C
levels predicted lymph node status in a variety of tumor types
including esophageal (37), gastric (38), and papillary thyroid
(39) cancers, and in malignant melanoma (40) and non–small
cell lung carcinoma (41). In addition to studies further
investigating the regulation of LVEPC numbers/function in
malignant disease, there is also a need, therefore, to better
clarify and understand the biological and clinical significance
of VEGF-C in SCLC.
In conclusion, in SCLC, as well as in most types of
malignant tumors, lymphatic metastasis is associated with
poor survival and is one of the factors associated with poor
prognosis. Whether lymphatic spread is a mechanism for poor
prognosis or a marker for aggressive biological behavior
remains to be decided. The current study shows, for the first
time, that the circulating numbers of bone marrow–derived
LVEPC are significantly increased in SCLC patients and that
these numbers correlate with the extent of tumor spread to
regional lymph nodes and with patients’ survival. Although
our data suggest a participation of LVEPC in lymphatic tumor
progression in SCLC patients, it is not clear yet whether
LVEPC play a role only in the lymphatic spread of the tumor,
or whether they also facilitate primary tumor growth and the
development of blood-borne metastases via the enhancement
of blood capillarization. Moreover, it has yet to be determined
if LVEPC can be used as a surrogate marker to monitor the
efficacy of standard or future anti(lymph)angiogenic therapies
Table 3. Multivariate analysis of various prognostic factors in patients with SCLC
Prognostic factor RR (95% CI) P
Age in y (<63 versus z63) 1.213 (0.747-1.969) 0.434
Gender (female versus male) 1.081 (0.655-1.782) 0.761
T stage (T1 versus T2-4) 2.024 (0.725-5.65) 0.178
N stage (N0-1 versus N2-3) 2.634 (1.215-5.711) 0.014
CD34+/VEGFR3+ LVEPC level (low versus high)* 5.379 (2.659-10.882) <0.01
VEGF-C serum level (low versus high)c 1.221 (0.76-1,961) 0.408
Abbreviations: RR, relative risk; 95% CI, 95% confidence interval.
*Cutoff value is median value.
cCutoff value is mean value.
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in SCLC. Further research is also needed on whether LVEPCs
can be targeted to treat patients with SCLC, or alternatively –
as they are endowed with the capacity to home to the tumor
lymphatic network – can be manipulated to deliver toxins or
lymph vessel–targeting agents. Finally, because the above
results are most likely not specific for SCLCs, they may lead to
a number of novel approaches in the diagnosis and treatment
of other malignant diseases as well.
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Circulating endothelial progenitor cells and depression:
a possible novel link between heart and soul
P Dome1,2, Z Teleki1, Z Rihmer2,3, L Peter4, J Dobos5, I Kenessey6, J Tovari5,6, J Timar6, S Paku7,
G Kovacs4 and B Dome5
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and Theoretical Mental Health, Kutvolgyi Clinical Center, Semmelweis University, Budapest, Hungary; 3Third Department of
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Although depression is known to be an independent risk factor for cardiovascular disorders,
the mechanisms behind this connection are not well understood. However, the reduction in the
number of endothelial progenitor cells (EPCs) in patients with cardiovascular risk factors has
led us to hypothesize that depression influences the number of EPCs. EPCs labeled with CD34,
CD133 and vascular endothelial growth factor receptor-2 (VEGFR2) antibodies were counted
by flow cytometry in the peripheral blood (PB) of 33 patients with a current episode of major
depression and of 16 control subjects. Mature (CD34þ /VEGFR2þ ) and immature (CD133þ /
VEGFR2þ ) EPC counts were decreased in patients (vs controls; P < 0.01 for both
comparisons), and there was a significant inverse relationship between EPC levels and the
severity of depressive symptoms (P < 0.01 for both EPC phenotypes). Additionally, we assayed
the plasma levels of VEGF, C-reactive protein (CRP) and tumor necrosis factor (TNF)-a and
observed significantly elevated TNF-a concentrations in patients (vs controls; P < 0.05) and,
moreover, a significant inverse correlation between TNF-a and EPC levels (P < 0.05). Moreover,
by means of a quantitative RT-PCR approach, we measured CD34, CD133 and VEGFR2
mRNA levels of PB samples and found a net trend toward a decrease in all the investigated
EPC-specific mRNA levels in patients as compared with controls. However, statistical
significance was reached only for VEGFR2 and CD133 levels (P < 0.01 for both markers). This
is the first paper that demonstrates evidence of decreased numbers of circulating EPCs in
patients with a current episode of major depression.
Molecular Psychiatry (2009) 14, 523–531; doi:10.1038/sj.mp.4002138; published online 8 January 2008
Keywords: cardiovascular diseases; mood disorders; depression; endothelial progenitor cells;
postnatal vasculogenesis
Introduction
Mood disorders with episodes of major depression (as
part of unipolar major depression and bipolar disorder)
are frequent illnesses with enormous personal and
society burdens worldwide. The life-time prevalence
of major depressive and of bipolar disorders are 5–17
and 0.3–7.2%, respectively.1 It is widely known that
major depression or depressive symptoms (as part of
dysthymia) are risk factors not only for suicide but also
for non-suicide mortality as well.2–6 Several studies
with prospective design—after controlling for possible
confounding factors such as hypertension, diabetes
mellitus, smoking and age—have concluded that
depression predicts the development of cardiovascular
diseases.4,7,8 Accordingly, depression confers a relative
risk between 1.5 and 2.0 for the onset of coronary
artery disease in physically healthy individuals and a
relative risk between 1.5 and 2.5 for cardiac morbidity
and mortality in patients with existing coronary artery
disease.9 Moreover, large-scale studies revealed an
association between mood disorders and susceptibility
to stroke.10–12 However, although numerous theories
have been proposed to explain the amplified risk of
cardiovascular disease in patients with depression
(reviewed by Everson-Rose and Lewis,3 Lett et al.9 and
Holtzheimer and Nemeroff13), the exact biological
mechanisms by which depression may increase the
risk of cardiovascular events have not been completely
elucidated so far.
Adult bone marrow contains a subtype of progenitor
cells that has the capacity to migrate to the circulation
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and to incorporate into the endothelial layer of blood
vessels. This cell population, endothelial progenitor
cells (EPCs), appears to be involved in both the main-
tenance of vascular integrity14 and postnatal vasculo-
genesis (for example, tumor vascularization).15–18
Since their identification by Asahara et al.,19 several
studies have shown reduced numbers and/or im-
paired function of EPCs in a variety of cardiovascular
risk states, including diabetes mellitus,20 hyper-
cholesterolemia,21 hypertension,22 chronic renal failure,23
rheumatoid arthritis24 and cigarette smoking.25 Alter-
natively, cardiovascular protective factors such as
exercise training,26 statin therapy,27 angiotensin II
receptor antagonists28 and peroxisome proliferator-
activated receptor agonists29 are known to increase
EPC number and function.
Because depression is characterized by increased
cardiovascular morbidity and mortality that cannot be
explained by traditional cardiovascular risk factors
alone and depressive disorders were found to be
associated with dysfunction of the immune system
and the bone marrow,30,31 we hypothesized that
depression influences the number of bone marrow-
derived EPCs as well. Hence, using peripheral blood
(PB) samples obtained from healthy individuals and
from patients with a current episode of major
depression, we assessed the numbers of circulating
EPCs by flow cytometry and investigated whether
these numbers may be related to the presence and
severity of depression. Furthermore, we measured the
levels of the key vasculogenic molecule vascular
endothelial growth factor (VEGF) and the proinflam-
matory cytokines tumor necrosis factor (TNF)-a and
C-reactive protein (CRP), and used real-time quanti-
tative reverse transcription (RT)-PCR to study the
expression of the EPC-specific markers CD34, CD133
and VEGF receptor-2 (VEGFR2) in the PB of depressed
patients and healthy controls.
Materials and methods
Clinical data
Thirty-three in- and outpatients diagnosed with a
major depressive episode in two psychiatric centers
participated in the study (Table 1). The presence of
a current major depressive episode was diagnosed
by the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) criteria.32 The
nine-item abbreviated version of the Beck Depression
Inventory (BDI) was used for the assessment of the
severity of depressive symptoms.33 During participant
enrollment, complete clinical (physical examination
including blood-pressure monitoring, height and body
weight) and laboratory evaluations were carried out
(Table 1). Patients with elevated levels of fasting
blood-glucose, creatinine, urea nitrogen or liver func-
tions, or with hypertension, comorbid psychiatric
diagnoses, BMI higher than 30 kg m2, higher choles-
terol or triglyceride levels than upper levels of Adult
Treatment Panel III34 defined borderline hypercholes-
terolemia (240 mg 100 ml1 or 6.2 mmol l1) and hyper-
triglyceridemia (200 mg 100 ml1 or 2.25 mmol l1), or
with signs of infection (subfebrile temperature, fever,
white blood cell number higher than 10 g l1, erythro-
cyte sedimentation rate higher than 20 mm h1) were
excluded from the study. Moreover, cardiovascular
Table 1 Baseline clinical characteristics and cytokine levels of patient and control groups
Patients (n = 33) Controls (n = 16) P-value
Gender (female/male) 29/4 (88 vs 12%) 14/2 (88 vs12%) 0.98w
Age (years) 40.6±10.6 40.3±9.5 0.93*
BUN (mmol l1) 4.26±1.52 5.14±1.18 0.055*
Body mass index (kg m2) 23.3±3.49 22.7±4.1 0.61*
White blood cells (109 per liter) 7.27±1.83 7.94±1.48 0.18*
Blood glucose (mmol per liter) 4.75±0.58 4.52±0.75 0.31*
Total cholesterol (mmol per liter) 4.69±0.82 5.11±0.93 0.14*
Triglyceride (mmol per liter) 1.17±0.5 0.89±0.57 0.11*
hs-CRP (mg dl1) 0.13±0.06 0.11±0.04 0.29*
TNF-a (pg ml1) 2.68±0.8 1.5±0.46 0.03*#
VEGF (pg ml1) 19.37±3.83 17.35±3.82 0.1
BDI score 38.6±10.7 0.9±1.44 < 0.01y#
Smoking status (current smoker/
nonsmoker)
19/14 (58 vs 42%) 10/6 (62.5 vs 37.5%) 0.748
Smoking amount in smoker
subgroups (no. of cigarettes per day)
23.1±11.7 15.3±9.3 0.064*
Abbreviations: BDI, beck depression inventory; BUN, blood urea nitrogen; hs-CRP, high sensitivity C-reactive protein; TNF-a,
tumor necrosis factor-a; VEGF, vascular endothelial growth factor.
Data are expressed as meanþ s.d.
*Independent-samples t-test
wFischer’s exact test.
yMann–Whitney’s test.
8w2-test.
#Significant difference between patient and control groups.
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risk factors (diabetes mellitus, hypertension, hyper-
cholesterolemia, hypertriglyceridemia, renal failure)
and cardiovascular diseases (acute myocardial infarc-
tion, arterial obstructive syndromes of limbs, ischemic
stroke) in the medical history of the patients were also
criteria for exclusion. Accordingly, no participants
received medications with known effects on EPC
numbers (Table 2). Data about the smoking habits
(smoking status and intensity, defined as self-reported
average number of cigarettes smoked daily) of patients
and healthy controls were collected as well (Table 1).
Based on smoking behavior, the following categories
were used: ‘non-smokers’ (ex- and never smokers) and
‘current smokers.’ Based on the observations of Kondo
et al.25 on the effects of smoking cessation on EPC
levels, ex-smokers were defined as those who had quit
smoking at least 1 month before taking the blood
sample.
The control group included 16 individuals matched
for age, gender and smoking status (Table 1). Smoker
and non-smoker subgroups of patients and controls
were also matched for age. Exclusion criteria for
control persons were the same as those for patients
with depression. Healthy controls had no previous or
current episode(s) of major depression. The study was
approved by the Local Ethical Committees of the
National Institute of Psychiatry and Neurology, Buda-
pest, and of the Central Hospital of the Hungarian
Army, Budapest. All subjects gave their informed
consent.
Enumeration of EPCs by flow cytometry from the
peripheral blood of controls and patients with
depression
To quantify the content of circulating EPCs by flow
cytometric analysis, following erythrocyte lysis, the
remaining PB mononuclear cell fraction was resus-
pended in 90ml of a fluorescence-activated cell-sorting
buffer containing phosphate-buffered saline and 0.1%
bovine albumin and incubated for 30 min at 4 1C with
R-Phycoerythrin (PE)-Cy5-conjugated anti-human
CD34 (BD Biosciences, San Jose, CA, USA) and allo-
phycocyanin (APC)-conjugated anti-human VEGFR2
(R&D Systems, Minneapolis, MN, USA) or with PE-
conjugated anti-human CD133 (Miltenyi Biotec, Ber-
gisch Gladbach, Germany) and APC-conjugated anti-
human VEGFR2. Appropriate fluorochrom-conjugated
isotype controls were used for each staining procedure.
After appropriate gating, the number of CD34þ /
VEGFR2þ and CD133þ /VEGFR2þ cells were quan-
tified and expressed as the number of cells per
milliliter of blood using the CyFlow SL flow cytometer
and the FlowMax software (both from Partec, Mu¨nster,
Germany).
Measuring the level of EPC markers by quantitative
real-time RT-PCR in the peripheral blood of controls
and patients with depression
PB was incubated for 10 min with Red Blood Cell
Lysing Buffer (Sigma-Aldrich, Budapest, Hungary),
and centrifuged for 20 s at full speed in a microcen-
trifuge. Total RNA was extracted from the remaining
PB mononuclear cell fraction after lysis using Qiagen
RNeasy Mini Kit (Hilden, Germany) and digested
with RNase-free DNase Set according to the manu-
facturer’s protocol. Total RNA (3 mg) was reverse
transcribed from each sample using deoxy-NTPs
(0.5 mM each), a mixture of random primer and oligo
dT (final concentration 3mM), RNasin ribonuclease
inhibitor (20 U per reaction, Promega, Madison, WI,
USA), reverse transcriptase buffer and M-MLV reverse
transcriptase (200 U per reaction, Sigma-Aldrich).
Samples (30ml) were incubated for 50 min at 37 1C
and then at 85 1C for 10 min. The sequences of
CD34 primers35 were 50-TTGACAACAACGGTACTGC
TAC-30 and 50-TGGTGAACACTGTGCTGATTAC-30.
The sequences of CD133 primers35 were 50-TGGATGC
AGAACTTGACAACGT-30 and 50-ATACCTGCTACGA
CAGTCGTGGT-30. The sequences of VEGFR2 primers35
were 50-CACCACTCAAACGCTGACATGTA-30 and
50-GCTCGTTGGCGCACTCTT-30. The real-time PCR
analysis was standardized by co-amplifying the genes
of interest with the housekeeping gene b-actin (pri-
mers: 50-TCTGGCACCACACCTTCTAC-30 and 50-CTCC
TTAATGTCACGCACGATTTC-30). The real-time PCR
reaction was run on the iCycler iQ (Bio-Rad,
Richmond, CA, USA) using standard conditions,
namely, an optimized concentration of primers (final
concentration 200 nM), iQ SYBR Green Supermix and
2 ml cDNA. A no-template control (containing water)
was used as a negative control for every different
primer-pair. The cycling parameters were 95 1C
Table 2 Medications of patients and control persons
Pychotropics No. of patients receiving
Anxiolyticsa 29
Second-generation
antipsychotics
4
Mood stabilizers 10
Hypnotics 8
SSRIs 19
SNRIs 7
Other antidepressants 13
Other medications No. of patients (P) or control
persons (C) receiving
Tiotropium bromide 1 (P)
Calcitonin 1 (P)
Piroxicam 1 (P)
Propranololb 2 (P)
L-Thyroxine 1 (P)
Calcium dobesilate 1 (P)
Diclofenac 1 (C)
Abbreviations: SNRI, serotonin norepinephrine reuptake
inhibitor; SSRI, selective serotonin reuptake inhibitor.
No participants received medications with known effects on
EPCs.
aBenzodiazepines were given to all except one patient, who
received hydroxyzine hydrochloride.
bFor tachycardia.
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(3 min), 50 cycles of 95 1C (30 s), 64 1C (30 s) and 72 1C
(1 min). The starting quantity of gene expression
in the sample was determined by comparison of
an unknown to a standard curve generated from a
dilution series of template DNA of known concentra-
tion, and normalized to its own b-actin expression.
Measuring the levels of CRP, VEGF and TNF-a in the
peripheral blood of controls and patients with
depression
For CRP, VEGF and TNF-a measurements, plasma
samples from all patients and controls were prepared
and stored at 80 1C until further analysis. Levels of
VEGF and TNF-a were quantified using commercial
enzyme-linked immunosorbent assay (ELISA) kits
(both from R&D Systems) according to the manufac-
turer’s instructions. Results were compared with
standard curves, and the lower detection limits were
VEGF, 5 pg ml1; TNF-a, 0.2 pg ml1. Measurements
were performed in duplicate. Concentrations of CRP
were determined by turbidimetric immunoassay
(Olympus CRP Latex assay, Hamburg, Germany).
Statistical analysis
Continuous variables were compared with Student’s
t-test. The differences among more than two groups
were analyzed with analysis of variance (ANOVA)
and Scheffe’s post hoc method. Continuous data
were compared with Mann–Whitney U-test if the
sample distribution was asymmetrical. Categorical
data were compared using Fishers’ exact probability
and w2-tests. Linear regressions were analyzed using
the simple regression model. Correlations of EPC and
cytokine levels were determined using Spearman’s
rank correlation test. Differences were considered
significant when P < 0.05. All statistical analyses were
carried out using Statistica 7.0 (StatSoft Inc., Tulsa,
OK, USA) software program.
Results
Characterization and numbers of EPCs in peripheral
blood samples of controls and patients with depression
EPCs are thought to derive from CD34þ hematopoietic
progenitor cells and can be identified by the expres-
sion of the cell surface markers CD34, CD133 and
VEGFR2.36 However, these surface molecules are
differentially expressed in late/mature and in early/
immature phenotypes and none of them by itself is
specific for EPCs. The lack of a special and exclusive
marker truly specific for EPCs dictates that combina-
tions of the above markers must be used to best
identify this cell population.14,18,37–39 Therefore, we
determined the numbers of both CD34þ /VEGFR2þ
(late/mature phenotype; Figure 1a, cells in Q2) and
CD133þ /VEGFR2þ (early/immature phenotype;
Figure 1b, cells in Q2) double-positive EPCs in the
PB of healthy individuals and depressed patients by
flow cytometry. By the same token, cell populations
positive for only one marker (Figures 1a and b, cells in
Q1 or Q4) were not considered in our experiments.
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Figure 1 Quantitative evaluation of circulating endothelial progenitor cells (EPCs) by flow cytometric analysis.
(a, b) Representative flow cytometric analyses for determining the number of CD34þ / vascular endothelial growth factor
receptor-2 (VEGFR2þ ) (a) and CD133þ /VEGFR2þ (b) double-positive cells. (c) Circulating EPC levels in healthy controls
(n = 16) and patients with depression (n = 33). Data are mean EPC numbers per milliliter of peripheral blood (PB)±s.d. In
(a), Q1 = CD34/VEGFR2þ , Q2 = CD34þ /VEGFR2þ , Q3 = CD34/VEGFR2, Q4 = CD34þ /VEGFR2 cells. In (b), Q1 =
CD133/VEGFR2þ , Q2 = CD133þ /VEGFR2þ , Q3 = CD133/VEGFR2, Q4 = CD133þ /VEGFR2 cells.
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In the patient population, both the levels of mature
(CD34þ /VEGFR2þ ) and immature (CD133þ /
VEGFR2þ ) EPCs per milliliter of PB were signifi-
cantly lower than those in the group of healthy
controls (P < 0.01 for both comparisons; Figure 1c).
There was no statistically significant correlation
between age and EPC levels either in the patient or
in the control group (data not shown). Nevertheless, it
is important to note that the patient and control
populations investigated in the current study
included mostly middle-aged individuals (Table 1).
EPC numbers of our participants were also evaluated
according to the severity of depressive symptoms
(as assessed by the BDI33). There was a statistically
significant inverse relationship between EPC levels
and BDI scores (P < 0.01 in cases of both EPC
phenotypes, data not shown) independent of the
phenotypes of EPCs.
Because cigarette smoking has recently been demon-
strated to decrease circulating EPC numbers,25,40
patients and controls were matched for smoking
habits, as shown in Table 1. In addition, smoker and
non-smoker subgroups of patient and control popula-
tions were also matched for age. In smoker subgroups,
the mean ages of patients and controls were
39.5±11.1 years and 39.7±7.71 years, respectively
(mean±s.d.; P = 0.95). In non-smoker subgroups, the
mean ages of patients and controls were 42.1±10.2
years and 41.3±12.65 years, respectively (mean±s.d.;
P = 0.9).
Assessment of EPC numbers using CD34/VEGFR2
labeling indicated a significant decrease among
smokers compared to non-smokers in both control
and patient groups (P-values are < 0.01 and < 0.001,
respectively; Figure 2a). Quantification of EPCs by
CD133/VEGFR2 labeling also revealed that the EPC
level in the control population was significantly
lower in smokers as compared with non-smokers
(P < 0.01; Figure 2b). Although a similar tendency was
observed, the difference in CD133þ /VEGFR2þ EPC
levels between smokers and non-smokers remained
statistically insignificant in the patient population
(P = 0.34; Figure 2b). When smoker controls were
compared with smoker patients and non-smoker
controls with non-smoker patients, both the
CD34þ /VEGFR2þ (Figure 2a) and the CD133þ /
VEGFR2þ (Figure 2b) EPC levels were significantly
lower in the patient groups.
Evaluation of EPC markers in peripheral blood samples
of controls and patients with depression by
quantitative real-time RT-PCR
CD34, CD133 and VEGFR2 mRNA levels in healthy
controls and in 33 patients with major depression
were determined by quantitative real-time RT-PCR
(Figure 3). Levels of VEGFR2 and CD133 were signi-
ficantly lower in the PB of patients when compared
with the levels of healthy controls (P < 0.01 for
both comparisons, (Figures 3b and c), whereas CD34
level was not significantly decreased in patients
with depression (P = 0.08, Figure 3a). Accordingly,
although there was a statistically significant inverse
relationship between VEGFR2 and CD133 mRNA
levels and BDI scores (P < 0.01 in cases of both
markers, data not shown), no such correlation was
present in the case of CD34. Furthermore, as in the
results of flow cytometric analyses, there was no
statistically significant association between age and
EPC marker levels either in the patient or in the
control group (data not shown). Finally, although we
also investigated the relationship between EPC
numbers and the levels of EPC-specific mRNA levels,
statistically significant results were found only in the
case of CD133 (P < 0.01 in cases of both mature and
immature EPC phenotypes, data not shown).
When subjects in the control and the patient groups
were classified according to their smoking status
(Table 1), no significant differences in CD34, CD133
and VEGFR2 mRNA levels between smokers and non-
smokers were demonstrated, either within the control
or within the patient population (P > 0.05 for all
analyses, Figure 4).
Comparisons of both smoker controls to smoker
patients and non-smoker controls to non-smoker
patients with respect to all the investigated EPC
markers showed higher levels of mRNA in the PB of
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Figure 2 Quantitative evaluation of circulating endothelial
progenitor cells (EPCs) by flow cytometric analysis based on
both CD34þ /vascular endothelial growth factor receptor-2
(VEGFR2þ ) (a, b) CD133þ /VEGFR2þ double labeling in
smoker and non-smoker subgroups of controls and patients.
Data are mean EPC numbers per milliliter of peripheral
blood (PB)±s.d. In (a), the single asterisk (*) marks
significant difference (P < 0.01) between smoker and non-
smoker controls. The double asterisks (**) mark significant
difference (P < 0.001) between smoker and non-smoker
patients. In (b), the single asterisk (*) marks significant
difference (P < 0.01) between smoker and non-smoker
controls.
Endothelial progenitor cells in depression
P Dome et al
527
Molecular Psychiatry
the healthy controls versus that of the depressed
patients. However, this tendency proved to be
statistically significant only in the case of CD133
(P < 0.01 for both comparisons, Figure 4b).
Peripheral blood levels of VEGF and the
proinflammatory cytokines TNF-a and CRP
Although patients with depression tended to have
higher CRP levels than healthy controls, the differ-
ence between the two groups remained insignificant
(P = 0.29, Table 1). Furthermore, we were unable to
detect a significant relationship between CRP con-
centrations and circulating CD34þ /VEGFR2þ or
CD133þ /VEGFR2þ EPC counts (P-values are 0.55
and 0.39, respectively, data not shown). However,
TNF-a levels of patients were significantly elevated as
compared with those of healthy controls (P = 0.03,
Table 1) and, moreover, a statistically significant
inverse correlation was observed between TNF con-
centrations and EPC numbers (P < 0.05, data not
shown).
No significant difference was detected in the plasma
levels of the key vasculogenic molecule, VEGF,
between controls and patients (P = 0.1, Table 1).
Furthermore, there was no statistically significant
correlation between VEGF concentrations and circu-
lating CD34þ /VEGFR2þ or CD133þ /VEGFR2þ
EPC counts (both P-values are 0.08, data not shown).
Discussion
There is a growing body of evidence that blood vessel
integrity not only depends on cells formerly residing
within the vascular walls, but also is considerably
controlled by bone marrow derived cells. Recent
studies suggest that a subset of these cells, EPCs,
may contribute to ongoing vascular repair by provid-
ing a circulating cell population that can home to the
blood vessel walls and incorporate into the injured
endothelial tube to replace dysfunctional endothelial
cells.14,36 Consequently, impairment of this EPC pool
is considered to have negative effects on the cardio-
vascular system and patients with reduced numbers
of EPCs are at increased risk for endothelial injury
and for arteriosclerotic plaque development.20–25
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A further established risk factor recognized today in
the pathogenesis of arteriosclerosis and cardiovascu-
lar disorders is depression. However, although an
association between mood disorders and susceptibil-
ity to cardiovascular events has been discovered by
several researchers,2,3,7–12,41–44 and altered circulating
EPC levels have been reported in various conditions
associated with vascular diseases,20–25 to date no
studies have attempted to evaluate the significance
of EPCs in patients with major depression. Therefore,
we investigated the significance of EPC numbers in
our study sample by using flow cytometry and found
a significant decrease in both mature (CD34þ /
VEGFR2þ ) and immature (CD133þ /VEGFR2þ ) cir-
culating EPC numbers in depressed patients versus
healthy controls, and moreover, a statistically sig-
nificant inverse relationship between EPC counts and
the severity of depression independent of EPC
phenotypes (as assessed by BDI scores33). Accord-
ingly, although statistical significance was reached
only for VEGFR2 and CD133 mRNA levels, there was
a net trend toward a decrease in all the investigated
EPC-specific mRNA (CD34, CD133 and VEGFR2)
levels in patients with depression as compared with
healthy controls. Interestingly, however, with the
exception of CD133 mRNA levels, we failed to show
a significant association between EPC-specific mRNA
levels and EPC numbers. The reasons for this
discrepancy between the results of flow cytometric
analysis and PCR technique are not fully understood.
However, it could be attributed to a complication that
arises in using real-time quantitative RT-PCR to
analyze mRNA levels in PB specimens. Although
the PCR method offers the potential to rapidly and
quantitatively analyze a number of gene products
with limited material, the diversity of cellular
populations present make it difficult to identify cell-
specific gene expression patterns. In other words,
possible reasons for the inconsistent results using two
different techniques may include variations in EPC
marker expression intensity at the stage of develop-
ment in which they were studied, namely in the
peripheral circulation following release from the bone
marrow but prior to homing at the blood vessel site.
The finding that EPC levels are decreased in
patients with depression may be secondary to a
variety of mechanisms: depletion of the pool of EPCs
in the bone marrow, reduced mobilization of the EPC
population, or reduced survival and/or differentiation
in the circulation. However, because VEGF is believed
to be the most important among the molecules that
participate in the regulation of EPCs,14,18 one can
assume that our observation on EPC numbers is the
result of the reduced levels of this cytokine. Hence,
we tested this hypothesis, but found normal VEGF
levels in our patient population. Consequently, the
possibility of insufficient bone marrow stimulation by
VEGF in depression is not supported by the current
results.
Recent experimental and clinical data also suggest
that a variety of inflammatory mediators could be
involved in the pathogenesis of low circulating EPC
counts in depression.42 Patients with depression who
are otherwise medically healthy have been observed
to have increased concentrations of proinflammatory
cytokines and acute phase proteins. Elevated serum
and/or plasma levels of CRP and/or interleukin-6
have been most frequently reported, although an
increase in TNF-a plasma concentrations have also
been described.31 Combined with data demonstrating
that CRP promotes apoptosis and attenuates the
function and differentiation of EPCs45 and TNF-a
reduces the number of EPCs,46 these findings sug-
gested to us that CRP and/or TNF-a might promote
EPC number reduction in depressed patients. Thus,
we assayed the plasma levels of both cytokines and
found that although CRP concentrations were, on
average, higher in patients than in the control
subjects, no statistically significant relationship exis-
ted between CRP concentrations and circulating
progenitors. Nevertheless, the levels of TNF-a were
significantly higher in the PB of patients when
compared with the levels of healthy controls and,
moreover, TNF-a levels inversely correlated with EPC
counts. Therefore, the results of a recent study on
rheumatoid arthritis reporting a significant increase
in EPC levels after a single dose of infliximab, a
monoclonal anti-TNF-a antibody,47 might be interest-
ing in this context. However, although the current
data suggest a possible link between TNF-a and a
decrease in circulating progenitors, chances are that
as in other (for example, cardiovascular, malignant or
inflammatory) disorders in which the interaction of
multiple growth factors controls EPCs14,18,36 the
dynamic balance of several inflammatory and non-
inflammatory cytokines is also likely to determine the
number and function of these cells in depression.
Therefore, additional studies are necessary to confirm
the role of inflammation in modulating EPC numbers/
function in depression.
The patient population analyzed in the current
study had reduced numbers of EPCs but was free from
confounding factors known to alter circulating EPC
numbers, with the exception of cigarette smoking.
Using flow cytometry, we found a significant decrease
in CD34þ /VEGFR2þ EPC counts among smokers,
regardless of the population category (patients or
controls). A similar tendency was observed among
smokers in the case of CD133þ /VEGFR2þ cells,
although statistically significant reduction of EPCs
with this phenotype was reached only in the control
population. Nevertheless, these findings accord with
the results of previous papers, in which smoking
was demonstrated to decrease circulating EPC
numbers.25,40 Surprisingly, there were no significant
correlations between the smoking status and the
EPC-specific mRNA levels as evaluated by real-time
quantitative RT-PCR. It is important to note, however,
that because our patients and controls were carefully
matched for smoking habits and because patients
had always significantly lower EPC counts (both in
the case of immature and mature EPCs, independent
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of their smoking status), the significant decrease
of EPC numbers and the tendency toward lower
EPC-specific marker levels in the patient group are
presumably attributable only to depression in the
current study.
In addition to the relatively low number of
participants, another limitation to this study was
that most members of the patient group received
some kind of psychotropic medicine while those in
the control group were medication free (except for
one person receiving diclofenac). However, the
following observations, taken together, allow us to
conclude that the observation of reduced EPC counts
in our patients is significant, even in the presence of
adequate pharmacological treatment. Firstly, none
of the psychotropic drugs used in the current
study has been reported to alter the number and/or
function of EPCs. Secondly, the main categories of
the psychotropic drugs used in the current study
(benzodiazepines and selective serotonin reuptake
inhibitor antidepressants) have been only very rarely
observed to cause disturbances in the function of
bone marrow (as a source of EPCs). Finally, and
most importantly, because CRP and TNF-a levels are
in an inverse relationship with the circulating
numbers of EPCs45,46 and because antidepressant
agents were reported to decrease the elevated con-
centrations of these molecules,48,49 one can assume
that antidepressants rather increase than decrease the
levels of EPCs.
In summary, EPCs are obviously involved in the
regeneration of injured endothelium, and their num-
ber is thought to be a surrogate marker of vascular
function.36 The current study demonstrates for the
first time that EPCs circulate in decreased numbers in
the PB of patients with depression and, furthermore,
opens a number of new perspectives in the patho-
genesis of cardiovascular disorders in depression.
However, although our results could be related to the
EPC suppressive role of proinflammatory cytokines,
further studies are needed to investigate the exact
pathomolecular background of the connection bet-
ween mood disorders and altered EPC counts. More-
over, it remains to be determined whether the EPC
number abnormalities are state- or trait-dependent
phenomena in affective disorders. Finally, our results
also suggest that individuals should be screened for
depression in future studies investigating EPC number
and function in patient populations with cardio-
vascular risk factors (diabetes mellitus,50 chronic
renal failure,51 smoking,52 rheumatoid arthritis53) or
with definitive cardiovascular diseases (myocardial
infarction,9 stroke10). It is especially crucial that the
depression be considered an independent variable in
such studies because depression is so highly comorbid
with these cardiovascular conditions and diseases.
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Apelin Expression in Human Non-small Cell Lung Cancer
Role in Angiogenesis and Prognosis
Judit Berta, MS,*† Istvan Kenessey, MD,‡ Judit Dobos, PhD,§ Jozsef Tovari, PhD,†
Walter Klepetko, MD,* Hendrik Jan Ankersmit, MD,*¶ Balazs Hegedus, PhD,*‡
Ferenc Renyi-Vamos, MD, PhD,*†# Janos Varga, MS,** Zsolt Lorincz, PhD,**††
Sandor Paku, PhD,‡‡ Gyula Ostoros, MD, PhD,† Anita Rozsas, MS,† Jozsef Timar, MD, PhD, DSc,‡
and Balazs Dome, MD, PhD*†
Introduction: The recently discovered bioactive peptide, apelin, has
been demonstrated to stimulate angiogenesis in various experimen-
tal systems. However, its clinical significance and role in tumor
vascularization have not yet been investigated in a human malig-
nancy. Therefore, our aim was to study whether apelin expression is
associated with angiogenesis and/or tumor growth/behavior in hu-
man non-small cell lung cancer (NSCLC).
Methods: A total of 94 patients with stage I–IIIA NSCLC and
complete follow-up information were included. Apelin expression in
human NSCLC samples and cell lines was measured by quantitative
reverse-transcriptase polymerase chain reaction, enzyme-linked im-
munosorbent assay, and immunohistochemistry. Effects of exoge-
nous apelin and apelin transfection were studied on NSCLC cell
lines in vitro. In vivo growth of tumors expressing apelin or control
vectors were also assessed. Morphometric variables of human and
mouse tumor capillaries were determined by anti-CD31 labeling.
Results: Apelin was expressed in all of the six investigated NSCLC
cell lines both at the mRNA and protein levels. Although apelin
overexpression or apelin treatments did not increase NSCLC cell
proliferation in vitro, increasing apelin levels by gene transfer to
NSCLC cells significantly stimulated tumor growth and microvessel
densities and perimeters in vivo. Apelin mRNA levels were signif-
icantly increased in human NSCLC samples compared with normal
lung tissue, and high apelin protein levels were associated with
elevated microvessel densities and poor overall survival.
Conclusions: This study reveals apelin as a novel angiogenic factor
in human NSCLC. Moreover, it also provides the first evidence for
a direct association of apelin expression with clinical outcome in a
human cancer.
Key Words: Non-small cell lung cancer, Apelin, Angiogenesis,
Prognosis.
(J Thorac Oncol. 2010;5: 1120–1129)
Lung cancer, the leading cause of cancer-related deaths inthe Western world,1 is currently classified into two major
groups: small-cell lung cancer (20% of all cases) and
non-small cell lung cancer (NSCLC, 80%). Even with
improving efficacy of surgery, irradiation, and chemotherapy,
poor prognosis for patients with NSCLC remains. For this
very reason, the identification of novel targets for NSCLC
treatment is needed.2
Apelin, initially isolated from bovine stomach homog-
enates, has been recognized as the endogenous ligand of the
human orphan G protein-coupled receptor APJ, a member of
the seven-transmembrane-receptor family.3,4 In mammals,
the apelin gene encodes a secreted prepropeptide of 77 amino
acids with a signal peptide, a prodomain, and a C-terminal
peptide, which is proteolytically cleaved to yield bioactive
apelin peptides, 36, 17, and 13 amino acids in size. However,
each of these predominant and most active isoforms contains
the extreme C-terminal region of the precursor protein, and
all bioactivity is thought to reside in the terminal 13-amino
acid fragment.5,6 During embryonic development, APJ ex-
pression is largely restricted to the endothelial cells (ECs) of
the developing vascular system,7 and apelin is essential for
regular vascular patterning of the embryo.8 Apelin and its
receptor are also highly expressed in the adult vessel walls,
especially in blood ECs.9 Apelin was reported to stimulate the
in vitro growth of human umbilical10 and mouse brain mi-
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crovasculature-derived ECs8 and the in vitro migration, pro-
liferation, and capillary-like tube formation of monkey retinal
ECs.11 In line with these findings, apelin was reported to
stimulate in vivo angiogenesis in the chicken chorioallantoic
membrane8 and in the mouse subcutaneous matrigel plug11
assay systems. Furthermore, apelin overexpression was
observed to enhance the vascularization and in vivo
growth of different murine tumors.12,13 Although the mo-
lecular mechanisms behind the regulation of apelin expres-
sion are not yet completely understood, it has been re-
ported recently that increased apelin expression by
hypoxia is mediated by the binding of hypoxia-inducible
factor-1 to a hypoxia-responsive element located within
the first intron of the apelin gene.14
Given the biologic and clinical significance of angio-
genesis in the progression of human NSCLC15 and the finding
that apelin expression is up-regulated in some human can-
cers,16–18 our aim was to examine the association between
apelin expression and tumor growth, angiogenesis, and clin-
ical behavior in human NSCLC.
PATIENTS AND METHODS
Human Lung Tissue Samples, Clinicopathologic
Data, and Cell Lines
For immunohistochemical analysis, a total of 94 pa-
tients with histopathologically defined NSCLC treated during
January 1997 to December 2001 were included in the study.
There were 68 male and 26 female patients with a median age
of 63 years (range, 44–81 years; Table 1). Formalin-fixed,
paraffin-embedded NSCLC samples were retrieved from the
files of our pathology department, with the approval of the
ethics committee of the host institutes and in accordance with
the ethical standards prescribed by the Helsinki Declaration
of the World Medical Association. Histologic diagnosis and
N stage were determined on hematoxylin and eosin-stained
sections. There were 35 squamous-cell carcinomas, 54 ade-
nocarcinomas, and 5 large-cell carcinomas. Samples of tu-
mor-free lung parenchyma were also obtained from lung
tissue distant from the tumor site. The cases were staged
according to operative and pathologic findings based on the
American Joint Committee on Cancer/Union Internationale
Contre le Cancer TNM classification.19
For polymerase chain reaction (PCR) analyses, fresh
surgical tumor and normal lung specimens of 46 NSCLC
patients were used. The tumor samples were obtained imme-
diately after surgical removal and cut in half. One half of each
specimen was embedded in paraffin and processed for routine
histologic examination, and the percentage of apelin-positive
tumor cells was determined by immunohistochemistry. The
other half was frozen in liquid nitrogen and stored at 80°C
until mRNA isolation.
All the tumor and normal lung samples were obtained
after elective surgery. None of the patients included in the
current study were treated with neoadjuvant therapy.
H358, H1650, H1975, and A549 cell lines were ob-
tained from American Type Culture Collection (Manassas,
VA). The LCLC-I03H and HCC15 cell lines were obtained
from the German Collection of Microorganisms and Cell
Cultures (Braunschweig, Germany). All cell lines were main-
tained in RPMI 1640 with 10% fetal bovine serum and 1%
penicillin/streptomycin (all from Sigma Chemical Co., St.
Louis, MO) at 37°C in a humidified incubator with 5% CO2.
Development of Stable Transfectant Cell Lines
Human apelin complementary DNA was purchased
from OriGene (Rockville, MD). The coding region was
amplified with the following primers: 5-CGCGAATTCG-
GCATGAATCTGCGGCTCTG and 5-GCGCTCGAGTCA-
GAAAGGCATGGGTCC. PCR products were subcloned
into the pcDNA 3.1. vector using EcoRI and XhoI restriction
enzymes (Invitrogen, Carlsbad, CA). The nucleotide se-
quence of the expression vector was confirmed by DNA
sequencing. H358 and H1975 cells, which had a relatively
low endogenous expression of apelin, were transfected with a
control or an apelin-encoding pcDNA 3.1 vector using the
FuGENE 6 transfection reagent (Roche Diagnostic, Mann-
heim, Germany) according to the manufacturer’s guidelines.
Stable transfectants were selected by their resistance to ge-
neticin (400 g/ml; GIBCO, Paisley, UK).
TABLE 1. Correlation of Clinicopathologic Features and
Expression of Apelin in Patients with NSCLC (n  94)
No. Patients
(%)
Apelin Expression
p
Low
(%)
High
(%)
All patients 94 (100) 30 (31.91) 64 (68.09)
Age (yr)a
63 45 (47.87) 11 (36.67) 34 (53.13)
63 49 (52.13) 19 (63.33) 30 (46.87) 0.14
Smoking
Nonsmoker 21 (22.34) 7 (23.33) 14 (21.88)
Current or ex-smoker 73 (77.66) 23 (76.67) 50 (78.12) 0.87
Gender
Male 68 (72.34) 21 (70) 47 (73.44)
Female 26 (27.66) 9 (30) 17 (26.56) 0.73
N stage
N0 35 (37.23) 12 (40) 23 (35.94)
N1 30 (31.92) 10 (33.33) 20 (31.25)
N2 29 (30.85) 8 (26.67) 21 (32.81) 0.83
T stage
T1 37 (39.36) 13 (43.33) 24 (37.5)
T2 32 (34.04) 8 (26.67) 24 (37.5)
T3 25 (26.6) 9 (30) 16 (25) 0.58
Histology
AC 54 (57.45) 18 (60) 36 (56.25)
SCC 35 (37.23) 10 (33.33) 25 (39.06)
LCC 5 (5.32) 2 (6.67) 3 (4.69) 0.62
MVDb
Low 51 (54.26) 21 (70) 30 (46.87)
High 43 (45.74) 9 (30) 34 (53.13) 0.04
a Cutoff value is median value.
b Cutoff value is mean value. Data shown in parentheses are column percentages.
NSCLC, non-small cell lung cancer; AC, adenocarcinoma; SCC, squamous-cell
carcinoma; LCC, large-cell carcinoma; MVD, microvessel density (n/mm2).
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In Vitro Cell Proliferation Studies
For in vitro cell growth studies, 1 to 2  104 cells per
well were cultured in triplicate in flat-bottomed 96-well plates
in serum-containing or serum-free medium with 0 to 106 M
apelin-36 (Phoenix Pharmaceuticals, Karlsruhe, Germany)
for 72 hours. Cell growth was assayed using 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Al-
drich Co.) as previously described.20 Each assay was done
with six measurements for each data point. Absorbance was
measured at 570 nm using an enzyme-linked immunosorbent
assay (ELISA) Microplate Reader (Bio-Rad, Hercules, CA).
Experiments were repeated three times.
Determination of Apelin Protein Expression
and Microvessel Density in Human and Murine
Tumors
Immunohistochemical stainings were performed on
samples fixed in 10% neutral buffered formalin and embed-
ded in paraffin. Five-micrometer paraffin sections were dew-
axed and rehydrated. For light microscopy, peroxidase was
quenched with methanol and 3% H2O2 for 15 minutes.
Antigen retrieval was performed in 0.1 M citrate buffer (pH
6) in an 800-W microwave for 15 minutes. Following se-
quential 15-minutes incubations with 0.1% avidin and 0.01%
biotin (Vector Laboratories, Inc., Burlingame, CA) to block
endogenous avidin and biotin, sections were incubated in a
mixture of 0.05% casein (Sigma Chemical Co.), 0.05%
Tween-20, and phosphate-buffered saline for 30 minutes to
block nonspecific protein binding. Slides were then incubated
with antibodies to mouse anti-human CD31 (DakoCytoma-
tion, Carpinteria, CA) and rabbit anti-human apelin-36 (Phoe-
nix Pharmaceuticals). The specificity of this antiapelin anti-
body, which recognizes all C-terminal fragments, has been
confirmed repeatedly.9,17,21–23 Normal mouse and rabbit im-
munoglobulin G’s (IgGs) were substituted for primary anti-
bodies as a negative control. Biotinylated anti-mouse IgG
(Vector Laboratories, Burlingame, CA) and F(ab)2 fragment
of swine anti-rabbit IgGs (DakoCytomation) served as the
secondary antibodies and were detected by streptavidin-
horseradish peroxidase, and colorized by 3-amino-9-ethylcar-
bazole (both from DakoCytomation). Finally, counterstaining
was performed using Mayer’s modified hematoxylin.
In the case of apelin staining, all samples were analyzed
by two investigators who had no information on the clinical
data. Disagreement in the evaluation was found in less than
10% of the samples examined, and consensus was reached on
further review. The expression of apelin was scored as a
fraction of positive NSCLC cells in the tumor area. The
degree of positivity was initially classified according to the
percentage of positive tumor cells as follows: () no tumor
cells positive, (1) 1 to 10% cells positive, (2) 10 to 50%
cells positive, and (3) more than 50% cells positive. Sec-
tions were examined using a Nikon Eclipse 80i microscope
and digital images were captured using a SPOT digital
camera (Diagnostic Instruments, Sterling Heights, MI).
Microvessel densities (MVDs) and perimeters were
determined by labeling of blood vessels with mouse anti-
human CD31 or rat anti-mouse CD31 antibodies (pur-
chased from DakoCytomation and Pharmingen, San Diego,
CA, respectively). Three sections per tumor were analyzed
using the CUE-2 computerized image analysis system
(consisting of special software, image processor, digital
camera, and video monitor; Olympus, Tokyo, Japan) as
described previously.20,24
Cellular Apelin Secretion
Cell culture supernatants of wild-type human NSCLC
cell lines (including H358, H1650, HCC15, LCLC-I03H,
H1975, and A549), and H358 and H1975 cells stably trans-
fected with a control or an apelin expression vector were
removed after 72 hours of culture. The concentration of
apelin in each sample was determined using a commercially
available ELISA directed against apelin-36, following the
manufacturer’s (Phoenix Pharmaceuticals) suggested proto-
col. This ELISA has 100% cross-reactivity to human apelin-
36, -13, and -12. Results were compared with standard
curves, and the lower detection limit was 0.08 ng/ml. Mea-
surements were performed in triplicate.
RNA Isolation and Reverse Transcription-PCR
Total RNA was extracted from human NSCLC cell
lines and from fresh frozen tumor and normal lung specimens
of 46 NSCLC patients using Qiagen RNeasy Mini Kit and
digested with RNase-free DNase Set according to the manu-
facturer’s protocol. Three micrograms of total RNA were
reverse transcribed from each sample using deoxy-NTPs (0.5
mM each), a mixture of random primer and oligo dT (final
concentration 3 M), RNasin ribonuclease inhibitor (Pro-
mega, 20 U/reaction), reverse transcription buffer, and M-
MLV reverse transcription (Sigma, 200 U/reaction). Thirty
microliters of the samples were incubated for 50 minutes at
37°C and then at 85°C for 10 minutes. The success of reverse
transcription and the purity of the samples were validated
using primers to -actin (sense, 5-GTGGGGCGCCCCAG-
GCACCA-3; and antisense, 5-CTCCTTAATGTCACG-
CACGATTTC-3).
Qualitative PCR was performed for apelin (sense, 5-
CTGCTCTGGCTCTCCTTGAC-3; and antisense, 5-
GAATTTCCTCCGACCTCCCTG-3) and -actin. Amplifi-
cation was done using the AmpliTaq Gold kit (Applied
Biosystems, Foster City, CA). The PCR cycling conditions
were as follows: 42 cycles of 1 minute at 94°C, 1 minute at
55°C, and 2 minutes at 72°C. PCR products were separated
by electrophoresis in a 2% agarose gel, visualized by
ethidium bromide staining and analyzed using the GelDoc
2000 (Bio-Rad) system. PCR products were isolated from the
agarose gel using the MEGA-spin Agarose Gel Extraction Kit
(iNtRON Biotechnology, Gyeonggi-do, Republic of Korea)
and were sequenced by the ABI-PRISM 310 DNA Sequencer
(AME Bioscience, Bedfordshire, UK) at the Laborigo Ltd.
(Budapest, Hungary) sequencing core.
The real-time PCR reaction was run on the iCycler iQ
(Bio-Rad) using standard conditions, namely, an optimized
concentration of primers (final concentration 200 nM), iQ
SYBR Green Supermix (BioRad), and 2 l of complemen-
tary DNA. No-template controls were included for each
primer pair. The cycling parameters were 95°C (10 minutes),
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50 cycles of 95°C (30 seconds), 64°C (30 seconds), and 72°C
(1 minute). Apelin expression level was determined after
normalization to -actin expression.
Xenograft Tumors
Growth of the apelin-transfected human NSCLC cells
were compared with those of control vector-expressing cells
in xenograft tumors formed in 6-week-old female athymic
(nu/nu) mice from Charles River Laboratories (Wilmington,
MA). According to the institutional animal welfare guide-
lines, all mice were maintained on a daily 12:12-hour light-
dark cycle and were housed under pathogen-free conditions
in microisolator cages with laboratory chow and water ad
libitum. H358 and H1975 cells stably expressing apelin or
transfected with control vector were grown to 80% conflu-
ence, harvested by trypsinization, and washed twice. NSCLC
xenografts were established by injecting mice subcutaneously
with 1  107 H358 or H1975 cells in Matrigel (Collaborative
Research Biochemicals, Bedford, MA). Tumor size was mea-
sured every 4 days with a caliper and expressed in mm3 by
the formula for the volume of a prolate ellipsoid (length 
width2 /6). Tumors were removed from mice after 32 days
of growth and were fresh-frozen in liquid nitrogen for further
analysis.
Statistical Analysis
Continuous variables were compared with Student t test
if the sample distribution was normal or with Mann-Whitney
U test if the sample distribution was asymmetric. Categorical
data were compared using Fisher’s exact probability and 2
tests. Correlations of apelin protein and mRNA expressions
were determined using Spearman’s rank correlation test.
Overall survival analyses were done using the Kaplan-Meier
method. Overall survival intervals were determined as the
time period from initial diagnosis to the time of death. The
comparison between survival functions for different strata
was assessed with the log-rank statistic. Multivariate analysis
of prognostic factors was done using Cox regression model.
Differences were considered significant if the p-value is less
than 0.05. All statistical analyses were done using Statistica
8.0 (StatSoft Inc. Tulsa, OK) software program.
RESULTS
Apelin mRNA and Protein Expression in Tumor
and Normal Lung Tissue Samples of NSCLC
Patients and in Human NSCLC Cell Lines
Apelin protein was expressed by the human bronchial
glands (Figure 1A) and epithelium adjacent to tumors, exhib-
iting a cytoplasmic pattern of expression. Alveolar cells were
negative. Typical patterns of apelin staining in human
NSCLC samples are shown in Figure 1B (low expression)
and Figure 1C (high expression).
Reverse-transcriptase (RT)-PCR demonstrated the
presence of apelin mRNA in six of six human NSCLC cell
lines (Figure 1D). An ELISA for apelin indicated that all
examined cell lines secreted the protein into their cell culture
medium (Figure 1E).
Quantitative RT-PCR analysis of 46 paired nontumor
and tumor mRNA extracts revealed that apelin levels were
significantly higher in the tumor samples of patients com-
pared with the levels of their normal lung tissue specimens
(p  0.01; Figure 1F). Moreover, when apelin mRNA levels
of human NSCLC specimens were compared with expression
levels detected by immunohistochemistry, a significant cor-
relation was found (p  0.01; Figure 1G).
Effect of Exogenous Apelin and Apelin
Overexpression on In Vitro and In Vivo NSCLC
Growth
To confirm or rule out that apelin influences NSCLC
cell growth in an autocrine manner, the effect of treatments
with different doses of apelin was studied on six different
human NSCLC cell lines. Importantly, exogenous apelin did
not stimulate the in vitro proliferation rate of these cells,
compared with untreated cells after 72 hours (Figure 2A–F).
To further investigate the influence of apelin on
NSCLC growth, H358 and H1975 cells with relatively low
levels of endogenous apelin were stably transfected with an
apelin expression vector to increase apelin levels. ELISA was
used to verify the elevated cellular secretion of apelin after
transfections. Although genetic modification of H358 and
H1975 cell lines resulted in a significant elevation in secreted
levels of apelin (p 0.05 in case of both cell lines, Figure 3A),
when the possible effect of this increase in apelin protein
expression was evaluated on cell growth in vitro, neither H358
nor H1975 cells overexpressing apelin showed an increased
proliferation rate compared with control vector–transfected cells
(p  0.05, in case of both cell lines, Figure 3B).
Next, we sought to test the effect of apelin on tumor
growth in vivo using xenografted human NSCLC cells in
immunodeficient mice. Therefore, in our next set of experi-
ments, the in vivo growth rates of tumors after subcutaneous
injection of H358 or H1975 cells expressing apelin or control
vectors were assessed. Tumor growth was significantly ac-
celerated in mice injected with apelin-overexpressing cells
compared with mice carrying cells transfected with the empty
control vector (Figure 4A, B).
Association of Apelin Expression with
Angiogenesis
As mentioned above, exogenous apelin (Figure 2A–F)
or overexpression of apelin by transfected NSCLC cells
(Figure 3B) did not seem to affect the growth rate of tumor
cells in vitro, but implantation of apelin-overexpressing tu-
mor cells into mice resulted in accelerated tumor growth in
vivo (Figure 4A, B). This observation, taken together with the
results of other studies demonstrating the angiogenic poten-
tial of apelin in different in vitro and in vivo experimental
models,8–13 prompted us to investigate whether apelin might
also induce angiogenesis in xenotransplanted human NSCLC
tumors in vivo. As expected, morphometrical analysis using
CD31 as an EC marker (Figure 5A–D) revealed a signifi-
cantly higher MVD present in the apelin-overexpressing
tumors compared with controls (p  0.05 in case of both
H358 and H1975 cell lines; Figure 5E). Moreover, assess-
ment of tumor capillary perimeters indicated a significant
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FIGURE 1. Apelin is expressed in normal human lung and non-small cell lung cancer (NSCLC) tissues and cell lines. A, Im-
munostaining of apelin in bronchial glands in normal human lung tissue. (B, C), Immunohistochemistry showing examples for
focal (B) and diffuse (C) apelin staining patterns (corresponding to low and high apelin expression, respectively) in human
NSCLC. (B) Arrows point at single apelin-expressing tumor cells within the tumor. Magnification, 200 (A–C). D, Reverse-tran-
scriptase polymerase chain reaction (RT-PCR) demonstrating the expression of apelin mRNA in human NSCLC cell lines and
-actin as control. E, Enzyme-linked immunosorbent assay detection of secreted apelin in conditioned medium from NSCLC
cell cultures. Columns, mean for three experiments; bars, standard deviation. F, Box plots showing significant a difference be-
tween apelin mRNA levels of tumor and normal lung specimens of patients with NSCLC as depicted by median (central dots),
25 to 75% quartile ranges (boxes), and minimum/maximum levels (whiskers) (n  46). G, Correlation between apelin mRNA
and protein expressions of human NSCLC specimens as determined by quantitative real-time RT-PCR and immunohistochem-
istry, respectively (n  46, R  0.59, p  0.01).
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increase in the cases of both H358 and H1975 cell lines in the
apelin-transfected compared with the control vector–trans-
fected tumors (p  0.05; Figure 5F).
To determine the clinical relevance of apelin expres-
sion, we performed comparative statistical analysis of apelin
expression and clinicopathologic variables (summarized in
Table 1). No significant associations with age, smoking
history, gender, tumor (T) status, lymph node (N) status, or
histologic type were detected (Table 1). However, corrobo-
rating the angiogenic potential of apelin seen in human
NSCLC xenograft tumors, high apelin expression was found
significantly more frequently in human NSCLC samples with
high MVDs compared with tumors with low MVDs (p 
0.04, Table 1). Accordingly, the mean number of blood
capillaries counted in high apelin-expressing tumors was
significantly greater than that in tumors with low apelin
protein expression, as determined by anti-CD31 immunohis-
tochemistry (p  0.002; Figure 6A).
The association of apelin expression with the angio-
genic activity of human NSCLCs, as determined by capillary
perimeters, was also studied. Although a tendency toward an
increased microvessel perimeter in the cases with high apelin
expression was observed, the difference in blood capillary
perimeters between tumors with high and low apelin protein
expression remained statistically insignificant (p  0.14;
Figure 6B).
Prognostic Significance of the Increased
Expression of the Apelin Protein
When initial apelin immunolabeling categories (, 1,
2, and 3) were tested for discriminating power in predict-
ing disease outcome, we found that patients whose tumor
samples were categorized by an apelin score  or 1 (i.e.,
10%; defined as “apelin low”) had significantly longer
survival times than those with “high” (10% of positive
cells) apelin expression. The 5-year survival rates of patients
with high apelin expression and patients with low apelin
expression were 29.9% and 63.3%, respectively (p  0.002,
log-rank test, Figure 6C).
Multivariate analysis (including standard prognostic
parameters, such as tumor extension, lymph node status, and
patient age) also showed that apelin expressions predicted
outcome independent of other variables (p 0.021; Table 2).
A further prognostic factor related to poor survival was
lymph node stage (p  0.01; Table 2).
DISCUSSION
Apelin has been reported to stimulate endothelial
growth in various in vitro and in vivo experimental sys-
tems,8–11 and recent studies have provided evidence for its
expression in human13 and angiogenic potential in murine
tumors.12,13 However, to date, no studies have attempted to
evaluate the role of apelin in human cancer vascularization,
FIGURE 2. Exogenous apelin does
not stimulate non-small cell lung
cancer (NSCLC) cell proliferation in
vitro. Wild-type H1650 (A), HCC15
(B), LCLC-I03H (C), H1975 (D),
H358 (E), and A549 (F) cells were
cultured in serum-containing (Se)
or serum-free (Se) medium. Ape-
lin-36 (0 to 106 M) was added to
the cells, and cell numbers were esti-
mated at 72 hours by 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide assay. No significant
effect of apelin on in vitro NSCLC
proliferation was found. Columns,
mean for three experiments; bars,
standard deviation.
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and no studies have been reported on its clinicopathologic
significance. To the best of our knowledge, our results pre-
sented here demonstrate for the first time a direct association
of apelin expression with angiogenesis and clinical outcome
in a human malignancy.
NSCLC remains the leading cause of cancer death in
both sexes and is one of the major challenges of medical
oncology.1 Even in surgically resectable cases, more than
50% of patients develop metastases within 5 years. The
mechanisms responsible for the aggressive behavior of this
cancer are not fully understood. A large body of preclinical
evidence has confirmed angiogenesis as a key process of
NSCLC progression, and several agents targeting the tumor
vasculature have been evaluated. However, because recent
clinical trials investigating these drugs have been both en-
couraging and disappointing,25,26 success with antivascular
strategies undoubtedly requires a deeper knowledge of the
clinical significance of the different angiogenic factors that
control NSCLC.
Apelin has been shown to be highly expressed in
normal lung tissue,27 and the up-regulation of apelin gene
expression in various human solid tumors (including lung
cancer) was also demonstrated recently.13,28 In the present
study, we further investigated the expression of apelin in
normal and tumorous human lung tissues, and found that
apelin, as measured by quantitative RT-PCR, is overex-
pressed in fresh frozen NSCLC samples at the mRNA level
and that these levels are commensurate with protein levels
detected by immunohistochemistry in corresponding forma-
lin-fixed, paraffin-embedded pathologic specimens. Apelin
was also present in all the investigated human NSCLC cell
lines both at the mRNA and the protein levels. Although
genetic manipulation to increase apelin expression in NSCLC
cells resulted in increased tumor growth in mice, neither
apelin transfection nor exogenous apelin stimulated NSCLC
cell proliferation in vitro. Thus, in agreement with the previ-
ous results of Sorli et al. in mouse melanoma12 and mammary
carcinoma,13 these findings suggested that apelin plays a role
in promoting NSCLC progression in vivo but did not indicate
the presence of an autocrine component to this effect. Given
FIGURE 3. Genetic manipulation increases cellular expres-
sion of apelin but does not stimulate in vitro proliferation of
non-small cell lung cancer cell lines. A, Enzyme-linked immu-
nosorbent assay demonstrating the effects of apelin overex-
pression on apelin levels in conditioned medium of H358
and H1975 cells stably transfected with either apelin or con-
trol vectors. Columns, mean for three experiments; bars,
standard deviation; *p  0.05 versus controls. B, No signifi-
cant difference in proliferation was found by a 72-hour
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay when comparing H358 and H1975 cells stably trans-
fected with control or apelin expression vectors. Columns,
mean for three experiments; bars, standard deviation.
FIGURE 4. Overexpression of apelin through genetic ma-
nipulation-stimulated in vivo growth of human non-small
cell lung cancer cells in nude mice. Growth curves of control
vector- and apelin-transfected H1975 (A) and H358 (B) cells.
(f) and (Œ), means for eight mice per group; bars, standard
deviation; *p  0.05 and **p  0.01 versus controls.
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its well-documented angiogenic functions,8–13 we hypothe-
sized, therefore, that apelin might enhance NSCLC growth by
exerting a stimulatory effect on blood capillaries. Investigat-
ing the association of apelin protein expression with the
angiogenic activity in tumor samples of NSCLC patients, we
found that the microvessel counts of high apelin expressors
were significantly higher than that of low apelin expressors.
This result was further corroborated by the observation that
apelin overexpression of transfected human NSCLC cells
significantly increased intratumoral MVDs of tumors grow-
ing subcutaneously in nude mice.
Apelin overexpression in experimental tumors was as-
sociated not only with a high number of intratumoral capil-
laries but with significantly increased vessel perimeters. Al-
though NSCLC patients who had tumor samples with high
apelin protein expression also tended to have larger intratu-
moral blood capillaries than those who had tumors with low
apelin expression, this tendency remained nonsignificant,
which may reflect the differences in tumor microenvironment
(such as extracellular matrix composition of the host tissue or
mechanical forces) between subcutaneously growing experi-
mental and human tumors. However, it is difficult to con-
clude, based on our results in clinical samples presented here,
that enlargement of blood vessels during the vascularization
of human NSCLC is definitely a result of apelin action, as
other recent studies investigating apelin-induced angiogene-
sis in developmental29 and experimental tumor13 models have
also found. Based on our above observations in human
NSCLC samples, one can rather hypothesize that apelin
predominantly acts as a branching factor during the develop-
ment of the vascular network of human NSCLCs. This
assumption is supported by recent results of chorioallantoic
membrane experiments in which, for example, apelin was
demonstrated to stimulate capillary branching 2.5-fold rela-
tive to controls approximately equivalent to the degree of
branching induced by vascular endothelial growth factor.5
The observed association between apelin expression
and angiogenic activity in NSCLC samples, taken together
with experimental and clinical evidence accumulated thus far
on the role of angiogenesis in NSCLC progression15,25,26
prompted our decision to investigate the associations between
apelin expression and the clinicopathologic parameters of our
patients. During the follow-up period of 5 years, a signifi-
cantly higher incidence of death from NSCLC was observed
in patients with high apelin protein expression compared with
patients with low apelin expression, and high apelin protein
FIGURE 5. Apelin overexpression
increases non-small cell lung can-
cer angiogenesis in vivo. Frozen
sections of 32-day-old apelin-over-
expressing H358 (C) and H1975
(D) tumors or of control H358 (A)
and H1975 (B) tumors were
stained for the endothelial cell
marker CD31 (red fluorescence).
Magnification, 200 (A–D). E, Mi-
crovessel densities (MVDs) of 32-
day-old apelin-overexpressing or of
control H358 and H1975 tumors.
MVDs are mean blood vessel
counts per square millimeter. F,
Microvessel perimeters of 32-day-
old apelin-overexpressing or of
control H358 and H1975 tumors.
Microvessel perimeters are ex-
pressed in micrometers. Columns,
means for eight mice per group;
bars, standard deviation; *p  0.05
versus controls.
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expression was found to be a significant independent factor
for predicting poor prognosis. Thus, this study reports, for the
first time, the presence and important prognostic role of
apelin as an angiogenic factor that increases the aggressive
behavior of human NSCLC. It is important to note, however,
that the vascularization process of solid tumors is tightly
regulated by the opposing effects of proangiogenic factors
and inhibitors, the balance of which may change at different
stages during tumor progression.30 The observation that ape-
lin signaling was demonstrated to regulate pathologic retinal
vascularization in a cooperative manner with vascular endo-
thelial growth factor or fibroblast growth factor31 further
supports this idea. Therefore, additional studies to reveal the
interrelationships between apelin and other angiogenic mol-
TABLE 2. Multivariate Analysis of Various Prognostic
Factors in Patients with NSCLC (n  94)
Prognostic Factor RR 95% CI p
Age in years (63 vs. 63) 1.577 0.9–2.761 0.111
Gender (male vs. female) 0.547 0.289–1.036 0.064
Histology (AC vs. SCC/LCC) 1.015 0.65–1.585 0.946
Pathologic T-stage (T1 vs. T2–3) 0.94 0.711–1.243 0.664
Pathologic N-stage (N0 vs. N1–2) 5.974 2.888–12.357 0.01
Apelin expression (low vs. high) 2.354 1.135–4.883 0.021
RR, relative risk; CI, confidence interval; AC, adenocarcinoma; SCC, squamous
cell carcinoma; LCC, large cell carcinoma.
FIGURE 6. Apelin expression is associated with angiogenesis and prognosis in human non-small cell lung cancer (NSCLC). A,
Box plots showing median (central dots), 25 to 75% quartile ranges (boxes), and minimum/maximum levels (whiskers) of mi-
crovessel densities (MVDs), as determined by CD31 immunolabeling, in human NSCLC specimens with low versus high apelin
protein expression. MVDs are mean blood vessel counts per square millimeter; n  94. B, Box plots showing median (central
dots), 25 to 75% quartile ranges (boxes), and minimum/maximum levels (whiskers) of microvessel perimeters, as determined
by CD31 immunostaining, in human NSCLC specimens with low versus high apelin protein expression. Microvessel perimeters
are expressed in micrometers; n  94. C, Kaplan-Meier curves for the overall survival of the patient population with NSCLC,
according to apelin expression as determined by immunohistochemistry. High apelin expression in the tumors was a signifi-
cant prognostic factor for reduced overall survival; n  94.
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ecules not only in NSCLC but also in other solid human
tumors are warranted. Nevertheless, our novel observations
add apelin to the growing list of angiogenic molecules in
NSCLC and open the door for the development of potential
future therapies targeting apelin signaling to treat human
NSCLC.
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Background: Despite improvements in surgery and chemo(radio)therapy which 
have allowed for modest advances in the treatment of patients with non-
small-cell lung cancer (NSCLC), survival remains poor and further improvements 
are needed. Attention over recent years has focused, therefore, on targeted 
therapies, with notable success in the development of antivascular drugs. 
Objective: To summarize the current knowledge on antivascular therapy in 
patients with NSCLC. Method: Review of randomized controlled trials exploring 
treatment of NSCLC patients with antivascular drugs. Results/conclusion: 
Bevacizumab, a humanized monoclonal antibody against the vascular endothe-
lial growth factor (VEGF), when added to cytotoxic chemotherapy, was the 
first treatment to prolong the overall survival of patients with advanced 
NSCLC beyond 12 months, a significant breakthrough in the management 
of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alterna-
tive antivascular strategies such as VEGF-trap and vascular disrupting agents 
are also being investigated and have shown promise in clinical trials. This 
review summarizes the most recent and important findings in antivascular 
agents in NSCLC.
Keywords: angiogenesis, antivascular drug, clinical trial, non-small-cell lung cancer
Expert Opin. Investig. Drugs [Early Online]
1.	 Introduction
Lung cancer, a serious public health problem and the leading cause of cancer-related 
death worldwide [1,2], is classified in two major groups: small-cell and non-small-cell 
cancer (SCLC and NSCLC, respectively). NSCLC accounts for the majority (∼ 85%) 
of all lung cancer cases. Unfortunately, more than 60% of patients with NSCLC 
present with locally advanced, unresectable or metastatic (stage III/IV) cancer at 
initial diagnosis and die from the disease.
Standard first-line chemotherapy for patients with advanced NSCLC is a platinum-
based doublet regimen incorporating a third-generation cytotoxic drug such as 
gemcitabine (Gemzar®; Eli Lilly and Company, Indianapolis, IN), paclitaxel (Taxol®; 
Bristol-Myers Squibb, Princeton, NJ), docetaxel (Taxotere®; Sanofi-Aventis, 
Bridgewater, NJ) or vinorelbine (Navelbin®; Pierre Fabre Medicament, Albi Area, 
France). However, although these combinations have improved survival compared 
with best supportive care, the response of NSCLC to first-line treatments is usually 
transitory, with progression occurring 4 – 6 months after chemotherapy is completed. 
Furthermore, the median overall survival (OS) is still only 8 – 11 months [3-5]. 
The benefit of first-line cytotoxic regimens for advanced NSCLC therefore seems 
to have reached a plateau, and more effective treatments are clearly required. The 
need for more successful anti-NSCLC treatments has led to the development of 
1.  Introduction
2.  Antivascular strategies  
for NSCLC
3.  Potential biomarkers for 
monitoring antivascular  
therapy in NSCLC
4.  Expert opinion
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new therapeutic approaches targeting molecular pathways 
involved in tumor progression. Targeted antivascular drugs 
have shown particular promise in preclinical NSCLC models, 
demonstrated notable success in clinical studies and are the 
focus of this review.
2.	 Antivascular	strategies	for	NSCLC
Any classification of antivascular treatments is difficult, with 
overlap in several features. However, the main categories of 
these drugs that have been developed are angiosuppressive 
(antiangiogenic) and vascular-disrupting agents (VDAs) 
(Table 1) [6]. As described in this review, many of these agents 
are at an early phase of development, but a number have 
reached later phases of testing (Table 2).
2.1	 Antiangiogenic	(angiosuppressive)	therapy
This approach is based on the observation that new blood 
vessel growth in tumors requires the induction of endothelial 
cell proliferation by specific or nonspecific mitogens. By 
inhibiting the production of endothelial mitogens, the mito-
gens themselves, their endothelial receptors, the associated 
signaling pathways, the endothelial integrins and the matrix 
metalloproteinases (MMPs), these agents specifically target 
endothelial sprouting (defined as the in situ proliferation and 
budding of endothelial cells [7]) and postnatal vasculogenesis 
(i.e., bone-marrow-derived endothelial progenitor cells, reviewed 
in [8]) in cancer.
2.1.1 Inhibitors of VEGF signaling
In order to develop and metastasize, growing tumors require 
an adequate blood supply. Similar to other solid tumors, 
NSCLCs achieve this by secreting various angiogenic cytokines 
that regulate the complex series of events of blood vessel growth. 
Among these angiogenic molecules, vascular endothelial 
growth factor (VEGF) has been identified as the key cytokine 
for endothelial sprouting in NSCLC [9]. The VEGF protein 
has four isoforms, VEGF 121, 165, 189 and 206 and is 
encoded on chromosome 6p21.3. At present, the VEGF family 
members (including placental growth factor 1 and 2, and 
VEGF A, B, C, D and E) act as ligands for three tyrosine 
kinase receptors: VEGFR-1 (flt1), VEGFR-2 (KDR) and 
VEGFR-3 (flk4). VEGFR-2 is the principal receptor for 
VEGF (VEGF-A) signaling, whereas VEGFR-1 functions as 
a decoy receptor to control the availability of VEGF. VEGF-C 
and D are ligands for VEGFR-3, which is predominantly 
expressed by lymphatic endothelial cells [10].
2.1.1.1	 Bevacizumab
Bevacizumab (Avastin®; Genentech/Roche, South San Francisco, 
CA, USA) is a humanized monoclonal antibody that acts 
by binding and neutralizing the VEGF-A isoform, thus 
preventing VEGF ligand-receptor binding. This agent has been 
studied in a variety of solid tumors both as a single agent 
and in combination with cytotoxic chemotherapy or with 
other targeted therapies. This is so far the first and only 
antivascular drug to be licensed for the treatment of NSCLC. 
Bevacizumab has also been approved for the treatment of 
breast [11], renal cell [12] and metastatic colorectal cancers [13] 
in Europe, while in the USA the FDA has approved beva-
cizumab in breast and colorectal cancers in addition 
to NSCLC.
2.1.1.1.1	 First-line	clinical	development	of	bevacizumab
In lung cancer, the first evidence for the benefit of bevacizumab 
came from a Phase II randomized trial for patients with 
advanced or recurrent NSCLC (Table 2) [14]. Results showed 
that those treated with higher bevacizumab doses (15 mg/kg) 
had a significantly increased time to progression (TTP) com-
pared with chemotherapy alone. In addition, there was a trend 
towards improved OS. However, this improvement was not 
statistically significant, possibly because of the large number 
of patients who crossed over from receiving chemotherapy 
only to receiving chemotherapy plus bevacizumab upon show-
ing signs of progression. In general, bevacizumab was well 
tolerated, although six patients on the bevacizumab arm devel-
oped severe pulmonary hemorrhage [14]. In a post hoc multi-
variate analysis, squamous cell histology was identified as an 
independent risk factor for bleeding [15]. Consequently, patients 
with squamous cell histology were excluded from most of 
the clinical trials of bevacizumab in NCSLC.
Subsequent to the above Phase II study, the Eastern 
Cooperative Oncology Group (ECOG) E4599 trial was 
initiated (Table 2) [16]. This study, which is the first published 
Phase III randomized trial of an antiangiogenesis agent in 
combination with chemotherapy in patients with advanced 
NSCLC, randomized chemotherapy-naive patients with 
predominantly non-squamous cell histology. In the bevaci-
zumab treatment arm, following completion of chemotherapy, 
single-agent bevacizumab was continued until disease pro-
gression. The primary study end point was OS. Results showed 
that the addition of bevacizumab was associated with a 
significant improvement in the median OS compared with 
chemotherapy alone. Progression-free survival (PFS) was also 
significantly improved (Table 2).
As a result of this study, the US FDA approved the use of 
bevacizumab in combination with carboplatin and paclitaxel 
for the initial systemic treatment of patients with unresectable, 
locally advanced, recurrent or metastatic, non-squamous 
NSCLC, and this treatment has become the standard of care 
for these patients in the USA.
A retrospective analysis of treatment outcomes in the 
E4599 trial based on different histologic subtypes was also 
presented by Sandler et al. [17]. For evaluable patients, the 
predominant tumor histology was adenocarcinoma (602 of 
878 patients; 68.6%). There were 165 patients (18.8%) with 
tumors of not otherwise specified histology, and 48 patients 
(5.5%) with large cell undifferentiated tumors. Fewer than 5% 
of patients had tumors of other histological subtypes. Baseline 
demographics and patient characteristics by histology type 
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Table	1.	Antivascular	agents	under	development	in	human	NSCLC.
Drug	name Developer Phase	of	development Study	status
Inhibitors	of	VEGF	signaling
Bevacizumab, Avastin Genentech, Inc. Approved
IMC-1121b ImCloneSystems, Inc. Phase II Ongoing
IMC-18F1 ImCloneSystems, Inc. Phase I Ongoing
Aflibercept, VEGF-Trap Regeneron Pharmaceuticals Phase III Ongoing
Tyrosine	kinase	receptor	inhibitors
Vandetanib, ZD-6474, Zactima Astra-Zeneca Phase III Completed
Cediranib, AZD2171, Recentin Astra-Zeneca Phase II Ongoing
Axitinib, AG-013736 Pfizer Phase II Completed
Sorafenib, BAY 43-9006, Nexavar Bayer Phase III Ongoing
Sunitinib, SU011248, Sutent Pfizer Phase III Ongoing
Motesanib, AMG-706 Amgen Phase III Ongoing
Vatalanib, (PTK787/ZK 222584) Bayer Phase II Completed
Pazopanib, GW786034 GlaxoSmithKline Phase II/III Ongoing
BIBF 1120 Boehringer Ingelheim Phase III Ongoing
ABT-869 Abbott Laboratories Phase II Ongoing
BMS-690514 Bristol Myers Squibb Phase II Ongoing
OSI-930 OSI Pharmaceuticals Phase I Ongoing
AEE788 Novartis International AG Phase II Completed
XL647 Exelixis Phase II Ongoing
XL999 Exelixis Phase I terminated
CP-547,632 Pfizer Phase II Completed
AV-951 Aveo Pharmaceuticals, Inc. Phase Ib/IIa Ongoing
Thalidomide	and	analogs
Thalidomide Celgene Phase III Ongoing
Lenalidomide, CC-5013, Revlimid Celgene Phase II Completed
Matrix	metalloproteinases
BMS-275291 Bristol Myers Squibb Phase III Completed
Other	antiangiogenic	agents
cilengitide, EMD 121974 Merck Phase II Ongoing
volociximab, M200 PDL BioPharma, Biogen Idec Phase I Ongoing
TNP-470 Takeda Chemical Industries, Inc. Phase I Completed
AMG-386 Amgen Phase I Completed
Vascular	disrupting	agents
DMXAA, ASA-404, AS1404 Novartis International AG Phase III Ongoing
Zybrestat, combrestatin, CA4P OxiGene, Inc. Phase II Ongoing
NPI-2358 Nereus Pharmaceuticals, Inc. Phase I Ongoing
ABT-751 Abbott Laboratories Phase II Completed
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Table	2.	Results	of	recent	Phase	II	–	III	clinical	trials	of	antivascular	agents	in	the	treatment	of	NSCLC.
Ref. Phase Setting Treatment No.	of	
patients
DCR	(%) OS	
(months)
TTP	
(months)
PFS	
(months)
[14] II (r) 1st line paclitaxel + carboplatin vs
paclitaxel + carboplatin +  
bevacizumab (7.5 mg/kg) vs  
paclitaxel + carboplatin +  
bevacizumab (15 mg/kg)
32
32
35
31*
22*
40*
14.9
11.6
17.7
4.2
4.3
7.4
NR
[17] III (r) 1st line paclitaxel + carboplatin vs
paclitaxel + carboplatin +  
bevacizumab
444
434
15*
35*
10.3
12.3
NR 4.5
6.2
[19] III (r) 1st line cisplatin + gemcitabine vs
cisplatin + gemcitabine +  
bevacizumab (7.5 mg/kg) vs
cisplatin + gemcitabine +  
bevacizumab (15 mg/kg)
347
345
351
20.1*
34.1*
30.4*
13.1
13.6
13.4
NR 6.1
6.7
6.5
[20] II 1st line pemetrexed + carboblatin + 
bevacizumab
50 55* 13.5 NR 9.3
[27] II (r) 2nd line chemo vs
chemo + bevacizumab vs
erlotinib + bevacizumab
41
40
39
39.0
52.2
51.3
8.6
12.6
13.7
NR 3.0
4.8
4.4
[28] III (r) 2nd line erlotinib vs
erlotinib + bevacizumab
317
319
34.0
45.2
9.2
9.3
NR 1.7
3.4
[40] II (r)
(2 parts)
2nd, 3rd line gefitinib vs vandetanib 85
83
34‡
45‡
7.4§
6.1¶
NR 1.9‡
2.5‡
[41] II (r) 2nd line docetaxel vs
docetaxel + vandetanib  
(100 mg) vs
docetaxel + vandetanib  
(300 mg) vs
41
42
44
56
83
63
13.4
13.1
7.9
NR 2.8
4.3
3.9
[42] II (r) 1st line paclitaxel + carboplatin vs
paclitaxel + carboplatin +  
vandetanib vs
vandetanib
52
56
73
58
57
NR
12.6
10.2
NR
NR 5.3
5.5
NR
[52] II All lines axitinib 32 9.4* 12.8 9.4 NR
[55] II 2nd line sorafenib 52 59 6.8 NR 2.7
[56] II 2nd line sorafenib 6 4/5 NR NR NR
[62] II 1st line 
maintenance
carboplatin + paclitaxel  
followed by sunitinib
87 NR 10.5 2.6 NR
[63] II 2nd, 3rd line sunitinib (continuous daily) 47 19 NR NR 2.8
[69] II 2nd line vatalanib (qd)
vatalanib (b.i.d.)
54
58
35
39
7.0
6.8
NR
NR
2.4
3.7
[70] II neoadjuvant pazopanib 35 86# NR NR NR
[74] II 2nd, 3rd line BIBF 1120 (250 b.i.d.)
BIBF 1120 (150 b.i.d.)
73 48 NR NR 1.6
[93] II 2nd, 3rd line XL999 9 3/9 NR NR NR
*Stable disease not reported.
‡Part A.
§Part B (switched to vandetanib from gefitinib).
¶Part B (switched to gefitinib from vandetanib).
#Primary end point = tumor reduction.
b.i.d.: Bis in die (twice daily); DCR: Disease control rate; NR: Not reported; OS: Overall survival; PFS: Progression-free survival; qd: Quaque die (every day);  
r: Randomized; TTP: Time to progression.
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Ref. Phase Setting Treatment No.	of	
patients
DCR	(%) OS	
(months)
TTP	
(months)
PFS	
(months)
[94] II (r) 1st line paclitaxel + carboplatin vs
paclitaxel + carboplatin +  
CP-547,632
17
14
25
28.6
NR 7.7
4.7
NR
[98] II 1st line carboplatin + irinothecan +  
thalidomide
36 74 7.3 3.6 NR
[99] II 1st line gemcitabine + irinothecan +  
thalidomide
11 50 NR 4.3 NR
[105] III (r) paclitaxel + carboplatin vs
paclitaxel + carboplatin +  
BMS-275291
387
387
81.9
78.6
9.2
8.6
NR 5.3
4.9
[118] II (r) 1st line paclitaxel + carboplatin vs
paclitaxel + carboplatin + ASA404
36
37
61.3
78.2
8.8
14.0
4.4
5.4
NR
*Stable disease not reported.
‡Part A.
§Part B (switched to vandetanib from gefitinib).
¶Part B (switched to gefitinib from vandetanib).
#Primary end point = tumor reduction.
b.i.d.: Bis in die (twice daily); DCR: Disease control rate; NR: Not reported; OS: Overall survival; PFS: Progression-free survival; qd: Quaque die (every day);  
r: Randomized; TTP: Time to progression.
Table	2.	Results	of	recent	Phase	II	–	III	clinical	trials	of	antivascular	agents	in	the	treatment	of	NSCLC	(continued).
were comparable among the paclitaxel/carboplatin (PC) and 
paclitaxel/carboplatin/bevacizumab (PCB) treatment arms. 
For patients with adenocarcinoma histology, median OS was 
10.3 months for PC alone and 14.2 months for PCB. Median 
PFS was 5.0 months for PC alone and 6.6 months for PCB.
A second Phase III trial, Avastin® in Lung (AVAiL), 
evaluating bevacizumab in combination with cisplatin and 
gemcitabine [18] (another commonly used and efficacious 
regimen in NSCLC) was originally initiated with a primary 
end point of OS. However, after the positive OS results of 
E4599, the study design was amended to change the primary 
end point from OS to PFS (this decision was made to ensure 
completion of the trial, to accelerate reporting of the efficacy 
data and thus expedite the availability of a potentially active 
treatment option for patients, and to avoid the risk of the 
OS end point being confounded by the increasing use of 
second-line therapies, including non-protocol crossover of 
patients in the placebo arm to bevacizumab). Patients were 
randomly assigned to receive cisplatin 80 mg/m2 and 
gemcitabine 1250 mg/m2 for up to six cycles plus low-dose 
bevacizumab (7.5 mg/kg), high-dose bevacizumab (15 mg/kg) 
or placebo every 3 weeks until disease progression. Between 
February 2005 and August 2006, 1043 patients were ran-
domly assigned (placebo, n = 347; low dose, n = 345; high 
dose, n = 351). PFS was significantly prolonged with 
bevacizumab (Table 2).
Interestingly, according to the final efficacy analysis, OS 
was > 13 months in all treatment groups (Table 2), which is 
the longest OS reported for advanced non-squamous NSCLC 
in a clinical trial setting, although it did not yield a statistically 
significant prolongation with either bevacizumab dose [19]. 
Among the possible explanations for these results are the good 
performance status of the placebo arm and the unprecedentedly 
high proportion of second-line and third-line line therapies 
administered to these patients. To support this assumption 
further, there was a trend towards improved OS in patients not 
receiving post-protocol therapies (HR = 0.84; bevacizumab 
to placebo).
As a result of the above trials, bevacizumab in combination 
with platinum-based chemotherapy was approved for the 
first-line treatment of patients with advanced NSCLC by 
the European Medicines Agency (EMEA), in August 2007.
2.1.1.1.2	 New	combinations	with	bevacizumab	in	the	first-
line	setting
Ongoing Phase II – III trials are evaluating bevacizumab with 
other platinum-based chemotherapy regimens.
A recent study of pemetrexed and carboplatin plus beva-
cizumab with maintenance pemetrexed and bevacizumab 
was designed to evaluate toxicities and estimate median TTP 
of this new regimen in advanced non-squamous NSCLC 
patients [20]. Results were based on 50 patients who received 
pemetrexed 500 mg/m2, carboplatin AUC 6, and bevacizumab 
15 mg/kg repeated every 21 days for six cycles. For patients 
with CR (complete response), PR (partial response), or SD 
(stable disease), pemetrexed 500 mg/m2 and bevacizumab 
15 mg/kg were continued as maintenance every 21 days until 
disease progression or toxicity (Table 2). There were no grade 
> 3 hemorrhagic events, nor did any patients experience grade 
3/4 hypertension.
A Phase II study has also evaluated the efficacy and 
safety of oxaliplatin and gemcitabine with bevacizumab 
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in non-squamous NSCLC patients [21]. Nineteen of 44 eligible 
patients had PR for an objective response rate (RR) of 43%. 
Sixteen patients had SD for a disease control rate of 80%. 
Median TTP was 5.5 months. Median OS was 13.7 months. 
The most common grade 3 or 4 adverse events were hyper-
tension (11%), neutropenia (9%), diarrhea (7%), dyspnea (7%) 
and thromboembolic events (7%). Pulmonary hemorrhage 
was not observed.
2.1.1.1.3	 Bevacizumab	in	combination	with	epidermal	
growth	factor	receptor	(EGFR)	inhibitors
2.1.1.1.3.1	 Bevacizumab	and	EGFR	inhibition:		
first-line	therapy
The safety and effectiveness of bevacizumab and erlotinib (an 
EGFR tyrosine kinase inhibitor) in the first-line setting is 
now being investigated in several Phase II studies. The 
SAKK 19/05 trial evaluates bevacizumab and erlotinib, followed 
by platinum-based chemotherapy at disease progression [22]. 
The INNOVATIONS study [23] compares bevacizumab and 
erlotinib with gemcitabine, cisplatin and bevacizumab. Both 
studies are actively recruiting patients.
In a Phase II study, the combination of bevacizumab, 
erlotinib and chemotherapy for first-line treatment was 
evaluated [24]. Patients received either up to four cycles of 
bevacizumab (15 mg/kg) and erlotinib (150 mg qd) or up to 
four cycles of carboplatin (AUC = 6), paclitaxel (200 mg/m2) 
and bevacizumab (15 mg/kg). Patients treated with erlotinib 
and bevacizumab who had achieved at least SD or any 
response continued treatment with bevacizumab and erlotinib 
until progression. The primary objective was to determine 
the rate of disease stabilization of the combination of 
bevacizumab and erlotinib. With 48 patients enrolled, the 
median OS for all patients was 12.9 months. Patients treated 
with erlotinib and bevacizumab who had disease stabili-
zation or response had a median survival of 23.2 months 
(vs 6.6 months, p < 0.001).
Another interesting approach is the four-drug regimen, 
which is subsequently being tested in the SWOG S0536 
trial [25]. Eligibility included patients with treatment-naive 
stage IIIb or IV incurable non-squamous cell NSCLC, 
and these patients were treated with carboplatin, paclitaxel, 
bevacizumab and cetuximab for up to six cycles, followed 
by bevacizumab and cetuximab until progression. The 
primary end point was feasibility defined by the frequency 
and severity of hemorrhagic toxicities. One hundred and 
ten patients were enrolled. Grade 4 adverse events occurred 
in 40 patients. The estimated rate of grade 4 or worse 
hemorrhage was 2%. Disease control rate was reported as 
74%, while PFS is 7 months and OS is 14 months. The 
combination of carboplatin, paclitaxel, bevacizumab and 
cetuximab demonstrated safety, tolerability and efficacy in 
patients with advanced NSCLC and was found to be the 
most active NSCLC regimen studied to date within SWOG 
(Southwest Oncology Group).
2.1.1.1.3.2	 Bevacizumab	and	EGFR	inhibition:	first-line	
maintenance	therapy
AVF3671g (ATLAS) is a Phase IIIb, placebo-controlled, 
double-blind, randomized trial to evaluate the efficacy of 
bevacizumab in combination with erlotinib for the first-line 
maintenance treatment of advanced non-squamous or periph-
erally located squamous NSCLC following four cycles of 
bevacizumab and chemotherapy. According to a press release [26], 
the study has met its primary end point, post-chemotherapy 
PFS, without new safety signals. Although final survival data 
have not yet been published, the results further indicate the 
notion that the dual inhibition of VEGF and EGFR path-
ways in the treatment of NSCLC may confer additional 
clinical benefit.
2.1.1.1.3.3	 Bevacizumab	and	EGFR	inhibition:		
second-line	setting
A multicenter, randomized Phase II trial evaluated the safety 
and efficacy of combining bevacizumab with either chemo-
therapy (docetaxel or pemetrexed) or erlotinib [27]. All patients 
had histologically confirmed non-squamous NSCLC that 
had progressed during or after one platinum-based regimen 
and were randomly assigned on a 1:1:1 basis to bevacizumab in 
combination with chemotherapy (docetaxel or pemetrexed), 
bevacizumab in combination with erlotinib, or chemotherapy 
alone (docetaxel or pemetrexed + placebo). The primary 
efficacy end point of the trial was PFS (Table 2). No unex-
pected adverse events were noted. Fewer patients (13%) in the 
bevacizumab-erlotinib arm discontinued treatment as a result 
of adverse events than in the chemotherapy alone (24%) or 
bevacizumab-chemotherapy (28%) arms.
BeTa Lung, a randomized Phase III trial comparing erlotinib 
monotherapy with erlotinib plus bevacizumab in the second-
line setting has also recently published its findings (Table 2). 
The primary end point of prolonging OS was not met 
(HR = 0.97; p = 0.7583). There was, however, clear evidence 
of clinical activity with improvements in secondary end points 
such as PFS (HR = 0.62, p < 0.0001) and RR (6.2 vs 12.6%) 
when bevacizumab was added to erlotinib compared with 
erlotinib monotherapy. As in the AVF3671g, no new safety 
signals were identified [28].
2.1.1.1.4	 Current	objectives	and	future	perspectives	
with	bevacizumab
Based on positive data from two completed Phase III trials 
(E4599 and AVAiL), bevacizumab has become the standard 
of care in the bevacizumab-eligible patient population in 
many western countries. Moreover, a wide range of clinical 
trial activities are underway to examine the potential role of 
bevacizumab in combination with cytotoxic chemotherapy 
or other biological agents not only in the first-line treat-
ment of NSCLC but also at subsequent stages. It should 
be emphasized, however, that defining the eligible patient 
pool based on an evaluation of safety issues is of the 
greatest importance.
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2.1.1.1.4.1	 Combination	of	bevacizumab	with	(chemo)
irradiation
Several Phase I studies are ongoing to investigate concurrent 
bevacizumab with radiotherapy, or concomitant chemoradia-
tion in combination with bevacizumab. A Phase I/II trial 
investigating the maximum tolerated dose (MTD) of bevaci-
zumab and erlotinib when given together with carboplatin, 
paclitaxel and thoracic conformal radiotherapy in stage IIIa/b 
NSCLC is now underway [29].
2.1.1.1.4.2	 Neoadjuvant	and	adjuvant	settings
Based on the unique mode of action of angiogenesis inhibitors, 
there is a strong rationale for investigating these drugs in the 
neoadjuvant and adjuvant settings.
The Phase II BEACON study, among other Phase II 
studies, is evaluating the role of neoadjuvant bevacizumab. Its 
primary goal is to show that the addition of bevacizumab to 
a cisplatin-based chemotherapy in the neoadjuvant setting 
for non-squamous NSCLC improves the rate of pathologic 
downstaging. The study is now recruiting participants [30].
Bevacizumab is also now being tested in the adjuvant 
setting in the ECOG E1505 trial. This trial aims to recruit 
1500 patients with completely resected stage Ib – IIIa tumors 
and compare postoperative chemotherapy using four cycles 
of cisplatin with vinorelbine, docetaxel or gemcitabine and 
with or without bevacizumab [31].
2.1.1.1.5	 Safety	and	tolerability	of	bevacizumab	in	
combination	with	chemotherapy
Since the publication of the AVF0757g trial [14], the risk of 
severe pulmonary hemorrhage has been an issue in patients 
with NSCLC treated with bevacizumab. Owing to the exclu-
sion of predominantly squamous cell cancer and clinically 
significant hemoptysis at baseline, the 9.1% incidence of 
severe pulmonary hemorrhage observed in the AVF0757g 
trial was reduced to 2.3% in the E4599 trial [16]. With the 
additional exclusion of patients with tumors invading or 
abutting major blood vessels, the incidence of this adverse 
event decreased to 1.5% in the AVAiL trial. By adopting 
essentially the same exclusion criteria in a large Phase IV trial 
(SAiL), based on 1699 patients as the safety population, 
Dansin et al. reported grade 3 – 5 hemoptysis in four cases 
(0.2%) only, underscoring the importance of patient selection 
in the improvement of patient safety [32].
The AVAiL data also indicate that the incidence of grade 
≥ 3 hypertension observed in bevacizumab-treated patients 
is likely to be dose-dependent (2%, 6% and 9% for placebo, 
low-dose bevacizumab and high-dose bevacizumab, respec-
tively). Patients with controlled hypertension at baseline 
are eligible for bevacizumab treatment. The incidence of 
bevacizumab-associated grade ≥ 3 hypertension was 2.6% in 
the SAiL study [32].
Although the number of grade ≥ 3 ischemic and venous 
thromboembolic events were not considerably different between 
the bevacizumab-treated patients and the control group in 
the Phase III AVAiL study, caution should be exercised when 
treating patients with a history of thromboembolic events or 
those aged over 65 years. Grade ≥ 3 bevacizumab-associated 
thromboembolic event was found in 2.2% in the SAiL study.
While there was a significantly higher frequency of febrile 
neutropenia in the bevacizumab arm of the Phase III E4599 
trial [16] compared with the control arm, the incidences of 
febrile neutropenia was only modestly higher in the beva-
cizumab arms of the Phase III AVAiL study [19] than in the 
placebo arm.
Higher incidence of proteinuria has been observed during 
bevacizumab treatment with the majority being grade 1. In 
the SAiL study, grade ≥ 3 bevacizumab-associated proteinuria 
was reported in 0.5% [32]. Monitoring of proteinuria by dip-
stick urinalysis is therefore recommended before starting and 
during therapy.
All in all, bevacizumab-based therapy until progression 
has a well-characterized safety profile. This was demonstrated 
in the E4599, the AVAiL and the Phase IV SAiL trials. 
Across all indications, the most frequently observed adverse 
drug reactions in patients receiving bevacizumab were hyper-
tension, fatigue or asthenia, diarrhea and abdominal pain. 
However, based on the results of the above trials with 
advanced NSCLC, hemorrhage (including pulmonary 
hemorrhage/hemoptysis), hypertension and arterial and venous 
thromboembolism, febrile neutropenia and proteinuria are 
the most relevant adverse events. Thus, according to the 
bevacizumab summary of product characteristics, therapy 
should be permanently discontinued in patients who develop 
any of the following symptoms: gastrointestinal perforation, 
grade 4 fistula, grade 4 proteinuria (nephrotic syndrome), 
arterial thromboembolic events, grade 4 pulmonary embolism, 
grade 3/4 bleeding, uncontrollable hypertension, hypertensive 
crisis or hypertensive encephalopathy [33]. However, addi-
tional studies are also in progress to evaluate the safety and 
efficacy of bevacizumab in subjects with squamous NSCLC 
or in patients with intracranial metastases. It is hoped that 
these studies will help to refine the role for bevacizumab 
in NSCLC.
AVF3744g (BRIDGE), an open-label, single-arm, multi-
center pilot study of bevacizumab plus carboplatin and pacli-
taxel in subjects with advanced, previously untreated, squamous 
NSCLC aimed to determine whether delayed bevacizumab 
administration could improve safety in patients with squamous 
cell NSCLC [34]. Patients received two cycles of carboplatin 
and paclitaxel, followed by four cycles of chemotherapy plus 
bevacizumab (15 mg/kg every 3 weeks), and then bevacizumab 
until disease progression. Eligible patients had stage IIIb/IV 
or recurrent squamous NSCLC. The primary end point of this 
study was the incidence of grade 3 or higher pulmonary hem-
orrhage. Altogether, 44 patients were enrolled; 27 patients 
had received at least one dose of bevacizumab. So far, there 
have been three reports of hemorrhage in two patients.
PASSPORT, a Phase II study, has assessed the efficacy and 
safety of bevacizumab combined with first- or second-line 
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systemic therapy in patients with non-squamous NSCLC and 
treated brain metastases [35]. Treatment for brain metastases 
included radiosurgery, neurosurgery or whole brain radiation 
therapy. Eighty-five subjects with treated brain metastases 
received bevacizumab without symptomatic grade > 2 hem-
orrhages observed during the main treatment (pre-progression) 
phase; no additional safety signals were identified.
Based on the safety data from clinical trials as well as the 
global safety database, the EMEA has recently removed a 
restriction in the product label which prevented the use of 
bevacizumab in patients with brain metastases.
2.1.1.2	 IMC-1121B
IMC-1121B (ImClone Systems, Inc.) is a fully humanized 
monoclonal antibody that blocks binding of the VEGF 
ligand to the extracellular domain of VEGFR-2. A Phase II 
study to evaluate the PFS rate at 6 months of IMC-1121B 
administered in combination with paclitaxel and carboplatin as 
first-line therapy for stage IIIb/IV NSCLC is ongoing [36].
2.1.1.3	 IMC-18F1
IMC-18F1 (ImClone Systems, Inc.) is a humanized mono-
clonal antibody against VEGFR-1. A Phase I study of weekly 
IMC-18F1 in patients with advanced and refractory solid 
tumors is ongoing [37].
2.1.1.4	 Aflibercept	(VEGF	trap)
Aflibercept is a recombinantly produced, fully human, soluble 
VEGF receptor fusion protein that scavenges both VEGF and 
placental growth factor removing important ligands for the 
VEGF receptors expressed on tumor endothelium. In a Phase II 
study of aflibercept in advanced NSCLC resistant or refractory 
to platinum-based chemotherapy and erlotinib, patients were 
given 4 mg/kg VEGF-trap every 2 weeks. Two patients (3.7%) 
achieved a PR and 34 (67%) maintained SD for more than 
60 days [38]. A Phase III second-line study (VITAL) of 
aflibercept in combination with docetaxel for advanced 
NSCLC is now recruiting patients [39].
2.1.2 Tyrosine kinase inhibitors with antiangiogenic 
effects
2.1.2.1	 Vandetanib
Vandetanib (Zactima®, ZD6474; AstraZeneca, Macclesfield, 
UK) selectively inhibits the tyrosine kinase activity of both 
VEGFR-2 and EGFR. In a comparative two-part study of 
vandetanib and gefitinib, 168 patients with previously treated 
stage IIIb – IV NSCLC were randomized to receive either 
vandetanib (300 mg p.o. o.d.) or gefitinib (250 mg p.o. o.d.) 
in part A of the study. At disease progression or develop-
ment of unacceptable toxicity, subjects were switched to the 
alternative treatment (part B) after a washout period of 
4 weeks. Response rate was 8% in the vandetanib arm com-
pared with 1% in the gefitinib arm, and a longer PFS time 
for vandetanib followed by gefitinib was observed (Table 2). 
Overall survival, a secondary assessment, was not significantly 
different between patients initially randomly assigned to either 
vandetanib or gefitinib [40].
The efficacy of vandetanib in combination with standard 
chemotherapy regimens compared with chemotherapy alone 
has been investigated in two subsequent randomized trials.
The results of the first, a randomized, placebo-controlled 
study of vandetanib (100 mg/day or 300 mg/day) plus 
docetaxel in 127 patients with NSCLC who have progressed 
after first-line platinum-based chemotherapy, have been pub-
lished (Table 2). The combination of vandetanib and docetaxel 
was generally well tolerated and adverse events manageable, 
with the incidence of vandetanib-associated toxicities increased 
at the higher dose level (diarrhea (grade 3/4), 50%; rash 
(grade 3), 46%; QTc-related events (grade 3/4), 16%) [41].
Another trial investigated vandetanib alone or with paclitaxel 
and carboplatin as first-line treatment for advanced NSCLC 
(Table 2) [42]. With a total of 181 subjects, the primary 
objective was met, with vandetanib + carboplatin-paclitaxel 
significantly prolonging PFS compared with carboplatin-
paclitaxel alone (HR = 0.76; p = 0.098). Given this encouraging 
Phase II data, Phase III studies evaluating vandetanib both 
as monotherapy and in combination regimens for NSCLC 
were started.
The developer of vandetanib also announced results from 
three Phase III studies of vandetanib in combination with 
the chemotherapy agents docetaxel (ZODIAC) and pemetrexed 
(ZEAL) and as monotherapy (ZEST) in relapsed NSCLC 
compared with erlotinib [43].
ZODIAC is a randomized, double-blind, placebo-controlled 
Phase III study evaluating the combination of vandetanib 
100 mg with docetaxel versus docetaxel alone. The study 
enrolled 1391 patients previously treated with one previous 
anticancer therapy for advanced NSCLC.
ZEAL is a randomized, double-blind, placebo-controlled 
Phase III study evaluating the combination of vandetanib 
100 mg with pemetrexed versus pemetrexed alone. The study 
enrolled 534 previously treated, advanced NSCLC patients. 
In both studies the addition of vandetanib to chemotherapy 
prolonged PFS, the primary endpoint, which achieved 
statistical significance in the larger ZODIAC study, but not 
in the smaller ZEAL study. Clinical benefits were seen in 
secondary end points. Both studies showed that adding 
vandetanib to chemotherapy significantly improved overall 
RR. Additionally, positive trends in prolongation of OS were 
seen, although these did not reach statistical significance.
ZEST, a randomized, double-blind Phase III study evaluating 
the efficacy of vandetanib 300 mg versus erlotinib 150 mg, did 
not meet the primary objective of demonstrating a statisti-
cally significant prolongation of PFS for vandetanib. However, 
vandetanib and erlotinib showed equivalent efficacy for PFS 
and OS in a pre-planned noninferiority analysis. The study 
enrolled 1240 patients with locally advanced or metastatic 
NSCLC after failure of at least one previous therapy.
The observed safety profile in these three Phase III studies 
was consistent with previous studies with vandetanib in 
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NSCLC. The most common adverse events associated with 
vandetanib included rash, diarrhea and hypertension.
ZEPHYR is a Phase III, randomized, double-blind, parallel-
group, multicenter study evaluating the efficacy of vandetanib 
300 mg plus best supportive care versus best supportive care 
in patients with locally advanced or metastatic (stage IIIb – IV) 
NSCLC after previous therapy with an EGFR inhibitor. 
The study is running in approximately 170 centers across 
23 countries [43].
Vandetanib is also being tested in the first-line maintenance 
setting. A multicenter, randomized, double-blind, placebo-
controlled Phase II study is comparing vandetanib (300 mg 
daily) plus best supportive care (BSC) to placebo plus BSC 
as maintenance treatment in patients with locally advanced 
or metastatic NSCLC, who have received and responded to 
prevoius platinum-doublet systemic chemotherapy. The primary 
objective of the study is to compare the PFS rate at 3 months 
in locally advanced or metastatic NSCLC patients with or 
without vandetanib maintenance. The study is actively 
recruiting patients [44].
A feasibility and safety study of the addition of vandetanib 
to carboplatin and paclitaxel administered neoadjuvantly in 
stage Ib, II and T3, N1 NSCLC was recently completed. 
Results have not yet been presented [45].
A Phase I/II dose-escalation and safety study of vandetanib 
in combination with irradiation is ongoing. The goal of 
the study is to assess the safety of vandetanib by evaluating the 
frequency, severity and duration of treatment-emergent adverse 
events in patients with poor prognosis lung cancer [46].
2.1.2.2	 Cediranib
Cediranib (Recentin, AZD2171, Astra-Zeneca, Macclesfield, 
UK) is an oral tyrosine kinase inhibitor (TKI) targeting 
VEGFR-1,2, and VEGFR-3. Phase I trials evaluated AZD2171 
with carboplatin and paclitaxel, and also with gemcitabine and 
cisplatin [47,48]. In both studies toxicities were manageable 
and antitumor activity was observed.
BR.24, a Phase II/III, double-blind, randomized trial of 
cediranib at 30 mg versus placebo in patients receiving pacli-
taxel and carboplatin chemotherapy for the first-line treatment 
of advanced or metastatic NSCLC was conducted by the 
National Cancer Institute of Canada Clinical Trials Group 
(NCIC-CTG). All NSCLC histologic subtypes were allowed, 
but patients with a central thoracic lesion with cavitation or 
clinically relevant hemoptysis within the preceding 4 weeks 
were ineligible. The NCIC-CTG has informed the developer 
that the study will not continue into Phase III following the 
planned end of Phase II efficacy and tolerability analysis by 
the study’s Data Safety Monitoring Committee. Although 
evidence of clinical activity was seen, there seemed to be an 
imbalance in toxicity and, therefore, the study was considered 
not to have met the predefined criteria for automatic 
continuation into Phase III [49].
N0528 is a randomized, Phase II, first-line trial run by 
the North Central Cancer Treatment Group investigating 
how the administration of gemcitabine and carboplatin 
together with cediranib works compared with gemcitabine and 
carboplatin without cediranib as first-line therapy in treating 
patients with stage IIIb or stage IV NSCLC [50].
The combination of cediranib with pemetrexed is also 
undergoing Phase II evaluation for relapsed NSCLC [51].
2.1.2.3	 Axitinib
Axitinib (AG-013736, Pfizer, New York, USA) is an oral TKI 
that inhibits all VEGF receptors, PDGFR-β (platelet-derived 
growth factor-β), and c-Kit. Axitinib as monotherapy has been 
evaluated in an open-label, multicenter, Phase II study of 
32 patients (adenocarcinoma histology in 75%) with advanced 
NSCLC (Table 2) [52]. Adverse events were generally man-
ageable, with grade 3/4 toxicities consisting mainly of fatigue 
(22%), diarrhea (6%) and hypertension (6%). Furthermore, 
a randomized, open-label, Phase II study comparing axitinib 
versus bevacizumab in association with carboplatin-paclitaxel 
in chemotherapy-naive patients with advanced, non-squamous 
NSCLC [53] has been recently approved. The enrollment of 
108 patients is expected and the main end point is PFS. 
Axitinib is also being tested in combination with cisplatin 
and gemcitabine in squamous cell lung cancer in a Phase II 
trial [54].
2.1.2.4	 Sorafenib
Sorafenib (Nexavar, BAY43–9006, Bayer Pharmaceuticals 
Corporation, West Haven, CT, USA) is an oral multitargeted 
TKI against B-RAF, C-RAF, VEGFR-2,3, PDGFR-β, and c-Kit. 
Tumor responses were observed in two Phase II trials inves-
tigating sorafenib monotherapy in relapsed advanced disease 
(Table 2) [55,56]. Sorafenib was well tolerated, with rash, diarrhea 
and fatigue as the most commonly cited toxicities.
Three Phase III first-line trials are randomizing patients 
to standard chemotherapy with sorafenib or placebo.
The Phase III ESCAPE study was stopped early after a 
planned interim analysis demonstrated that the trial would 
not meet its primary end point of an improvement in OS. 
In this study, 926 previously untreated NSCLC patients 
were randomized to receive either sorafenib or a placebo in 
combination with carboplatin and paclitaxel. Median OS 
was similar in the two treatment groups. However, in the 
subset of patients with squamous cell histology, there was 
significantly greater mortality in the sorafenib group [57].
The Phase III NEXUS trial is comparing the efficacy of 
gemcitabine, cisplatin and sorafenib to gemcitabine, cisplatin 
and placebo. When the ESCAPE trial was halted, the developer 
approached the data-monitoring committee of the NEXUS 
study and asked to see the results obtained so far, particularly 
for the subset of patients with squamous cell carcinoma. 
Although there was no signal in this subset of patients, the 
committee recommended that squamous cell patients taking 
part in the NEXUS study withdraw and that no further squamous 
cell patients be recruited. The study was formally amended 
and is now is continuing in non-squamous NSCLC [58].
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In a dose-escalation trial, 31 patients received oral 
sorafenib (200 – 400 mg) twice daily with gefitinib (250 mg 
orally) once daily. One patient had PR; 20 patients had SD 
≥ 4 months. Most adverse events were grade 1/2. The most 
frequent grade 3/4 events included diarrhea and elevated 
alanine aminotransferase [59].
Sorafenib is also being tested for recurrent/refractory 
NSCLC in several Phase II trials either in monotherapy or 
in combination with erlotinib. A Phase I/II trial evaluates 
sorafenib with concurrent thoracic radiotherapy for poor 
prognosis NSCLC [60].
2.1.2.5	 Sunitinib
Sunitinib (Sutent, SU11248, Pfizer, New York, USA) is also 
an orally available multitargeted TKI against VEGFR-1,2, 
PDGFR and c-Kit. A randomized Phase II trial (SABRE-L) 
evaluated the safety and efficacy of combining sunitinib with 
bevacizumab + paclitaxel/carboplatin as first-line treatment 
for metastatic non-squamous NSCLC. Treatment in Phase I 
of this three-phase study: bevacizumab (15 mg/kg) + paclitaxel/
carboplatin q3w, +/- sunitinib (25 mg) qd 2 weeks on, 1 week 
off. If tolerated, Phase II would include a patient arm with 
sunitinib at 37.5 mg qd; Phase III would include sunitinib 
at the highest tolerable dose (25 or 37.5 mg qd). Owing to poor 
tolerability, patients were never escalated to 37.5 mg sunitinib 
and the study was closed. At the time of analysis, estimated 
mean treatment duration was 9.5 weeks for the bevacizumab + 
paclitaxel/carboplatin arm and 7.6 weeks for the bevacizumab + 
paclitaxel/carboplatin + sunitinib arm [61].
A Phase II study assessed the clinical activity and safety of 
sunitinib when used as maintenance therapy following stan-
dard first-line chemotherapy in patients with locally advanced 
or metastatic NSCLC (Table 2) [62].
The efficacy and safety of continuous daily sunitinib dosing 
in previously treated advanced NSCLC was evaluated in a 
Phase II trial [63]. Forty-seven patients received oral sunitinib 
37.5 mg/day continuously in 4-week cycles (Table 2). Sunitinib 
was generally well tolerated; most adverse events were grade 1/2 
and included fatigue/asthenia, pain/myalgia, nausea/vomiting, 
diarrhea, dyspnea and stomatitis/mucosal inflammation.
Sunitinib + erlotinib is a new VEGFR-PDGFR-EGFR 
triple inhibition treatment strategy that may confer additive 
or synergistic antitumor effects and increase clinical benefit 
in patients with advanced NSCLC. Under the umbrella of the 
SUN program, two ongoing studies will assess the efficacy 
and tolerability of this combination. Both studies included 
NSCLC patients with 1/2 previous chemotherapy regimens. 
SUN 1058 is a randomized, multicenter, Phase II study 
evaluating the safety/tolerability of sunitinib at 37.5 mg as a 
continuous daily dose (CDD) + erlotinib 150 mg/day versus 
placebo + erlotinib 150 mg/day (4-week cycles); a nonran-
domized lead-in cohort was used to evaluate safety/tolerability. 
SUN 1087 is a randomized, multicenter, pivotal Phase III study: 
956 patients will be randomized to sunitinib 37.5 mg CDD + 
erlotinib 150 mg/day or to placebo + erlotinib 150 mg/day 
(4-week cycles). The primary end point for SUN 1058 and 
SUN 1087 is PFS and OS, respectively; secondary end points 
include OS and PFS, respectively. Both studies will evaluate 
1-year survival, duration of confirmed response, safety and 
patient-reported outcomes. Sunitinib + erlotinib was well 
tolerated in the lead-in cohort of the SUN 1058 study, and 
2/12 patients had durable PR. Enrollment is ongoing in the 
randomized Phase II portion of SUN 1058 and SUN 
1087 [64].
2.1.2.6	 Motesanib
Motesanib diphosphate (AMG706, Amgen, Inc., Thousand 
Oaks, CA, USA) is an orally bioavailable small molecule 
inhibiting VEGFR-1,3, PDGFR and c-Kit. Preliminary results 
indicate that motesanib can be combined safely with paclitaxel/
carboplatin and/or the investigational EGFR-targeted agent, 
panitumumab, in patients with advanced NSCLC. Treatment-
related adverse events were generally mild to moderate in 
severity [65].
A Phase II randomized trial compares the objective tumor 
RR as primary end point between paclitaxel/carboplatin plus 
motesanib and paclitaxel/carboplatin plus bevacizumab in 
subjects with advanced non-squamous NSCLC [66].
A Phase III multicenter, randomized, placebo-controlled, 
double-blind trial of motesanib in combination with paclitaxel 
and carboplatin for advanced NSCLC (MONET1) recruited 
1240 patients. The primary end point was OS. Patients 
were randomized 1:1 to receive paclitaxel and carboplatin 
administered every 3 weeks with or without 125 mg motesanib 
taken daily. In November 2008 an independent data moni-
toring committee (DMC) recommended treatment discon-
tinuation in subjects with squamous histology and enrollment 
suspension in subjects with non-squamous histology. This 
recommendation was based on an observation of higher 
early mortality rates in the motesanib group compared with 
the placebo group and a higher incidence of hemoptysis in 
the squamous population. Patients with non-squamous 
NSCLC receiving motesanib were allowed to continue treat-
ment during the temporary suspension. In February 2009, 
the DMC recommended the trial resume enrollment of 
patients with non-squamous NSCLC following a 3-month 
enrollment suspension [67].
2.1.2.7	 Vatalanib
Vatalanib (PTK787/ZK222584, Novartis International AG, 
Basel, Switzerland) also inhibits VEGFR-1,2,3, PDGFR-β, and 
c-Kit. Clinical evaluation is ongoing in NSCLC in a Phase II 
trial (GOAL) of vatalanib monotherapy at 1250 mg in relapsed 
or refractory NSCLC patients (Table 2) [68,69]. No additional 
study is ongoing with this agent.
2.1.2.8	 Pazopanib
Pazopanib (GW786034, GlaxoSmithKline, Middlesex, UK) 
inhibits VEGFR-1,2,3, PDGFR-α, PDGFR-β and c-Kit. 
Preliminary results of a Phase II trial to evaluate the safety 
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and efficacy of pazopanib as neoadjuvant treatment-naive 
subjects with stage Ia or Ib, resectable NSCLC have been 
recently presented (Table 2) [70]. Before surgery, patients 
received pazopanib 800 mg qd for 2 – 6 weeks followed by 
a 7-day washout period before surgery. The primary end point 
was tumor volume change. Pazopanib treatment was associated 
with reduction of sVEGFR-2. A significant correlation between 
baseline levels of 11 cytokines/angiogenic factors and tumor 
reduction was observed. Multivariate classification analysis 
identified hepatocyte growth factor (HGF) and IL-12 as 
predictive of response in 81% of cases.
The effect of adjuvant pazopanib versus placebo on post-
surgical disease-free survival in patients with stage I NSCLC 
is now being investigated in a Phase II/III trial [71].
A Phase II, nonrandomized, multicenter study to evaluate 
the efficacy and safety of Pazopanib (GW786034) mono-
therapy in patients with advanced stage IIIb/IV NSCLC has 
just finished recruitment [72].
2.1.2.9	 BIBF	1120
BIBF 1120 (Boehringer Ingelheim, Ingelheim, Germany) is 
a potent inhibitor of VEGF, PDGF and FGF receptors. 
Thirty-nine patients with a variety of advanced solid malig-
nancies, including NSCLC, were enrolled in a Phase I study. 
Ten patients had SD. Overall, BIBF 1120 was well tolerated, 
and 400 mg once-daily was defined as the MTD [73].
BIBF 1120 has also been investigated in a randomized 
Phase II trial as second-line or third-line treatment of NSCLC. 
Of 73 treated patients, there were no objective responses but 
SD was observed in 48% (Table 2) [74].
The effect of BIBF 1120 in advanced/recurrent NSCLC 
is being evaluated in two parallel Phase III trials. LUME 
Lung 1 and LUME Lung 2 studies are comparing BIBF 1120 
with placebo in addition to standard second-line docetaxel 
or pemetrexed, respectively [75,76].
2.1.2.10	 ABT-869
ABT-869 (Abbott Laboratories, Abbott Park, IL, USA) is an 
oral and structurally novel multitargeted TKI that potently 
inhibits all members of the VEGF and PDGF receptor fami-
lies. A Phase II study of efficacy and tolerability of ABT-869 
has enrolled 139 NSCLC patients who have received at least 
one line of therapy in the metastatic setting [77].
Another Phase II study evaluating carboplatin/paclitaxel 
in combination with ABT-869 versus carboplatin/paclitaxel 
alone in subjects with advanced or metastatic NSCLC as 
first-line treatment is ongoing [78].
2.1.2.11	 BMS-690514
BMS-690514 (Bristol Myers Squibb, New York, USA) is a 
multitargeted TKI that inhibits all members of the EGF 
and VEGF receptor families. A Phase I study to determine 
the safety, pharmacokinetics and pharmacodynamics of 
BMS-690514 in combination with paclitaxel/carboplatin in 
solid tumors is ongoing [79].
The rationale behind the Phase II randomized trial of 
BMS-690514 versus erlotinib in previously treated NSCLC 
patients [80] is that preclinical studies have demonstrated 
activity of BMS-690514 in erlotinib-resistant NSCLC cell 
lines [81].
2.1.2.12	 OSI-930
OSI-930 (OSI Pharmaceuticals, Melville, NY, USA) is a potent 
oral multitargeted TKI that inhibits c-Kit and kinase insert 
domain receptors. It is now in Phase I clinical trials. Preclinically, 
OSI-930 demonstrated significant antitumor activity as a 
monotherapy in a variety of tumor xenograft models. In 
xenograft models showing initial sensitivity to erlotinib, after 
tumor progression on erlotinib monotherapy, the addition 
of OSI-930 with the continuation of erlotinib treatment 
resulted in significantly delayed tumor growth [82].
A Phase I study was performed to determine the MTD 
and evaluate safety, pharmacokinetics/pharmacodynamics and 
efficacy of OSI-930 with two dosing schedules [83]. Alto-
gether 27 patients have been treated. Common grade 1/2 
toxicities (per patient) were limited to fatigue (7), diarrhea 
(5), nausea (5) and rash, lymphopenia and anorexia (2). 
OSI-930 was well tolerated with promising antitumor activity 
in previously treated patients.
A Phase I dose-escalation study of daily oral OSI-930 and 
erlotinib in patients with advanced and refractory solid tumors 
is ongoing [84].
2.1.2.13	 AEE788
AEE788 (Novartis International AG), a multitargeted TKI, 
inhibits EGFR, HER2 and VEGFR-2. Dual tyrosine kinase 
inhibition with AEE788 in combination with the mTOR 
inhibitor RAD001 of human NSCLC cell-lines resistant to 
gefitinib resulted in effective growth inhibition [85]. AEE788 
has been investigated in Phase I trials including patients 
with NSCLC [86,87]. A Phase I/II, dose-escalation study of 
oral AEE788 on intermittent dosing schedules in patients 
with advanced cancer to assess the safety, pharmacokinetic/
pharmacodynamic profiles and clinical activity of AEE788 
has recently been completed [88].
2.1.2.14	 XL647
XL647 (Exelixis, Inc., South San Francisco, CA, USA) is 
an oral multitargeted TKI with activity against EGFR, 
HER2, EphB4 and VEGFR-2. In Phase I trials, XL647 
has been studied using two different dosing schemes, an 
intermittent schedule with 5 days of treatment every 14 days 
and a continuous schedule [89,90]. In the first reported 
Phase II trial of this agent in an NSCLC patient popula-
tion enriched for likelihood of having an EGFR mutation, 
XL647 seemed to have activity and to be well tolerated. 
The preliminary data from this Phase II trial show a RR of 
29% (10/34) [91].
Recruitment has recently stopped in a Phase II trial in 
which patients with NSCLC who have developed progressive 
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disease after 3 months of previous treatment with erlotinib 
or gefitinib are being treated with continuous XL647 [92].
2.1.2.15	 XL999
XL999 (Exelixis, Inc., South San Francisco, CA, USA) is an 
oral multikinase inhibitor. A Phase II study determined the 
efficacy, safety, and tolerability of XL999 [93]. Eligible patients 
had previously treated, stage IIIb/IV NSCLC (Table 2). Two 
tumor responses and one SD were reported.
2.1.2.16	 CP-547,632
CP-547,632 (Pfizer, New York, USA) is an inhibitor of 
VEGFR-2 and PDGFR. The combination of CP-547,632 
and paclitaxel and carboplatin was assessed in a Phase I/
randomized Phase II study (Table 2) [94]. Patients with 
stage IIIb/IV or recurrent NSCLC receiving first-line 
chemotherapy were treated with oral daily CP-547,632 in 
combination with paclitaxel and carboplatin. Sixty-eight 
patients were treated, 37 in Phase I and 31 in Phase II. 
Dose-limiting toxicity at 250 mg was grade 3 rash and 
grade 3 diarrhea. In Phase I, seven subjects (22.6%) had a 
confirmed PR. In Phase II, four subjects in each arm 
(chemotherapy + CP-547,632: 28.6%; chemotherapy alone: 
25%) had a confirmed PR.
2.1.2.17	 AV-951
AV-951 (Aveo Pharmaceuticals, Cambridge, MA, USA) is a 
new, highly potent and specific inhibitor of VEGF receptors 
1, 2 and 3. Strong activity was observed in a Phase I study 
consisting of 40 patients with advanced solid tumors; AV-951 
was also found to be well tolerated [95]. A Phase Ib and a 
Phase IIa trial will examine the safety, tolerability and MTD 
of AV-951 with a once-daily oral dosing schedule, as well as 
overall RR of AV-951 administration in NSCLC [96].
2.1.3 Thalidomide and its analogs
2.1.3.1	 Thalidomide
Thalidomide (Celgene, Summit, NJ, USA) is thought to exert 
antiangiogenesis activity partially by antagonizing basic 
fibroblast growth factor (bFGF)-induced angiogenesis [97]. 
Phase II studies of thalidomide in patients with advanced 
NSCLC have shown promising activity (Table 2) [98,99]. Several 
ongoing trials are examining the potential role of thalido-
mide in the treatment of advanced NSCLC. A Phase II 
trial will determine the RR of 37 patients with stage III 
or IV NSCLC treated with second-line docetaxel and thali-
domide [100]; another Phase II trial will determine the RR of 
21 patients with stage II or IIIa NSCLC receiving neoad-
juvant carboplatin, gemcitabine and thalidomide [101]. 
Recruitment has stopped for both studies; final data 
collection is in progress.
A Phase III study to evaluate the survival and TTP of 
patients with stage III NSCLC when treated with carboplatin-
paclitaxel and radiotherapy with or without thalidomide is 
ongoing (ECOG3598) [102].
2.1.3.2	 Lenalidomide
Lenalidomide (Revlimid, CC-5013, Celgene; Summit, NJ, 
USA) is a thalidomide analog. A Phase I study that investi-
gated lenalidomide monotherapy in 55 pretreated patients 
with advanced solid tumors demonstrated three radiologic 
responses. The drug was well tolerated, although grade 3 or 
4 neutropenia was observed in four patients [103]. A Phase II 
study to evaluate lenalidomide monotherapy in 40 patients 
with recurrent NSCLC has been completed [104]. The final 
results have not yet been published.
2.1.4 Matrix metalloproteinase inhibitors
2.1.4.1	 BMS-275291
BMS-275291 (Bristol Myers Squibb, New York, USA) is a new 
broad-spectrum sulfhydryl-based second-generation matrix 
metalloproteinase (MMP) inhibitor rationally designed to 
spare a class of closely related metalloproteinases known as 
sheddases. The interim analysis of a large, randomized, 
Phase III study of the MMP inhibitor, BMS-275291 con-
ducted in advanced lung cancer in 774 patients demonstrated 
no survival benefit from addition of this MMP inhibitor to 
chemotherapy with carboplatin and paclitaxel (Table 2) [105]. 
Moreover, the combination of the MMPI with chemotherapy 
caused an increased toxicity in the experimental arm, and 
study treatment was stopped.
2.1.5 Other antiangiogenic agents
2.1.5.1	 Cilengitide
Cilengitide (EMD 121974, Merck, Darmstadt, Germany) 
binds to and inhibits the activities of the αvβ3 and αvβ5 
integrins, thereby inhibiting endothelial cell–cell interactions, 
endothelial cell-matrix interactions and angiogenesis. After 
Phase I studies proved the tolerability of cilengitide [106,107], 
a randomized Phase II study with a safety run-in part was 
started to investigate cilengitide in combination with cetuximab 
and platinum-based chemotherapy compared with cetuximab 
and platinum-based chemotherapy alone as first-line treatment 
for patients with advanced NSCLC (CERTO) [108].
2.1.5.2	 Volociximab	(M200)
Volociximab (M200, PDL Biopharma, Incline Village, NV, 
USA) is a chimeric monoclonal antibody jointly developed by 
PDL BioPharma and Biogen Idec for treatment of a variety 
of advanced solid tumors. It binds to and inhibits the func-
tional activity of α5β1 integrin. The results of a Phase I, 
pharmacokinetic, and biological correlative study of volocix-
imab have recently been published [109]. Twenty-one patients 
with advanced solid malignancies, including one NSCLC 
patient, were treated with escalating doses of volociximab. 
Treatment was well tolerated, and dose-limiting toxicity was 
not identified over the range examined. One minor response 
(renal, 7 months) and one durable SD (melanoma, 14 months) 
were reported.
Two Phase Ib studies investigating the effect of volociximab 
in combination with carboplatin and paclitaxel [110], and 
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carboplatin, paclitaxel and bevacizumab [111] in previously 
untreated advanced (stage IIIb/IV) NSCLC patients are 
now recruiting.
The effect of dual inhibition with volociximab and erlotinib 
in advanced refractory NSCLC is also being evaluated in a 
Phase II study [112].
2.1.5.3	 TNP-470
TNP-470 (Takeda Chemical Industries Ltd, Osaka, Japan) 
blocks angiogenesis by inhibiting methionine aminopeptidase, 
an enzyme critical for endothelial cell proliferation. The 
combination of TNP-470 administered at 60 mg/m2 three 
times a week and paclitaxel 225 mg/m2 administered every 
3 weeks was defined as both the MTD and the optimal dose 
in a Phase I study involving 32 patients with solid tumors, 
including 16 NSCLC [113]. TNP-470, at present, is not going 
forward in development.
2.1.5.4	 AMG	386
AMG-386 (Amgen, Inc.) is an intravenously administered 
recombinant Fc-peptide fusion protein (peptibody) that 
inhibits angiogenesis by preventing interaction between angio-
poietins and Tie2 receptors. The safety and pharmacokinetics 
of AMG 386 either in monotherapy [114] or in combination 
with paclitaxel [115] in advanced solid tumors were examined 
in two Phase I trials. The treatments were well tolerated. 
Efficacy data are limited. Phase I and II studies are ongoing 
with solid tumors other than NSCLC.
2.2	 Vascular	disrupting	agents	(VDAs)
Targeting of VEGF has been shown to result in apoptosis 
only in newly formed, immature tumor vessels and in the 
developing vasculature of the neonatal mouse, but not in the 
tumor vessels of adult mice or in quiescent tumor vascular 
networks [116]. Vascular targeting therapy recognizes that clini-
cal diagnosis of cancer commonly occurs when the tumor 
tissue has already established its vasculature. VDAs specifically 
target pre-existing tumor capillaries, resulting in rapid cancer 
tissue ischemia and secondary tumor cell death in the central 
regions of tumors, although they leave the perfusion in 
peripheral tumor regions relatively intact. The two major 
categories of VDA that are in clinical development are the 
small-molecule VDAs and ligand-directed VDAs [117]. While 
small-molecule VDAs achieve selective occlusion of tumor 
vessels by exploiting phenotypic differences between tumor 
and host tissue ECs (i.e., increased reliance on the tubulin 
cytoskeleton to maintain cell shape and accelerated prolifera-
tion), ligand-directed VDAs use toxins and pro-coagulant 
agents coupled to peptides or antibodies that selectively bind 
to the endothelial tube. Although animal studies with ligand-
directed VDAs have certainly been elegant, and, furthermore, 
several potential target molecules exist that are upregulated 
on tumor versus host tissue capillaries, testing of ligand-based 
agents are still in the preclinical phase. For that reason, and 
because they are at a much more advanced stage of clinical 
development, only representatives of small molecule VDAs 
are discussed here.
2.2.1 DMXAA (5,6 dimethylxanthenone-4-acetic acid)
The combination of DMXAA (AS1404 or ASA404, Antisoma, 
London, UK) with carboplatin and paclitaxel was evaluated 
in a Phase II trial in previously untreated IIIb or IV NSCLC 
(Table 2) [118]. Safety profiles were similar and manageable 
in both groups, with most adverse effects attributed to 
standard therapy.
Two large Phase III trials are ongoing to investigate ASA404 
in the treatment of NSCLC. ATTRACT-1 evaluates ASA404 
in combination with paclitaxel and carboplatin as first-line 
treatment [119], whereas ATTRACT-2 compares ASA404 
with placebo in combination with docetaxel in the second-line 
treatment of patients with stage IIIb/IV NSCLC [120].
2.2.2 Zybrestat
Zybrestat (CA4P, Combretastatin A4 Phosphate, Oxigene, 
Inc., Waltham, MA, USA) is a phosphate prodrug of the 
tubulin-binding agent combrestatin A4. Because the CA4P-
bevacizumab combination has appeared safe, resulted in 
significantly decreased tumor blood-flows and shown clinical 
activity without simultaneous chemotherapy, the developer 
initiated a controlled Phase II study to assess the safety and 
efficacy of the combination of carboplatin, paclitaxel and 
bevacizumab ± CA4P in chemotherapy-naive, stage IIIb/IV 
non-squamous NSCLC histology. Patients who complete the 
first six cycles of therapy and have not experienced disease 
progression will receive maintenance therapy with bevacizumab 
alone or with bevacizumab plus CA4P [121].
2.2.3 NPI-2358
NPI-2358 is a synthetic analog of diketopiperazine phenyla-
histin (halimide), a natural product that was isolated from a 
marine and a terrestrial fungus Aspergillus sp. Dose escalation 
of NPI-2358 was conducted in a Phase I trial that enrolled 
patients with advanced solid tumors and lymphomas [122]. 
Twenty-five subjects were enrolled. A recommended Phase II 
dose of 30 mg/m2 was selected based on toxicities of nausea, 
vomiting, fatigue, fever, tumor pain and transient elevations 
in blood pressure.
A Phase I/II study of NPI-2358 in combination with 
docetaxel in patients with advanced NSCLC that has 
progressed after treatment with at least one chemotherapy 
regimen is ongoing [123].
2.2.4 ABT-751
ABT-751 (Abbott Laboratories, Abbott Park, IL, USA) is an 
orally bioavailable antimitotic sulfonamide. ABT-751 binds to 
the colchicine-binding site on beta-tubulin and inhibits the 
polymerization of microtubules. There have been three pub-
lished Phase I trials of ABT-751 in patients with hematological 
malignancies and in adult and pediatric solid tumors [124-126]. 
In advanced NSCLC, a Phase I/II trial is evaluating ABT-751 
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in combination with pemetrexed. The recruitment period for 
this study has been closed [127]. Another Phase I/II study eval-
uating the safety and efficacy of ABT-751 in combination with 
docetaxel versus docetaxel alone in advanced NSCLC has been 
terminated [128]. A Phase II study of ABT-751 in patients with 
NSCLC refractory to taxane regimens has been completed, 
but the results have not yet been released [129].
3.	 Potential	biomarkers	for	monitoring	
antivascular	therapy	in	NSCLC
Tumor response to antivascular treatments is frequently asso-
ciated with cavitation rather than shrinkage. Antivascular ther-
apy represents an exciting advance in the management of 
NSCLC, although even massive cavitation in the absence of 
shrinkage may not be defined as a response using the Response 
Evaluation Criteria in Solid Tumors [130]. Therefore, there is 
an urgent need in this field to identify patients responsive to 
these therapies, to predict the efficacy of combinations that 
include antivascular drugs and, moreover, to identify 
biomarkers that can help recognize tumor resistance.
Some of the most promising biomarkers for antivascular 
treatments are the circulating populations of endothelial pro-
genitor cells (EPCs) and mature, desquamated ECs (circulating 
endothelial cells; CECs) [131]. Accordingly, the clinical value 
of peripheral blood EPC and CEC measurements is being 
studied in many ongoing clinical trials, including those 
investigating patients with NSCLC [132-134].
Although the use of cytokines as biomarkers of angiogenesis 
can be complicated by the release of angiogenic growth factors 
from platelets, there are also several studies of angiogenic 
molecules as surrogate markers of response to antivascular 
treatments in solid malignancies, including NSCLC [135,136]. 
However, the practical utility of using changes induced by 
antivascular agents in circulating EPC, CEC or angiogenic 
cytokine levels as diagnostic or surrogate biomarkers remains to 
be confirmed, and their use might be confounded by cytokine 
concentration and circulating EPC/CEC level changes 
associated with tumor resistance or progression [137].
Measuring the efficacy of antivascular therapy could also 
be achieved by imaging the tumor capillaries themselves 
(i.e., direct imaging by agents targeted at cytokines or receptors 
involved in tumor vascularization) or investigating the result 
of such treatments on the anatomic features and the blood 
supply of tumors (indirect imaging). Although the impact of 
vascular imaging techniques on decisions during anticancer 
drug development is still modest, their clinical value is under 
investigation in many ongoing clinical studies, and angiogen-
esis imaging will certainly play a key role in shaping the next 
decade’s cancer management [138].
In brief, because antivascular treatments are developing at 
a rapid pace, there is an urgent need to identify reliable 
biomarkers for the efficacy of these therapies. Even though 
some pieces of the puzzle are already in place, monitoring 
techniques should be explored further to understand fully 
their possible implications in solid tumors, as well as in 
NSCLC. At present, the optimal technique for evaluating the 
effects of antivascular treatments in cancer patients remains 
a matter of active discussion among experts.
4.	 Expert	opinion
Agents that target tumor capillaries, in particular bevacizumab, 
a humanized anti-VEGF monoclonal antibody, have become 
an important option for many patients with NSCLC and have 
opened a clear path for further research on the role of antivas-
cular drugs in NSCLC. However, clinical experience in this 
field is still limited and several questions remain unanswered. 
Most important are the problems in elucidating the optimal 
biologic dose as well as the best possible combination treat-
ment strategy of these agents in the setting of chemoradio-
therapy. Furthermore, routine assessment of tumor response 
may be inadequate for antivascular agents. Tumor shrinkages 
characterized by cavitation have been observed and these do 
not meet the usual standard radiologic criteria for response. An 
additional relevant clinical challenge is, therefore, to find the 
best techniques for monitoring the effects of antivascular drugs. 
In line with that, efforts have been made to assess angiogenesis 
during antivascular treatments and to identify patients respon-
sive to these therapies, recognize tumor resistance and predict the 
efficacy of antivascular agents. In fact, identifying biomarkers 
for individualized antivascular strategies may not only improve 
efficacy, but through better patient selection, could also decrease 
the unnecessary use of these expensive agents and result in 
improvements in the cost-effectiveness of these agents.
Hypertension is the most frequent adverse event reported with 
the antivascular agents, although it is usually reversible with 
a standard management algorithm. However, because the long-
term side effects of antivascular agents are not known, establishing 
their toxicity profile over the long term remains essential.
In summary, although antivascular drugs have changed 
the landscape of the clinical management of NSCLC and 
the results of ongoing studies are eagerly awaited, additional 
studies are required to define the precise and optimal role of 
these agents in the NSCLC treatment paradigm.
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Abstract
Vascularization, a hallmark of tumorigenesis, is classically thought to occur exclusively through angiogenesis (i.e. endothelial sprouting).
However, there is a growing body of evidence that endothelial progenitor cells (EPCs) and proangiogenic hematopoietic cells (HCs) are able to
support the vascularization of tumors and may therefore play a synergistic role with angiogenesis. An additional cell type being studied in the
field of tumor vascularization is the circulating endothelial cell (CEC), whose presence in elevated numbers reflects vascular injury. Levels of
EPCs and CECs are reported to correlate with tumor stage and have been evaluated as biomarkers of the efficacy of anticancer/antiangiogenic
treatments. Furthermore, because EPCs and subtypes of proangiogenic HCs are actively participating in capillary growth, these cells are
attractive potential vehicles for delivering therapeutic molecules. The current paper provides an update on the biology of CECs, EPCs and
proangiogenic HCs, and explores the utility of these cell populations for clinical oncology.
© 2008 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
It has been over 30 years since Judah Folkman hypoth-
esized that neovasculature plays a significant role in tumor
progression and might well be an optimal target for anti-
cancer strategies [1]. Subsequent research has led to the
identification of several regulators of angiogenesis, some
of which represent therapeutic targets. However, it is also
well established now that tumor vasculature does not neces-
sarily derive from endothelial cell (EC) sprouting; instead,
tumors can acquire their vasculature by various mechanisms
including postnatal vasculogenesis, a process during which
circulating bone marrow (BM)-derived endothelial progen-
itor cells (EPCs) home to sites of neovascularization and
differentiate into ECs [2]. EPCs therefore resemble embry-
onic angioblasts, which are anchorage-independent cells
having the capacity to proliferate, migrate and differentiate
into mature ECs. Since the first description of EPCs by Asa-
hara et al. [3], several authors have found decreased numbers
and/or impaired function of EPCs in a variety of cardio-
vascular diseases. In contrast, blood levels of EPCs tend to
increase in cancer patients and to correlate with the stage of
the malignant disease [4].
Infiltration of human tumors by certain types of leuko-
cytes, like lymphocytes and dendritic cells (DCs) is often
associated with better prognosis and overall survival. How-
ever, other leukocyte subsets such as macrophages can
enhance tumor angiogenesis and progression [5]. Moreover,
several studies on experimental tumor models have been pub-
lished suggesting that even before the onset of the so called
“angiogenic switch” [6], various types of hematopoietic cells
(HCs) are recruited to the tumor tissue to enhance new blood
vessel formation by secreting angiogenic molecules and/or
by trans-differentiation into endothelial-like cells [7]. These
observations have led to the concept that certain populations
of HCs are proangiogenic and co-mobilized from the BM
with EPCs [8].
Another related cell type is the circulating endothelial cell
(CEC). These cells are thought to be mature ECs that have
detached from their basement membrane in response to some
form of blood vessel injury. Accordingly, increased num-
bers of CECs, rare in healthy individuals, are observed in
a broad range of conditions/diseases associated with vascu-
lar perturbation, including tumor-induced neovascularization
[9]. Therefore, although their biology is still obscure, there is
a growing belief that together with EPCs, CECs may evolve
into a surrogate biomarker for monitoring tumor angiogenesis
and the efficacy of anticancer/antiangiogenic therapies.
This review starts with a summary on the phenotype, enu-
meration strategies and clinical significance of CECs. We
then discuss the characterization of EPCs and proangiogenic
HCs, as well as the molecules that regulate their release from
the BM and their homing to or incorporation into neovas-
cular networks. Finally, we review the potential therapeutic
and diagnostic implications of EPCs and HCs in medical
oncology.
2. Circulating endothelial cells
Although CECs were first described over 30 years
ago through methods such as vital light microscopy,
May–Grünwald–Giemsa staining and separation by Ficoll
density centrifugation [10,11], the development of specific
monoclonal antibodies has only recently provided an oppor-
tunity to investigate the pathophysiology of these cells. In
1991, monoclonal antibodies to two novel EC specific sur-
face antigens (HEC19 [12] and S-Endo-1 [13], later described
as CD146 [14]) were developed and used to quantify CECs.
More recently, these authors and others have used the
immunobead technique and/or flow cytometry to investigate
the significance of CECs in a variety of diseases including
infections, cardiovascular, inflammatory and autoimmune
syndromes and cancer (reviewed in ref. [9]).
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2.1. Characterization and enumeration of circulating
endothelial cells
In practice, the main problem in clinical studies with the
quantification of CECs is their low frequency in the peripheral
blood (PB). To quantify these rare cells, different tech-
niques of cell enrichment together with immunocytochemical
detection have been applied, such as density centrifugation
methods, cell culture and immunomagnetic separation (IMS).
The latter technique, developed by George et al., includes
mixing PB with immunomagnetic beads coated with anti-
CD146 antibodies, which then bind to CD146-expressing
CECs and are selected by magnet retrieval [15]. However,
although it is most frequently used for CEC enumeration,
CD146 expression has also been reported in pericytes, bone
marrow fibroblasts, cancer cells, trophoblasts, and activated
lymphocytes; thus, caution in interpreting results with CD146
alone is advised [16,17]. Nevertheless, unspecific CD146
expression should not necessarily considered as a techni-
cal limitation in the detection of CECs, since CD146-based
IMS has been adapted to cope with it. IMS is best accom-
panied by an additional specific characterization step, such
as Ulex Europaeus lectin-1 (UEA-1), CD31 or von Wille-
brand factor (vWf) labeling to confirm that all sorted cells
are CECs. This methodology has been used successfully in a
large number of studies showing altered CEC levels in vari-
ous diseases. Accordingly, the authors of a recent multicentric
study defined CECs as cells that exceed 10m in size and
have more than five immunomagnetic beads attached. The
rosetted cells stain positive with at least two EC markers (for
example, CD146 and UEA-1) and are negative for leukocyte
markers (for example, CD14 and CD45, Table 1) [18].
A widespread alternative to the IMS technique is flow
cytometry, during which whole PB is usually labeled with
endothelial-specific antibodies conjugated with different
fluorochromes. An advantage of flow cytometry is rapid
multiparametric analysis and the ability to detect sub-
populations, such as “bright” versus “dim” labeling, and
activated (e.g. expressing CD106) or resting, although CECs
separated by the IMS method can also be multiply labeled.
For example, Duda et al. recently reported a cytometry proto-
col for phenotypic identification and quantification of CECs
in human PB. Using four surface markers (CD31, CD34,
CD133 and CD45) and multicolor flow cytometry, their group
has proposed a surface phenotype of viable CECs (defined
as CD31brightCD34+CD45−CD133− cells) [19]. However,
there are substantial differences between IMS and flow cyto-
metric techniques, as indicated by the high variation in
reported CEC numbers. On the basis of CD31bright/CD45−
staining, the amount of cells recorded per milliliter of PB
is about 1000- to 100,000-fold higher than the number of
CECs reported in healthy controls and in different categories
of patients using CD146-based IMS. The recent results of
Strijbos et al. [20] may, in part, explain the significantly
higher CD146+ CEC levels as reported using the single-
platform flow cytometric assay and those determined by
CD146-based IMS techniques. In their study, these authors
focused on confirming the widely used single-platform flow
cytometric assay for CECs, as per the method of Man-
cuso et al. [21], using their previously reported CEC profile
[forward scatter (FSC)low-to-intermediate, side scatter (SSC)low,
CD31bright/CD146+/CD45−]. Interestingly, by using reverse
transcription polymerase chain reaction, electron microscopy
and fluorescence in situ hybridization (FISH), Strijbos et al.
demonstrated that cells with the above phenotype are in fact
not CECs but large platelets [20].
In light of these results, CEC enumeration is far from being
a standardized procedure and the confusion in CEC num-
bers does raise serious questions concerning the reliability of
the above techniques. Because there are no studies currently
available demonstrating the superiority of one technique over
the other, more research is required to measure/correlate the
accuracy of the above methods.
2.2. Circulating endothelial cells in human
malignancies (Table 2)
Elevated levels of CECs have been repeatedly found in
different types of human malignancies. This observation first
appeared in the literature in 2001 when Mancuso et al.,
using 4-color flow cytometry, found that in breast cancer and
lymphoma patients, both resting and activated CECs were
increased significantly [21]. In addition, CEC levels were
similar to healthy controls in lymphoma patients achieving
complete remission after chemotherapy, and activated CECs
were found to decrease in breast cancer patients evaluated
after surgery. Although they employed different methods of
assessing CEC levels and disease stage, Beerepoot et al. also
reported a significant CEC elevation in cancer patients with
progressive disease, whereas their patients with stable disease
had CEC levels comparable to those of healthy individuals
[22].
Subsequent studies yielded similar results. Zhang et
al. investigated CECs in multiple myeloma, demonstrating
increased numbers of these cells (P < 0.001 vs. healthy con-
trols) [23]. Wierzbowska et al. evaluated CEC levels by
4-color flow cytometry in acute myeloid leukemia (AML) and
reported elevated numbers of both resting and activated CECs
[24]. In their study, CEC levels were correlated with disease
status and response to treatment as well. In another study
on breast cancer, CECs were found to be significantly ele-
vated in cancer patients and decreased during chemotherapy
[25]. More recently, Rowand et al. observed that CEC counts
were significantly higher in metastatic carcinoma patients
compared to healthy controls [26]. Similarly, increased CEC
levels have been reported in the PB of patients with gastroin-
testinal stromal tumor (GIST) [27], myelodysplastic syn-
drome [28] and chronic lymphocytic leukemia (CLL) [29].
Taken together, it is apparent that CECs are increased in
patients with different types of malignancies. Furthermore,
there is a growing body of evidence that this cell population
may evolve into a surrogate biomarker for measuring the
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Table 1
CECs, EPCs and proangiogenic HCs in cancer
Cell type Source Morphology/phenotype/molecular
profile
Role/significance in
tumor vascularization
Proliferative potential Ref.
CEC Blood vessel wall Mature circulating
cells < 50m in diameter;
CD146, CD31, CD34, vWf,
VE-cadherin, UEA-1, acLDL
Biomarker of endothelial
injury, angiogenesis
and/or the efficacy of
anticancer
(antiangiogenic) therapy
No [16–19]
EPC BM Immature circulating cells
∼20m in diameter; CD133,
CD34, VEGFR2, CD38,
c-kit, CD31, CXCR4
Support of tumor
vascularization/biomarker
of endothelial injury,
angiogenesis and/or the
efficacy of anticancer
(antiangiogenic)
therapy/vehicle for drug
delivery
Yes [33,43]
CFU-EC Culture PBMNCs growing in
colonies for ∼7 days
Support of tumor
vascularization/biomarker
of endothelial injury,
angiogenesis and/or the
efficacy of anticancer
(antiangiogenic)
therapy/vehicle for drug
delivery
Yes [39]
CAC Culture PBMNCs growing in the
presence of angiogenic
cytokines for ∼4–6 days
Support of tumor
vascularization/biomarker
of endothelial injury,
angiogenesis and/or the
efficacy of anticancer
(antiangiogenic)
therapy/vehicle for drug
delivery
Yes [40]
ECFC Culture PBMNCs growing in
cobblestone patterned
colonies for ∼21 days
Support of tumor
vascularization/biomarker
of endothelial injury,
angiogenesis and/or the
efficacy of anticancer
(antiangiogenic)
therapy/vehicle for drug
delivery
Yes [42]
TEM BM CD11b, CD45, TIE2 Support of tumor
vascularization
Yes [68]
DC BM
MHC II+/CD11c+
conventional/myeloid DCs
Support of tumor
vascularization
[119]
CD123+/CD303+
plasmacytoid DCs
Support of tumor
vascularization
[119]
CD11c+/CCR6+/MHC II+
TADCs
Support of tumor
vascularization
Yes [120,121]
MDSC BM CD11b, Gr-1 Support of tumor
vascularization
Yes [100,106]
TASC BM CD45, VEGFR2 Support of tumor
vascularization
Yes [122]
RBCC BM CD45, CD11b, CXCR4,
VEGFR1
Support of tumor
vascularization
Yes [123]
VEGFR1+ HC BM VEGFR1, VLA-4 Support of tumor
vascularization/initiation
of the pre-metastatic
niche
Yes [124]
BM, bone marrow; CAC, circulating angiogenic cell; CEC, circulating endothelial cell; CFU-EC, colony-forming unit-endothelial cells; DC, dendritic cell;
ECFC, endothelial colony-forming cell; EPC, endothelial progenitor cell; MDSC, myeloid-derived suppressor cells; PBMNC, peripheral blood mononuclear
cell; RBCC, recruited blood circulating cell; TADC, tumor-associated dendritic cell; TASC, tumor-associated stromal cell; TEM, TIE2-expressing monocyte;
VEGFR1, vascular endothelial growth factor receptor-1.
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Table 2
Levels of CECs and EPCs in patients with malignant diseases
Tumor type Number
of cases
Enumeration Phenotype Mean CEC levels (patients
vs. controls, n/mL of PB)
Mean EPC levels (patients vs.
controls, n/mL of PB)
Ref.
CEC EPC
Breast cancer, lymphoma 76 FC CD45−/CD146+/CD31+/CD34+ CD45−/CD31+/CD133+ 39,100 vs. 7900 Below 500 both in patients
and controls
[2]
Variousa 95 CD146-IMS CD146+/CD31+/vWF+/VEGFR2+ NA 438 vs. 121b NA [22]
Multiple myeloma 31 FC + culture CD34+/CD146+/CD105+/CD11b− CFU-ECs CFU score ∼6-fold higher in
patientsc
NA [23]
AML 48 FC CD45−/CD31+/CD34+CD146+ CD45−/CD31+/CD34+CD133+ 36,700 vs. 3200 700 vs. 100 [24]
Myelofibrosis 110 FC NA CD133+/CD34+/VEGFR2+ NA 165 vs. 0 [88]
CLL 20 FC CD45−/CD31+/CD146+ NA 26.5 vs. 18.5 NA [29]
MDS 128 FC CD45−/CD34+/CD146+/CD133− NA 512 vs. 153 NA [28]
Breast cancer 16 FC CD45−/CD146+/CD31+/CD34+ CD34+/VEGFR2+ 5700 vs. 1300 370 vs. 140 [25]
Breast cancer 47 FC NA CD34+/VEGFR2+ NA 0.44 vs. 0.18d [84]
Breast cancer 25 FC NA CD133+/VEGFR2+ NA 0.032 vs. 0.023d,e [85]
Gastric/breast cancer 71 Culture NA CFU-ECs NA 40.2 vs. 37.6 (n.s.)f [155]
Lung cancer 53 FC NA CD34+/VEGFR2+ NA 1162 vs. 345 [80]
Lung cancer 10 FC CD34-IMS
Cytospin
NA CD45−/CD34+/VEGFR2+ and
CD45−/CD133+/VEGFR2+
NA 90 vs. 42 and 0.3 vs. 0.1g [83]
Liver cancer 80 Culture NA CFU-ECs NA CFU score 10-fold higher in
patients
[46]
Liver cancer 64 Culture NA CFU-ECs NA CFU score ∼2-fold higher in
patients
[79]
Glioma 32 FC CD34+/CD146+/VEGFR2− CD133+/CD34+/VEGFR2+ n.s. 0.18 vs. 0.01d [89]
Varioush 206 IMS CD45−/CD146+/CD105+ NA 111 vs. 21 NA [26]
Variousi 44 FC CD45−/CD34+/CD133−/CD105− CD45−/CD34+/CD133+/CD105− 470 vs. 140 (n.s.) 90 vs. 30 (n.s.) [154]
GIST 16 FC CD45−/CD31+/P1H12+/CD133− NA 1090 vs. 540 NA [27]
CEC, circulating endothelial cell; CLL, chronic lymphocytic leukemia; CFU-ECs, colony-forming unit-endothelial cells; EPC, endothelial progenitor cell; FC, flow cytometry; GIST, gastrointestinal stromal
tumor; IMS, immunomagnetic separation; MDS, myelodysplastic syndrome; n.s., non-significant; PB, peripheral blood.
a Different cancer patients with progressive disease. Tumor types included head and neck (10 patients), colon (13 patients), prostate (25 patients), gastric (3 patients), esophagus (3 patients), renal cell (6
patients), breast (10 patients), ovarian (5 patients), cervical cancer (2 patients), carcinoid (3 patients), melanoma (3 patients), glioma (2 patients), and 10 patients with other tumor types.
b Patients with stable disease had CEC numbers equal to that circulating in healthy subjects (P = 0.69).
c Raw data not supplied.
d % of PB mononuclear cells.
e Stage III vs. stage IV patients.
f Stated per unit area (mm2).
g % of CD34 enriched cells.
h 50 cases of breast cancer, 49 of colorectal cancer, 35 of lung cancer, 48 of prostate cancer, and a group of other carcinomas consisting of 8 ovarian/pancreatic, 3 renal, 2 bladder, 2 thyroid, 2 gastric, and 1
breast/colon, colon/prostate, esophageal, gastric, carcinoid tumor, squamous cell, tongue, and mandibular cancer.
i Patients with different refractory solid malignancies pretreated with chemotherapy. Details of the patient population not supplied.
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effectiveness of conventional and targeted (antiangiogenic)
anticancer therapy. What is less clear is whether or not CECs
are simply biomarkers of the accelerated endothelial turnover
of tumor capillaries, or are active participants of tumor pro-
gression and vascularization. However, it is also possible that
CECs are not being desquamated from activated tumor vas-
culature. Instead, their increased number in the PB may be
the result of a more generalized systemic (i.e. paraneoplastic)
endothelial damage and/or activation.
3. Endothelial progenitor cells
3.1. Characterization and enumeration of endothelial
progenitor cells
EPCs were discovered and identified in 1997 by Asahara
et al. [3] on the basis of vascular endothelial growth fac-
tor receptor-2 (VEGFR2) and CD34 co-expression. Since
then, the emergence of specific membrane markers and
molecular probes has facilitated the identification and purifi-
cation of functional stem and progenitor cells. A number of
researchers have set out to better characterize these cells,
and EPCs were subsequently shown to express fibroblast
growth factor receptor (FGFR), CD38, c-kit, CD31, CXCR4,
vWf, vascular endothelial cadherin (VE-cadherin), Tie-
2/TEK (angiopoietin-1 receptor precursor or tunica intima
EC kinase) and CD133 [30–33]. However, it is still extremely
difficult to differentiate EPCs from HCs or CECs, since the
markers used to separate EPCs are expressed on subsets of
HCs (CD34, VEGFR2, CD133, VE-cadherin) and mature
ECs/CECs (CD34, VE-cadherin) as well. In fact, the pop-
ulation of EPCs may include a group of cells existing in a
variety of stages ranging from immature HSCs to completely
differentiated ECs.
Although to date no clear phenotype of EPCs exists and
their putative precursors and the exact differentiation lineage
remain to be determined, at present it is widely accepted that
early EPCs (localized in the BM or immediately after migra-
tion into the bloodstream) are CD133+/CD34+/VEGFR2+
cells, whereas circulating EPCs are positive for CD34 and
VEGFR2, lose CD133 and begin to express membrane
molecules typical to mature ECs [2]. Thus, the major can-
didate for a specific circulating EPC marker is the CD133,
an orphan receptor specifically expressed on early EPCs, but
whose expression is lost once these progenitors differenti-
ate into mature ECs [34]. Unfortunately, because in humans
CD133 is expressed by HSCs as well [35], the techniques for
phenotypic differentiation between vasculogenic-restricted
immature EPCs, committed HSCs and their putative com-
mon precursor (bi-potential hemangioblast) have yet to be
developed further.
Results on PB EPC levels in the bloodstream are vari-
able, ranging from 70 to 210 cells/mL of PB [36] to
3000–5000 cells/mL of PB [37], depending most likely on
the isolation technique used. These relatively low numbers
of circulating EPCs as measured by flow cytometry are in
sharp contrast to the high numbers of adherent cells (often
confusingly defined as “EPCs” too) that are observed in PB
mononuclear cell cultures (∼105 from 1 mL blood) (Table 1).
In general, three different methods for culturing “EPCs” have
been reported [38]. In the original approach, in which the
identification of EPCs is based on their clonogenic and pro-
liferative potential, PB mononuclear cells (MNCs) are plated
on fibronectin-, gelatin- or collagen-coated dishes. Discrete
colonies appear in a week, containing round cells centrally
and spindle-shaped cells peripherally. The cells of these
colonies are usually referred to as colony-forming unit-ECs
(CFU-ECs) [39]. In the second method, MNC cultures are
treated with angiogenic cytokines for 4–6 days, whereupon
non-adherent cells are discarded, resulting in a target adherent
cell population [40]. Because these adherent cells have been
reported to enhance angiogenesis in vivo [41], they have been
defined as circulating angiogenic cells (CACs). Although
CACs do not form colonies and are observed in cultures
in larger numbers than CFU-ECs, they express endothelial
markers such as CD31, vWF, VE-cadherin and Tie-2/TEK,
bind Bandeiraea simplicifolia (BS-1) and UEA-1 lectins, and
have the potential to take-up acetylated low-density lipropro-
tein/acLDL. Therefore, CACs appear analogous to CFU-ECs
in surface molecular profile and in vitro properties. The third
and least known type of “EPC” is now defined as “endothe-
lial colony-forming cell” (ECFC). In this method, MNCs
are growing in the presence of endothelial-specific growth
factors. After removal of non-adherent cells, ECFC colonies
displaying cobblestone pattern typical of ECs emerge from
the adherent cell population. Because ECFCs emerge much
later in culture than CFU-ECs or CACs, they have also been
termed “late outgrowth EPCs” [42].
3.2. Regulation of endothelial progenitor cells
In order for EPCs to facilitate the growth of tumor cap-
illaries, they must respond to signals released from the BM,
home to the tumor site, and differentiate into mature ECs.
Although the exact molecular background of EPC mobiliza-
tion remains vague, VEGF is thought to be the key cytokine
in the regulation of EPC mobilization and homing [43]. In
animal models, VEGF through interaction with its receptors,
VEGFR2 and VEGFR1 expressed on EPCs and HSCs [44],
effectively induces the mobilization of these cell populations
into the circulation; EPC levels in the PB rise within 24 h fol-
lowing exogenous VEGF administration [45]. Accordingly,
the increased circulating VEGF level triggers the release of
EPCs from the BM of cancer patients [25,46].
Cytokines that induce the release of white and red blood
cells may also trigger EPC mobilization. Elevated levels
of EPCs were reported in mice subsequent to granulocyte-
macrophage colony-stimulating factor (GM-CSF) treatment,
and accelerated corneal angiogenesis with BM-derived cells
was found in animals treated with GM-CSF [47]. In another
animal model, granulocyte colony-stimulating factor (G-
Author's personal copy
114 B. Dome et al. / Critical Reviews in Oncology/Hematology 69 (2009) 108–124
CSF) markedly enhanced growth of a colorectal carcinoma
cell line, in part mediated by EPCs incorporated into sites of
active blood vessel growth, whereas it had no effect on can-
cer cell proliferation in vitro [48]. Similarly, administration of
recombinant human erythropoietin (rHuEPO) increased both
the level of functionally active EPCs by differentiation in vitro
in a dose-dependent manner and also the number of function-
ally active EPCs in human PB [49]. In addition, serum levels
of EPO were found to be significantly associated with the
number and function of circulating EPCs [50]. Interestingly,
although EPO has a similar potency for the stimulation of
EPC mobilization as VEGF [51] and it is widely used for
correction of hemoglobin level by increasing the number of
red blood cells, there is no data on the effect of rHuEPO
on EPC mobilization and recruitment when it is delivered
to tumor-bearing animals or cancer patients. However, in
addition to the potential effects of rHuEPO on cancer cell
proliferation, the expression of EPO receptor (EPOR) in ECs
and their progenitors raises the possibility that exogenous
rHuEPO may enhance the processes of angio- and/or vascu-
logenesis in tumors (reviewed in ref. [52]). Nevertheless, as
it has been suggested by recent studies, the overall direct
effect of EPO-EPOR signaling on tumor progression and
therapy is not a straightforward one. For instance, rHuEPO
administration has recently been shown to be associated with
decreased intratumoral hypoxia-inducible factor-1 (HIF-
1) and VEGF expression and increased sensitivity to radio-
and chemotherapy of human tumor xenografts [53,54].
In addition to the above molecules, recent results indi-
cate that PlGF (placental growth factor) [55], Ang-1
(angiopoietin-1) [56], PDGF-CC (platelet-derived growth
factor-CC) [57], SDF-1 (stromal cell-derived factor-1)
[58], NO (nitric oxide) [59], 3-hydroxy-3-methylglutaryl
coenzyme-A reductase inhibitors (statins) [60], estrogens
[61] and physical training [62] enhance EPC mobilization as
well. In contrast, tumor necrosis factor-alpha (TNF-) and
C-reactive protein (CRP) promote apoptosis, attenuate the
function and decrease the level of EPCs [63,64].
3.3. Endothelial progenitor cells in animal tumor
models (Fig. 1)
The observation that EPCs are capable of enhancing tumor
vascularization means that although these progenitor cells
are primarily programmed to support embryogenic vascu-
logenesis, they retain this capability within an angiogenic
milieu in the adult. But what evidence is there that EPCs
actually support new blood vessel growth in tumors? The first
report on the role of EPCs in tumor-induced vasculogenesis
dates back to 2001, when Lyden et al. [65] demonstrated that
EPCs contribute about 90% to vascularization in lymphomas
grown in angiogenesis-defective Id-mutant mice in which
implanted tumors rapidly regress, most probably because of
the weak angiogenic potential of these animals. BM trans-
plantation from wild-type mice, not from Id-mutant mice,
restored the tumor neovascularization and growth in Id-
mutant mice. However, the high contribution of EPCs in
the neovessels of this tumor model almost certainly results
from the fact that recipient Id-deficient mice are angiogenic-
deficient as well, and therefore compensatory mechanisms
(such as tumor-induced vasculogenesis) are activated to sus-
tain tumor growth. In subsequent animal transplantation
models, EPCs incorporated into neovessels, sometimes by as
much as 50% [66], whereas other authors reported lower but
significant levels between 10% and 20% [67]. These reports
have been challenged by some other experiments in which
EPCs had no significant contribution to the tumor vasculature.
For example, De Palma et al. [68] found that TIE2-expressing
monocytes (TEMs), rather than EPCs, homed to tumors and
interacted with vascular ECs. Interestingly, these authors did
not observe EPCs in the tumor vasculature. Similarly, based
on their observations in a transgenic mouse model, Gothert et
al. failed to observe EPCs in tumor capillaries [69]. Although
possible reasons for such inconsistent results might include
the use of differing experimental models/techniques to iden-
tify EPCs, recent data suggest that the involvement of EPCs in
experimental tumor vascularization might also vary depend-
ing on tumor stage and/or grade. Using different mouse
models, a German group reported recently that only advanced
tumors recruit and incorporate EPCs into neovessels, possibly
to further compensate for escalating blood supply require-
ments [70]. Along this line, Ruzinova et al. found that the
contribution of EPCs to the tumor vasculature depends on
the tumor grade, since EPCs distinguished between well- and
poorly differentiated carcinoma cell lines [71]. Finally, vari-
ations in EPC levels and their involvement in the actual phase
of tumor growth might also be caused by chemotherapy.
The evidence for this assumption comes from another animal
study in which mice were treated with the maximum tolera-
ble dose (MTD) versus metronomic (i.e. antiangiogenic [72])
chemotherapy. Surprisingly, while animals treated with the
MTD chemotherapy experienced a robust EPC mobilization
a few days after the end of a cycle of drug administration, the
administration of metronomic chemotherapy was associated
with a consistent decrease in EPC levels [73].
In addition to the physical contribution of EPCs to newly
formed capillaries, the angiogenic cytokine release of EPCs
may be a supportive mechanism to improve neovasculariza-
tion as well [74]. This idea is supported by a recent report by
Gao et al. [75]. These authors found that although only 12% of
the new blood vessels showed incorporation of EPCs, block-
ing EPC mobilization caused severe angiogenesis inhibition
and significantly impaired tumor progression. Moreover, in
the same study, gene expression analysis of EPCs revealed
up-regulation of a variety of key proangiogenic genes.
In conclusion, EPCs seem to have both paracrine and
structural roles in new vessel growth. However, although
EPCs are obviously able to support tumor vascularization,
the involvement of this cell population may vary depending
on circumstances such as the experimental model or detec-
tion method used, the histology and stage of the tumor, and
the type of the anticancer treatment.
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Fig. 1. Schematic representation of the roles of CECs, EPCs and HCs in cancer. CECs represent a population of mature ECs that have desquamated from their
basal membrane into the circulation in response to some form of blood vessel injury [16]. CEC levels are elevated in patients with different types of malignancies
and in various other conditions including ischemic, infective, autoimmune and inflammatory diseases [17]. EPCs are circulating, BM-derived cells that appear
to enhance neovascularization in both physiologic and pathologic settings. These cells have been found in decreased numbers and/or with impaired function in
a variety of cardiovascular diseases. In contrast, circulating levels of EPCs tend to increase in cancer patients and to correlate with the stage of the malignant
disease [43]. In addition to EPCs, tumor vascularization and growth might be modulated by some other BM-derived cells including (but not limited to) RBCCs,
TASCs, DCs, TEMs and MDSCs. Mediated by SDF1, a chemokine induced by tumor-derived VEGF in activated perivascular myofibroblasts, RBCCs enhance
new capillary growth from a perivascular position [123]. TASCs colonize the tumor stroma and are thought to enhance tumor capillary sprouting in a paracrine
manner by inducing or increasing the expression angiogenic cytokines [122]. DCs might promote angiogenesis through different mechanisms: by stimulating
EC sprouting through the expression of angiogenic molecules and by differentiating into endothelial-like cells. Besides inhibiting the functional maturation
of DCs, VEGF is thought to be a major player in these processes [119]. TEMs are monocytes that express the TIE2 receptor, are recruited to periendothelial
tumor sites and promote angiogenesis in a paracrine manner [68]. MDSCs contribute to tumor growth and angiogenesis by producing MMP9, incorporating
into the endothelial tube and differentiating into ECs [106].
3.4. Endothelial progenitor cells in human tumors
The involvement of EPCs in the vascularization process
of human tumors has been investigated in some recent stud-
ies as well. Peters et al. studied tumor samples from patients
who developed malignancies after BM transplantation with
donor cells derived from individuals of the opposite sex.
By using FISH with sex chromosome-specific probes, these
authors reported that the percentage of BM-derived ECs
in the tumors ranged from 1% (head and neck sarcoma)
to 12% (lymphoma) [76], which was closer to the num-
bers observed in spontaneous animal tumors than the zero
or extremely high numbers found when implanting tumor
cells. Recent studies have demonstrated the presence, based
on their CD133 immunoreactivity, of incorporated EPCs in
the walls of human tumor blood vessels as well [77–80].
Accordingly, CD133 mRNA expression in the PB of can-
cer patients was shown to be an independent predictor for
overall survival in patients with bone metastases [81] and
for recurrence in colorectal cancer patients [82]. However,
because CD133 expression is continuously decreasing on
the cell surface of circulating EPCs and lost once EPCs
differentiate into more mature ECs in the endothelial tube
[2,33,43], it seems obvious that based on CD133 staining, the
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rate of incorporated EPCs in cancer capillaries is inevitably
underestimated.
Recently reported data also indicate that EPCs circulate
in increased numbers in the PB of patients with various types
of cancers. Elevated EPC levels have been reported in the PB
of patients with lung [80,83], hepatocellular [46,79], breast
[25,84,85] and colorectal [86,87] cancers, as well as multiple
myeloma [23], myelofibrosis [88], non-Hodgkin’s lymphoma
[77], AML [24] and malignant gliomas [89] (Table 2).
4. Proangiogenic hematopoietic cells (Fig. 1)
Hematopoiesis has an evolutionarily conserved relation-
ship with vascular development [90]. HSCs adhere closely
to ECs at various sites in the embryo, including the yolk sac
and the dorsal aorta [91,92]. In turn, yolk sac ECs can sup-
port the proliferation of multipotent hematopoietic stem cells
[93]. Furthermore, as mentioned above, HCs and ECs are
believed to originate from a common precursor cell, known
as the hemangioblast [94,95]. Accordingly, in the adult, sub-
stantial evidence indicates that beside EPCs, hematopoietic
lineage cells also support the process of tumor vasculariza-
tion, although most of them are localized to periendothelial
tumor sites.
Mast cells (MCs) participate in various angiogenesis-
dependent diseases/states including rheumatoid arthritis,
ovulation, wound healing and tumor growth. Accordingly,
several MC mediators are angiogenic and control EC prolifer-
ation and function. MCs express interleukin-8 (IL-8), MMPs,
basic FGF, TNF- and VEGF. Moreover, they can enhance
tumor vascularization indirectly by producing MC-specific
serine proteases (MCP-4 and MCP-6) that activate pro-
MMPs (reviewed in ref. [96]). MCs are also able to produce
histamine and heparin, which can stimulate EC sprouting
(directly or indirectly by the stabilization of growth factors)
and may have a role in the leakiness of immature tumor
capillaries. Finally, reduction of tumor MC density/function
has been shown to inhibit angiogenesis and, therefore, tumor
growth [97,98].
Most cancers appear to be infiltrated by tumor-associated
macrophages (TAMs), which can comprise more than
50% of the total tumor mass. Depending on forms of
activation, macrophages can show two general types of
polarization, M1 and M2 (described in detail in ref. [99]).
Although M1-polarized macrophages have the potential to
kill tumor cells, many observations indicate that TAMs more
likely represent an M2-polarized macrophage population
exhibiting protumor functions, including the secretion of
angiogenic molecules [99,100]. Indeed, in most human stud-
ies, macrophage infiltration of the tumor was associated with
poor prognosis, and generally correlated with vascular den-
sity [101–103].
A heterogeneous population of cells sharing their differ-
entiation pathway with TAMs is designated myeloid-derived
suppressor cells (MDSCs). MDSCs are myelomonocytic
cells lacking the markers of mature myeloid cells and
expressing CD11b and Gr-1 in mice. They have been
reported to accumulate in tumor-bearing hosts and to suppress
T-cell-mediated antitumor immune responses by diverse
mechanisms [100,104,105]. Furthermore, when co-injected
with tumor cells, CD11b+Gr-1+ cells promoted tumor vas-
cularization by producing MMP-9, and were also found to
directly incorporate into tumor capillaries [106]. However,
the human equivalents of MDSCs are less well characterized,
although immunosuppressive granulocyte subpopulations
and immature myeloid cells have been described in several
cancer types [107–109].
TIE2-expressing monocytes (TEMs, a subset of circu-
lating and tumor-infiltrating monocytes), identified by De
Palma et al. [68], are recruited to periendothelial positions and
enhance tumor vascularization in a paracrine manner in mice.
They are CD11b+/CD45+/TIE2+ cells, but do not express
VEGFR2 or any established EC or pericyte-associated mark-
ers (e.g. CD31, CD34 or SMA and NG2). In subsequent
studies, the same authors demonstrated that TEMs are specif-
ically recruited to spontaneously arising murine pancreatic
carcinomas and to human glioma xenografts [110]. The
surface-marker profile and angiogenic behavior of human
TEMs were found to be reminiscent of those of previously
described murine TEMs [111].
In contrast to TAMs, most studies on infiltrating DCs
have demonstrated that high DC density in tumors is associ-
ated with good prognosis and reduced incidence of recurrent
disease in various malignancies [112–114]. However, some
DC subsets, such as CD123+/CD303+ plasmacytoid DCs or
immature or incompletely matured DCs have been suggested
to mediate tolerance instead of immune activation [104,115].
It is also important to note that tumor-derived factors, such as
VEGF and TGF-, can inhibit functional maturation of DCs
[116,117] and that VEGF expression negatively correlated
with DC density in tumors [112,116,118].
Recent results also suggest that different DC subtypes
express and release a wide range of pro- and antiangio-
genic molecules depending on their activation status and
cytokine milieu. A major subset of DCs, MHC II+/CD11c+
myeloid DCs, for example was shown to express the proan-
giogenic molecules VEGF, bFGF, TNF-, IL-6 and the
antiangiogenic cytokines IL-10, IL-12, IL-18 and TSP-1
(thrombospondin-1) as well. Similarly, depending on the
stimulus, plasmacytoid DCs, the other major DC subtype,
can also release both angiogenic (TNF-, CXCL8) and
angiosuppressive IFN- (interferon-) molecules (reviewed
in ref. [119]). Moreover, a novel DC subpopulation
(CD11c+/CCR6+/MHC II+ DC precursors, tumor-associated
DCs, TADCs, Table 1) that supports tumor vascularization
was described recently by Conejo-Garcia et al. [120,121].
In their experiments, these authors found that -defensins
recruited dendritic precursors through CCR6 into the tumor,
where VEGF-A transformed them into endothelial-like cells.
Unlike TEMs, these cells mainly migrated to the endothelial
tubes, becoming true endothelial-like cells. All in all, DCs
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might enhance tumor vascularization by two different but
possibly interconnected mechanisms: by promoting endothe-
lial sprouting through the expression of angiogenic cytokines
and by supporting vasculogenesis via trans-differentiation
into endothelial-like cells (reviewed in ref. [119]).
Further proangiogenic HCs that have been directly impli-
cated in tumor vascularization include tumor-associated
stromal cells (TASCs) [122], recruited blood circulating cells
(RBCCs) [123] and VEGFR1+ hematopoietic progenitors
[65] (Table 1).
Tumor-associated stromal cells (TASCs) were described
by Udagawa et al. [122]. These CD45+/VEGFR2+ double
positive cells have the ability to enhance tumor angiogene-
sis, although are minimally recruited into the tumor capillary
walls. Instead, these authors suggested that TASCs might
indirectly augment tumor vascularization in a paracrine man-
ner by inducing or increasing the angiogenic molecules that
stimulate in situ vessel formation (endothelial sprouting).
Like TEMs and TASCs, RBCCs [123] were shown to sup-
port new blood vessel growth via secreting proangiogenic
factors from a perivascular position. RBCCs are positive for
CD45, CD11b, CXCR4 and VEGFR1 but not for VEGFR2,
indicating that they are recruited by VEGF and CXCL12 and
are predominantly hematopoietic in nature. It is also impor-
tant to note that Lyden et al. recently described VEGFR1+
hematopoietic progenitors that proliferate in the BM, mobi-
lize to the bloodstream along with VEGFR2+ EPCs, and
incorporate into pericapillary connective tissue, thereby sta-
bilizing tumor vasculature [65]. More interestingly, these
cells appear to home in before the metastatic tumor cells
arrive to the target organ, promoting the metastatic process by
forming niches where cancer cells can locate and proliferate
[124]. However, to what extent these VEGFR1+ progenitors
overlap with RBCCs remains to be elucidated.
The aforementioned studies together with Harraz et al.’s
[125] suggestion that CD34-angioblasts are a subset of
CD14+ monocytic cells, Rehman et al.’s [126] demonstra-
tion of the isolation of CACs from the monocyte/macrophage
fraction of PB, and Yoder et al.’s [127] finding that CFU-ECs
expressed colony-stimulating factor-1 receptor (CSF-1R) and
actively phagocytosed Escherichia coli highlighted the abil-
ity of proangiogenic HCs to enhance tumor vascularization.
These studies also demonstrated that hematopoietic and
endothelial lineage cells share functional and phenotypical
features, including the expression of common metabolic and
surface molecules, as well as the capacity to shape vascular-
like structures. However, these experiments with the cell
populations growing in the above-described cell cultures con-
taining the PB mononuclear cell fraction have also led to some
controversy over whether CACs and CFU-ECs represent
EPCs or in fact identify monocytes/macrophages. To clar-
ify the complex nomenclature and the relationships among
EPC types to mononuclear cell subtypes, an elegant work-
ing hypothesis was suggested recently by Prater et al. [38].
According to the proposal of these authors, CACs represent
the largest population of cultured EPC types, comparable in
size to PB monocytes, which are hypothesized to belong to the
CAC population. These authors also suggested that CD45+
proangiogenic HCs overlap with CFU-ECs to an undefined
degree and that ECFCs are included in the CEC population.
It is also important to note that beside the above described
proangiogenic HCs that are directly implicated in tumor vas-
cularization, other HC types such as polymorphonuclear cells
(PMNs), NK cells and T and B lymphocytes may also par-
ticipate in the vascularization process. Activated PMNs are
reported to secrete a number of angiogenic molecules includ-
ing MMPs, VEGF and IL-8. However, the PMN population
was demonstrated to be a source of endogenous angiogen-
esis inhibitors (such as angiostatin, IL-12-inducible protein
10, and IFN-) as well [5]. To make the picture more com-
plex, PMNs also secrete chemotactic factors to recruit other
PMNs, monocytes, T cell subsets and immature DCs [5].
Regarding lymphocytes, Qin et al. found that the primary
mechanism of tumor rejection by CD8+ T cells in mouse mod-
els was angiostasis mediated by IFN- [128]. On the other
hand, production of VEGF by tumor-infiltrating T cells has
been described, which could play a role in tumor angiogen-
esis [129]. In cutaneous melanoma, we found a correlation
between peritumoral microvessel density and the infiltration
by T cells [130]. In some animal models, a role of NK cells
as angiogenesis inhibitors via IL-12 and IFN- secretion has
been suggested [131]. Few data are available on the effect of
B lymphocytes on tumor vascularity; in a transgenic mouse
model, transfer of B cells from HPV16 mice into T and B
cell-deficient/HPV16 mice restored chronic inflammation in
premalignant skin and reinstated regulatory mechanisms nec-
essary for angiogenesis [132]. Taken together, although all
these cell types have been reported to express a wide reper-
toire of pro- and antiangiogenic factors, their “angiogenic
function” has been poorly investigated and their exact role in
the blood supply of tumors remains unclear (reviewed in ref.
[103]).
In summary, tumor-derived angiogenic factors do not
merely trigger the release of EPCs, but also enhance the
co-mobilization of proangiogenic HCs to the tumor vascu-
lar network and/or stroma. This co-recruitment of different
lineages may support capillary sprouting and stabilization of
immature cancer capillaries through the release of additional
proangiogenic factors or by generating permissive conditions
in the tumor stroma that favor the survival and/or growth of
preexisting tumor vessels.
5. Antiangiogenic and/or anticancer therapy via
EPCs, proangiogenic HCs and CECs
One of the greatest hopes for the study of EPCs and, to
a lesser extent, of proangiogenic HCs and CECs, is their
potential use in cancer therapy as cellular vehicles for deliver-
ing suicide genes, toxins or antiangiogenic molecules. These
novel anticancer techniques, typically with the ex vivomanip-
ulation of these cells, have been applied to transplantation
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models and, to some extent, have reduced cancer progres-
sion. For example, Ferrari et al. transduced human EPCs with
a retroviral vector expressing the herpes simplex virus thymi-
dine kinase (HSV-TK) transgene, and then injected these cells
intravenously into sublethally irradiated mice bearing subcu-
taneous or intracranial tumors. Ganciclovir treatment resulted
in significant tumor regression in mice previously injected
by TK-expressing EPCs with no systemic toxicity [133]. In
a similar study, unsorted murine BM cells were transduced
with a retroviral vector to express truncated soluble VEGFR2
(tsVEGFR2) together with green fluorescent protein (GFP) or
GFP alone. The subsequent experiments have demonstrated
that GFP-positive BM-derived cells contributed to tumor
capillaries and, when modified to express the angiogene-
sis inhibitor tsVEGFR2, restricted tumor growth [134]. In
another gene delivery approach, ex vivo expanded EPCs that
were genetically modified with a suicide gene specifically
and efficiently eradicated hypoxic lung metastases [135].
Differentiated endothelial cells have also been employed
for experimental tumor therapy. In a murine metastatic
melanoma model, the intravenous administration of genet-
ically modified CECs expressing a human IL-2 transgene
abrogated the tumor metastases and prolonged survival of
the animals [136]. Similarly, co-injections of HSV-TK-
expressing ECs and tumor cells reduced in vivo tumor growth
and provided a statistically significant survival benefit in
experimental animals [137].
Finally, the observation that proangiogenic HCs are
able to support tumor growth and home to sites of active
angiogenesis suggests that these cells may provide the
means for selective gene delivery and targeted inhibition of
tumor angiogenesis as well. Consistent with this hypothe-
sis, De Palma et al. transduced TEMs with lentiviral vectors
expressing genes from transcription-regulatory elements of
TIE2/TEK gene and achieved a substantial inhibition of
angiogenesis and slower tumor growth without systemic tox-
icity by delivering a “suicide” gene [68].
Taken together, the use of the above cells in cancer ther-
apy as cellular vehicles for delivering suicide genes, toxins or
anticancer/antiangiogenic agents opens new ways to hinder
tumor growth. However, given the existence of alternative
vascularization mechanisms in cancer [4], the different EPC
and CEC counts reported in various tumor models/cancer
types, the association of EPC levels with the histological
type/stage of the tumor, and the unresolved question of
whether or not CECs are active participants in tumor vas-
cularization, the applicability of these cell populations as
“Trojan horses” in anticancer therapy certainly needs further
investigation.
6. EPCs and CECs: potential biomarkers of tumor
angiogenesis?
The efficacy of conventional antitumor treatments (i.e.
chemo- and radiotherapy) is typically assessed by measuring
their direct effects on tumor size and/or survival. Because
antiangiogenic drugs specifically target the tumor vascula-
ture, in case of these treatments, assessment of the above
parameters is an inadequate strategy and we need to be able to
evaluate the biological effects of antiangiogenic drugs on the
tumor capillaries independently of their general anticancer
activity.
The biomarkers used to measure the efficacy of thera-
peutic drugs of any type can be classified as either direct
or surrogate (indirect) in nature. In case of antiangiogenic
drugs, the direct biomarker is the actual capillary network in
the tumor, which is generally difficult to depict and quantify
[138]. Consequently, reliable surrogate markers are needed
that indirectly indicate the effect of antiangiogenic therapy on
tumoral blood vessels and that can help to identify patients
responsive to these therapies, recognize resistance and pre-
dict the efficacy of combinations that include antiangiogenic
drugs [139,140].
Although currently no single reliable biomarker is avail-
able, encouraging results from different disciplines have been
reported.
One of the potential strategies is the measurement of
serum/plasma angiogenic cytokine and/or soluble growth
factor receptor levels in the blood and/or urine. For exam-
ple, plasma concentrations of total VEGF and PlGF were
observed to be significantly elevated in bevacizumab-treated
colon carcinoma patients [87]. In another clinical study
on patients with colorectal cancer, an elevation of plasma
VEGF-A and bFGF was found following the first cycle of
PTK787/ZK222584 (an angiogenesis inhibitor targeting all
known VEGF receptor tyrosine kinases) treatment [141].
Similarly, a progressive increase of total VEGF levels after
initiation of treatment with bevacizumab in renal cancer was
reported [142]. However, the use of cytokines as biomarkers
of angiogenesis is complicated by the release of angiogenic
growth factors from platelets and there are several studies of
angiogenic molecules as surrogate markers that have yielded
inconclusive evidence of their reliability [139].
Measuring the efficacy of antivascular therapy could also
be achieved by imaging the tumor capillaries themselves (i.e.
direct imaging by agents targeted at cytokines or receptors
involved in tumor vascularization) or investigating the result
of such treatments on the anatomic features and the blood sup-
ply of tumors (indirect imaging). Currently, almost all direct
techniques are available solely in murine models, whereas
indirect techniques are typically used in clinical settings
[138]. Accordingly, with the exceptions of a few recent stud-
ies [143,144], experience with vascular imaging in human
studies has been gained primarily by indirect techniques.
These include measurements of contrast enhancement, blood
volume and oxygen saturation with computed tomography
(CT), magnetic resonance imaging (MRI), positron emission
tomography (PET) and single photon emission computed
tomography (SPECT) (reviewed in ref. [138]).
Circulating EPC/CEC levels as surrogate markers of
angiogenesis have also been investigated recently. Based
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on results from studies on murine tumor systems, there is
a clear relationship between tumor burdens and EPC/CEC
counts in the PB [145]. Moreover, circulating CEC and EPC
counts have also been demonstrated to change with anti-
cancer/antiangiogenic treatments in preclinical models. For
example, as mentioned above, Bertolini et al. found that when
tumorous mice are treated with MTD chemotherapy, there
is a marked elevation in EPC counts in the PB during the
drug-free break periods. This tendency was not observed
when the same drug was administered metronomically. In
fact, the opposite was reported; namely, almost total sup-
pression of EPC and CEC numbers and viabilities [73].
In other murine studies, treatment of tumor-bearing mice
with vascular disrupting agents (VDAs) led to an abrupt
release of EPCs, which incorporated into the capillaries of
viable peripheral tumor areas (tumor rims) that characteris-
tically survive after such treatment. Suppression of this EPC
mobilization by antiangiogenic agents resulted in marked
reductions in tumor rim size and blood flow as well [146].
Moreover, endostatin decreased EPC numbers in the PB
along with tumor regression [147,148], and VEGFR2 tar-
geting caused a dose-dependent decrease in EPC counts that
paralleled the anticancer activity of the experimental agent
[149].
More importantly, techniques for EPC/CEC detection
and counting have been tested in the clinics [9], and stud-
ies have been undertaken measuring the numbers of these
cells in cancer patients treated with antiangiogenic thera-
pies. Particularly encouraging in this regard is a phase 1 trial
in which bevacizumab, an anti-VEGF antibody, decreased
tumor perfusion, vascular volume, microvascular density,
interstitial fluid pressure and the number of EPCs and
CD31bright/CD45− viable CECs in rectal carcinoma patients
[86,87]. Interestingly, in a vigorously criticized [150] subse-
quent study [151], the investigators of the above trial were
unable to detect significant changes in CD146+ CEC levels
during VEGF blockade.
Subsequent studies have yielded promising but sometimes
inconsistent results likely dependent on the type and stage
of the malignant disease and, moreover, on the therapeu-
tic regime and enumeration technique chosen. In a phase
I/II study of patients with imatinib-resistant metastatic GIST,
the authors investigated plasma and PB cellular biomarkers
for sunitinib malate, a multitargeted tyrosine kinase inhibitor
with activity against VEGFR1, VEGFR2, VEGFR3, PDGF
receptor, KIT, and FLT-3 (FMS-like tyrosine kinase 3) and
found that changes in CECs, but not the plasma markers
(VEGF and soluble VEGFR2), differed between the patients
with clinical benefit and those with progressive disease [27].
A phase II prospective study of low-dose cyclophosphamide
given continuously (i.e. metronomically) in combination with
celecoxib in adult patients with relapsed or refractory aggres-
sive non-Hodgkin’s lymphoma has recently demonstrated
that CECs and EPCs declined and remained low in respon-
ders, whereas plasma VEGF tended to decline in responding
patients but increase in nonresponders [152]. Similarly, CEC
and EPC counts were found to be correlated with disease
activity (i.e. levels of serum M protein and 2 microglobu-
lin) and response to thalidomide therapy in multiple myeloma
[23]. Moreover, in a phase I trial of pediatric patients with
refractory solid tumors, although not statistically signifi-
cantly, CECs tended to increase with bevacizumab therapy
[153]. There are other studies, however, in which no corre-
lation between circulating levels of CECs/EPCs and tumor
progression/response was found. For example, in a phase I
study of patients with refractory solid malignancies, the dif-
ferences in the numbers of CECs and EPCs between patients
and controls were not statistically significant and, further-
more, no changes in the levels of these cells were observed
during low-dose cyclophosphamide and celecoxib or low-
dose etoposide and celecoxib therapy [154]. Similarly, in a
phase I study of the protein kinase C inhibitor enzastaurin in
combination with gemcitabine and cisplatin in patients with
advanced tumors, the single-agent enzastaurin had no effect
on any of the angiogenesis biomarkers analyzed (circulating
CEC levels and mRNA expression of CD133 and CD146 in
the PB).
As antivascular therapies for cancer become increasingly
integrated into routine oncology care, there is an urgent need
for the proper selection of the patients most likely to benefit
from these treatments. The results described above are par-
ticularly significant in this regard, as they may establish the
role of EPC/CEC quantification not only in the evaluation
of the efficacy of antiangiogenic treatments, but also in the
definition of optimal biologic dose ranges as well. More stud-
ies, however, are needed to expand and validate these initial
findings.
7. Conclusions
The key role of the vasculature during tumor progression
is unquestionable. Moreover, it is becoming clear that BM-
derived EPCs and proangiogenic HCs are involved in the
process of neovascularization and that CEC and EPC levels
can be biomarkers of targeted anticancer/antivascular thera-
pies. Recent reports also suggest that BM-derived circulating
cells can be used as cellular vehicles to deliver anticancer
agents. Questions remain, however, regarding the precise
functional and phenotypic nature of these circulating cells
and whether certain HCs will have any value as biomarkers as
well. Hence, further studies and consensus is required regard-
ing the phenotype and enumeration approaches of these cell
populations in order to help define their optimal role in clin-
ical oncology.
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Circulating Bone Marrow-Derived Endothelial
Progenitor Cells: Characterization, Mobilization, and
Therapeutic Considerations in Malignant Disease
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 Abstract
Until recently, tumor vascularization was thought to occur exclusively through angio-
genesis. However, recent studies using different animal models of cancer suggested the
importance of bone marrow-derived endothelial progenitor cells (EPCs) (i.e. postnatal
vasculogenesis) in tumor vascularization and growth. EPCs are present in the periph-
eral blood, their levels are increased in response to certain signals/cytokines, and they
home into the neovascular bed of malignant tissues. Furthermore, at the clinical level,
evidence is emerging that changes in EPC levels might predict the efﬁcacy of anticancer
drug combinations that include antiangiogenic agents. On the basis of these observa-
tions, EPCs have attractive potential diagnostic and therapeutic applications for
malignant diseases. In this paper, we review biological features of EPCs and speculate
on the utility of these progenitor cells for medical oncology. ' 2007 International Society
for Analytical Cytology
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UNTIL recently, it was generally accepted that in adults the formation of new blood
vessels results exclusively from the proliferation and migration of preexisting, com-
pletely differentiated endothelial cells (ECs) (a process referred to as angiogenesis).
Vasculogenesis (deﬁned as the in situ differentiation of vascular ECs from primitive
precursor cells) was thought to occur only in the embryonic phases of vascular devel-
opment. Recent studies have shown, however, that circulating bone marrow (BM)-
derived endothelial progenitor cells (EPCs) home to sites of neovascularization and
differentiate into ECs (1). EPCs therefore resemble embryonic angioblasts, which are
anchorage-independent cells having the ability to proliferate, migrate, and differenti-
ate into mature ECs. Since the identiﬁcation of this cell population by Asahara et al.
(2), several studies have shown reduced numbers and/or impaired function of EPCs
in a variety of cardiovascular risk states, including diabetes mellitus (3), hypercholes-
terolaemia (4), hypertension (5), chronic renal failure (6), rheumatoid arthritis (7),
and cigarette smoking (8). Alternatively, cardiovascular protective factors such as
exercise training (9), statin therapy (10), angiotensin II receptor antagonists (11),
and peroxisome proliferator-activated receptor agonists (12) are known to increase
EPC number and function. However, in addition to their role in the maintenance of
vascular integrity, EPCs (i.e. postnatal vasculogenesis) are thought to participate in
the process of tumor vascularization as well (13). This review focuses on the pheno-
type of EPCs, as well as the molecules that control their mobilization from the BM
and their recruitment to sites of tumor vessel formation. In addition, we discuss the
clinical signiﬁcance of EPCs and the potential therapeutic implications in anticancer
treatments.
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CHARACTERIZATION OF ENDOTHELIAL PROGENITOR CELLS
AND THE COMOBILIZED HAEMATOPOIETIC PRECURSORS
EPCs were initially identiﬁed and isolated in 1997 by Asa-
hara et al. (2) on the basis of vascular endothelial growth fac-
tor receptor-2 (VEGFR2) and CD34 coexpression of these
cells. However, in the past few years the emergence of speciﬁc
surface markers and molecular probes has facilitated the iden-
tiﬁcation and puriﬁcation of functional stem and progenitor
cells. EPCs, ECs, and haematopoetic stem cells share not only
the aforementioned but many other surface markers (Table 1).
As a result, to date no simple deﬁnition of EPC exists. Since
the initial report, a number of groups have set out to better
deﬁne this cell population, and EPCs were subsequently
shown to express ﬁbroblast growth factor receptor, CD38, c-
kit, CD31, CD146, CXCR4, von Willebrand factor (vWF), vas-
cular endothelial cadherin (VE-cadherin), Tie-2/TEK (angio-
poietin-1 receptor precursor or tunica intima EC kinase), and
CD133 (14,27–29). The term ‘‘EPC’’ may therefore encompass
a group of cells existing in a variety of stages ranging from pri-
mitive haemangioblasts to fully differentiated ECs. Although
their putative precursors and the exact differentiation lineage
of EPCs remain to be determined, at present it is widely
accepted that early EPCs (localized in the BM or immediately
after migration into the circulation) are CD1331/CD341/
VEGFR21 cells, whereas circulating EPCs are positive for
CD34 and VEGFR2, lose CD133 and begin to express cell sur-
face markers typical to mature ECs (14). Thus, the major can-
didate for a speciﬁc EPC marker is the CD133, an orphan re-
ceptor speciﬁcally expressed on early EPCs, but whose expres-
sion is lost once these progenitors differentiate into more
mature ECs (30). Unfortunately, because in humans CD133 is
expressed by haematopoietic stem cells as well (31), the meth-
ods for phenotypic differentiation between vasculogenic-re-
stricted immature EPCs, committed haematopoietic progeni-
tors, and their putative common precursor (bipotential hae-
mangioblast) have yet to be developed further.
Reports on the number of EPCs in peripheral circulation
are variable, ranging from 70–210 cells/mL of blood (32) to
3,000–5,000 cells/mL of blood (33), depending most likely on
the isolation procedure used. These relatively low levels of cir-
culating EPCs as assessed by ﬂow cytometry are in sharp con-
trast to the high numbers of attached cells (often confusingly
referred to as ‘‘EPCs’’ too) that are obtained (105 from 1 mL
blood) from cell cultures containing the blood mononuclear
cell fraction. In general, three different methods for culturing
‘‘EPCs’’ have been described (18). In the original method, pe-
ripheral blood mononuclear cells (PBMNCs) are plated on ﬁ-
bronectin-, gelatin-, or collagen-coated dishes. After the pre-
plating step to reduce the numbers of differentiated ECs and
adherent macrophages, the nonadherent cells are removed and
replated on additional dishes. Discrete colonies appear in a
week, containing round cells in the center with spindle-shaped
attaching cells proliferating peripherally. These colonies are
usually deﬁned as colony-forming unit-ECs (CFU-ECs) (16).
In the second commonly used technique, PBMNCs are cultured
in the presence of angiogenic cytokines for 4–6 days, where-
upon nonadherent cells are discarded, leading to a target adher-
ent cell fraction (34). Because these adherent cells have been
demonstrated to support angiogenesis in animal models of
myocardial or limb ischemia (17), they have been deﬁned as
circulating angiogenic cells (CACs). Although CACs do not ex-
hibit the colony morphology of CFU-ECs and can be assembled
from culture in larger numbers than CFU-ECs, they have an en-
dothelial phenotype (they bind Bandeiraea simplicifolia/BS-1
and Ulex europeus Agglutinin-1/UEA-1 lectins, express CD31,
vWF, VE-cadherin, and Tie-2/TEK, and have the potential to
take-up acetylated low-density lipoprotein/acLDL) and thus
appear analogous to CFU-ECs in surface molecular proﬁle and
in vitro properties. Consequently, both cell populations have
often been termed in the literature as ‘‘EPCs’’ (18). The third
and least studied type of ‘‘EPCs’’ is now termed ‘‘endothelial
colony-forming cells’’ (ECFCs). In this method, PBMNCs are
cultured in the presence of endothelial-speciﬁc growth media.
After removal of nonadherent cells, ECFC colonies displaying
cobblestone appearance typical of ECs emerge from the adher-
ent cell population. Given that ECFCs emerge much later in
culture when compared with both CFU-ECs and CACs, they
have also been named ‘‘late outgrowth EPCs’’ (19).
Harraz et al.’s (35) suggestion that CD342 angioblasts
are a subset of CD141 monocytic cells, Rehman et al.’s (36)
demonstration of the isolation of CACs from the monocyte/
macrophage fraction of PB, and Yoder et al.’s (37) ﬁnding that
CFU-ECs expressed colony-stimulating factor-1 receptor and
actively phagocytosed Escherichia coli have all led to some con-
troversy over whether CAC and CFU-EC represent EPCs or in
fact identify monocytes/macrophages. To clarify the complex
nomenclature and the relationships among EPC types to
mononuclear cell subtypes, an elegant working hypothesis was
suggested recently by Prater et al. (18). According to the pro-
posal of these authors, CACs represent the largest population
of cultured EPC types, comparable in size to PB monocytes,
which are hypothesized to belong to the CAC population. The
aforementioned authors also suggested that CD451 haemato-
poietic progenitor cells overlap with CFU-ECs to an undeﬁned
degree, and that ECFCs are included in the circulating EC
(CEC) population.
To make the picture more complex, recently various
authors have described different CD451 (sub)types of BM-
derived circulating cell populations that contribute to tumor
angiogenesis (38), although most of them are localized in peri-
endothelial tumor sites and some are presumably included in
the aforedescribed cell populations growing in cultures.
TIE2-expressing monocytes (TEMs), discovered by De
Palma and coworkers (20,21), are recruited to periendothelial
positions and promote angiogenesis in a paracrine manner.
They express CD11b, CD45, and TIE2, but not VEGFR2 or
any established EC or pericyte-associated markers (e.g. CD31,
CD34 or a-smooth muscle actin, and NG2).
Tumor-associated stroma cells (TASCs) were described by
Udagawa et al. (23). These CD451/VEGFR21 double positive
cells have the ability to promote tumor angiogenesis, although
are minimally incorporated into the endothelial tubes of tu-
mor vasculature. Instead, these authors found that TASCs
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indirectly facilitated tumor vascularization in a paracrine
manner by inducing or increasing the angiogenic factors that
stimulate in situ vessel formation (endothelial sprouting).
Like TEMs and TASCs, recruited bone marrow-derived
circulating cells (RBCCs) (24) were demonstrated to augment
proliferation of preexisting ECs cells via secreting proangio-
genic factors from a perivascular position. RBCCs express
CD45, CD11b, CXCR4, and VEGFR1, but not VEGFR2, indi-
cating that they are recruited by VEGF and CXCL12 and are
predominantly haematopoietic in nature. It is also important
to note that Lyden et al. recently identiﬁed VEGFR11 haema-
topoietic progenitors that proliferate in the BM, mobilize to
the circulation along with VEGFR21 EPCs, and incorporate
into pericapillary connective tissue, thereby stabilizing tumor
vasculature (25). More interestingly, these cells appear to
home in before the metastatic tumor cells arrive to the target
organ, promoting cancer growth by forming niches where tu-
mor cells can locate and proliferate (26). However, to what
extent these VEGFR11 progenitors overlap with RBCCs
remains unclear.
A further novel leukocyte progenitor population
(CD11c1CCR61 dendritic cell precursors, tumor-associated
dendritic cells) that enhances tumor vascularization was
described recently by Conejo-Garcia et al. (22). In their experi-
ments, these authors found that b-defensins recruited dendri-
tic precursors through CCR6 into the tumor, where VEGF-A
transformed them into endothelial-like cells. Unlike TEMs
and TASCs, these cells mainly migrate to the capillary walls,
becoming true endothelial-like cells.
In conclusion, tumor-derived angiogenic cytokines do
not merely induce the mobilization of EPCs, but also enhance
the corecruitment of haematopoietic precursors to the tumor
vascular bed and/or stroma. This comobilization of different
lineages may promote sprouting and stabilization of ECs
through the release of additional proangiogenic cytokines or
by generating permissive conditions in the tumor stroma that
support the in situ growth of resident blood vessels.
MOBILIZATION OF EPCS
To support tumor vascularization, EPCs must respond to
signals released from the BM, home to the tumor site, and dif-
ferentiate into mature ECs. Although the molecular pathways
involved in EPC mobilization are in the early stage of deﬁni-
tion, VEGF is thought to be the most signiﬁcant of the other
molecules (15). VEGF can activate matrix metalloproteinase-9
(MMP-9) that cleaves the membrane-bound stem cell cytokine
mKitL in BM stromal cells to liberate soluble sKitL, which
then stimulates cKit-positive EPCs to migrate from a quiescent
BM niche to a permissive BM microenvironment, the so called
vascular zone. This translocation activates EPCs from a quies-
cent to a proliferative state (39). Furthermore, VEGF has been
found to upregulate stromal cell-derived factor-1 (SDF-1, also
known as CXCL12) and CXCR4 (the SDF-1 receptor) (40,41).
SDF-1 is chemotactic for EPCs and recruits EPCs to sites of
neovascularization (42). Accordingly, in a recent animal study,
CXCR4 blockade abrogated progenitor homing, whereas local
injection of SDF-1 into the target organ increased their hom-
ing (43). However, in the same study, SDF-1 in the absence of
VEGF failed to enhance BM-derived cell recruitment, whereas
blocking of CXCR4 activity reduced BM-derived cells in the
target organ even in the presence of high levels of VEGF.
Therefore, it appears that SDF-1 is not sufﬁcient to recruit
EPCs to tumors without an additional signal, such as VEGF.
On the other hand, because additional studies have demon-
strated that SDF-1 is essential for the adhesion of BM-derived
cells, it may signiﬁcantly help to sequester EPCs at the site of
vessel formation (41). Taken together, VEGF, through interac-
tion with MMP-9 and SDF-1, rapidly triggers the release of
EPCs into the bloodstream; EPC levels in the circulation rise
within 24 h following VEGF treatment (44). Accordingly, the
increased circulating VEGF induces the mobilization of EPCs
from the BM of cancer patients (45,46).
Molecules that induce leukocyte or erythrocyte mobiliza-
tion may similarly inﬂuence EPC mobilization. Increased
numbers of EPCs were found in animals following exogenous
granulocyte macrophage colony stimulating factor (GM-CSF)
administration, and accelerated corneal blood vessel growth
with BM-derived cells was observed in animals treated with
GM-CSF (47). In another murine model, granulocyte colony-
stimulating factor markedly promoted growth of colon cancer
cells inoculated subcutaneously in mice, in part mediated by
BM-derived cells incorporated into new blood vessels (48).
Similarly, administration of recombinant human erythropoie-
tin (rHuEPO) increased both the number of functionally
active EPCs by differentiation in vitro in a dose-dependent
manner and also the number of functionally active EPCs in
human PB (49). In addition, serum levels of EPO were found
to be signiﬁcantly associated with the number and function of
circulating EPCs (50). Interestingly, although EPO elicits a
similar potency for the improvement of EPC mobilization as
VEGF (51), there are no data on the effect of rHuEPO on EPC
mobilization and recruitment when it is delivered to tumor
bearing animals or cancer patients.
In addition to the above factors, recently collected data
indicate that placental growth factor (52), angiopoietin-1 (53),
platelet-derived growth factor-CC (54), nitric oxide (55), 3-
hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors
(statins) (56), physical training (57), and estrogens (58) sti-
mulate EPC mobilization as well. In contrast, C-reactive pro-
tein and tumor necrosis factor-a promote apoptosis, attenuate
the function, and reduce the number of EPCs (59,60).
CONTRIBUTION OF EPCS TO TUMOR VASCULARIZATION
The fact that EPCs are able to facilitate tumor-induced
vasculogenesis means that although they are primarily pro-
grammed to support blood vessel growth during embryogen-
esis, this progenitor population retains this capability within
an angiogenic milieu in the adult. But what evidence is there
that EPCs actually facilitate tumor vascularization? The ﬁrst
description of tumor-induced vasculogenesis was reported in
2001 by Lyden et al. (25). These authors demonstrated that
EPCs contribute about 90% to vascularization in lymphomas
grown in angiogenesis-defective Id-mutant mice in which
implanted tumors rapidly regress in association with poor de-
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velopment of tumor neovessels. BM transplantation from
wild-type mice, not from Id-mutant mice, restored the tumor
neovascularization and growth in Id-mutant mice. However,
this high EPC contribution in the tumor vasculature is most
probably due to the fact that recipient Id-deﬁcient mice are
unable to sustain endothelial sprouting to support tumor
growth, and therefore, alternative vascularization mechanisms
will be activated. In subsequent animal transplantation mod-
els, EPCs were incorporated into neovessels, sometimes by as
much as 50% (61), whereas other authors reported lower but
signiﬁcant levels between 10 and 20% (62). These observations
have been challenged by some other studies in which EPCs
had no measurable contribution to tumor neovessels. For
example, De Palma et al. (63) reported that TEMs rather than
EPCs homed to tumors and interacted with vascular ECs.
Interestingly, these authors did not ﬁnd EPCs in tumor vessels.
Similarly, based on their observations in a transgenic mouse
model, Gothert et al. suggested that EPCs might not contri-
bute to tumor endothelium (64). Although possible reasons
for such conﬂicting results might include the use of differing
experimental models/techniques to identify EPCs, recent data
suggest that their involvement in experimental tumor vascu-
larization might also vary depending on tumor stage (65).
The contribution of EPCs in the vasculature of human
malignancies has been assessed in some recent studies as well.
Peters et al. investigated patients who developed malignancies
after BM transplantation with donor cells derived from indivi-
duals of the opposite sex. By using ﬂuorescence in situ hybri-
dization with sex chromosome-speciﬁc probes, these authors
found that the percentage of BM-derived ECs in the tumor
vasculatures ranged from 1% (head and neck sarcoma) to
12% (lymphoma) (66), which was closer to the numbers
observed in spontaneous mouse tumors than the zero or
extremely high numbers observed when implanting tumor
lines. Recent studies demonstrated the presence of CD1331
EPCs in the endothelial tubes of human tumor capillaries as
well (67–69) (Fig. 1). Moreover, EPCs have been detected at
increased frequency in the PB of patients with various malig-
nancies including lung (69), hepatocellular (46), breast (43)
and colorectal (70) cancers, and myeloma multiplex (71),
myeloﬁbrosis (72), non-Hodgkin’s lymphoma (67), acute my-
eloid leukemia (73), and malignant gliomas (74).
In conclusion, although it seems obvious that EPCs are
able to support tumor vascularization, the involvement of
these cells may vary depending on circumstances such as the
experimental model or detection technique used, the histolog-
ical type and stage of the tumor, and whether anticancer treat-
ment has been started.
ENDOTHELIAL PROGENITOR CELLS AS POTENTIAL
BIOMARKERS OF HUMAN TUMOR ANGIOGENESIS
Because vascularization is seen as fundamental in tumor
progression, efforts have been made to assess angiogenesis
(75,76) and to identify patients responsive to antivascular
therapies, recognize tumor resistance, and predict the efﬁcacy
of combinations that include antiangiogenic drugs (77). How-
ever, currently there are no proven biomarkers of tumor
angiogenesis. Thus, development of noninvasive biomarkers
of tumor response/relapse is a crucial objective to help in the
management of patients treated with antivascular agents.
As mentioned, mouse models demonstrated a correlation
between circulating EPC levels and tumor volume (25,61,62).
However, other researchers have found that the number of
EPCs also changes with anticancer/antiangiogenic therapy. For
example, maximum tolerable dose chemotherapy was
reported to provoke an EPC elevation, in contrast to metro-
nomic chemotherapy [targeting tumor ECs (13)], which sup-
pressed EPC numbers/viability (78). In additional studies, the
mobilization of EPCs by vascular disrupting agents was dis-
rupted by the administration of antiangiogenic agents (79),
and endostatin was shown to reduce circulating EPC numbers
along with tumor regression (80,81). In addition, treatment
with a targeted VEGFR2 antibody caused a dose-dependent
reduction in EPC levels that paralleled the antitumor activity
of the experimental drug (82). More importantly, methods for
EPC measurements have been tested in cancer patients
(45,46,69,71–73), and studies have been undertaken assessing
EPC levels in individuals treated with antiangiogenic drugs.
Figure 1. Example for the identification of EPCs by using confocal
laser scanning microscopy. In mouse Lewis lung carcinoma,
CD1331 EPCs (green fluorescence) were arrested mainly in small
CD311 intratumoral capillaries (red fluorescence), or much less
frequently, in the alveolar capillaries of the peritumoral lung tis-
sue. White broken line represents the border between tumor and
host tissues. The tumor is present at the upper left.
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Particularly encouraging in this regard are two recent clinical
trials. In a Phase 1 trial, bevacizumab, an anti-VEGF antibody,
reduced the tumor vascular density and the number of EPCs
in rectal carcinoma patients (70). In a subsequent Phase 2 trial
on AZD2171 therapy in glioblastoma (83), progression on
treatment with this pan-VEGF receptor tyrosine kinase inhibi-
tor was associated with an increase in CEC (84), SDF-1, and
FGF-2 levels, whereas progression after drug interruptions cor-
related with elevations in EPC counts and FGF-2 levels. More-
over, the elevation in the levels of these circulating biomarkers
correlated with the magnetic resonance imaging measure-
ments, demonstrating an increase in the relative capillary den-
sity and perimeters.
With the rapid increase in the number of the cancer
patients treated with antivascular agents, there is an urgent
need to deﬁne biomarker algorithms for the follow up. These
studies are especially important in this regard, as they suggest
the potential of EPC quantiﬁcation not only to assess antian-
giogenic therapy efﬁcacy, but to help deﬁne optimal biologic
dose ranges, establishment of appropriate tumor response cri-
teria, and, hopefully, reduction of the adverse effects.
ENDOTHELIAL PROGENITOR CELLS AS CELLULAR VEHICLES
FOR ANTICANCER THERAPY
The ﬁnding that circulating BM-derived EPCs are
recruited to tumor capillaries suggests novel strategies to halt
tumor growth. This might be achieved by using ex vivo
manipulated EPCs as cellular vehicles to deliver suicide genes,
toxins, or antiangiogenic drugs. These novel approaches have
been applied to transplantation models and, to some extent,
reduced cancer progression (85–87). However, given the exis-
tence of different vascularization mechanisms in cancer (13),
the variability in EPC levels reported in different experimental
models, and the association of vasculogenesis with the histo-
logical type and stage of the tumor, the use of EPCs as ‘‘Trojan
horses’’ in an antiangiogenic gene therapy-mediated antican-
cer strategy certainly deserves further investigation.
CONCLUSIONS
In summary, EPCs obviously contribute to the vasculari-
zation of malignant tumors. It is not clear yet, however,
whether they are indispensable for this process or what the
relative contribution of vasculogenesis (i.e. BM-derived EPCs)
is compared with that of in situ angiogenesis (i.e. endothelial
sprouting). Moreover, it still remains to be determined
whether EPCs can only be used as surrogate biomarkers for
monitoring anticancer/antiangiogenic drug efﬁcacy or can be
targeted to treat certain types of malignancies, or alterna-
tively—as they are endowed with the capacity to home to the
tumor vasculature—can be applied to deliver therapeutic
genes, toxins, or vascular targeting agents.
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Abstract: Erythropoietin (EPO) has long been recognized as the major hematopoietic cytokine regulating nor-
mal erythropoiesis. Moreover, there is a growing interest in the non-erythropoietic, tissue-protective effects of 
EPO. Because of its potential to correct anemia, EPO has been increasingly prescribed to cancer patients. 
However, although recombinant human Epo (rHuEPO) significantly reduces the risk for red blood cell transfu-
sions in cancer patients, recent clinical studies have reported decreased survival and disease control following 
rHuEPO treatment in patients with different cancer types. The issue of EPOR expression in tumor cells is criti-
cal in this respect. The expression of EPOR in tumor cells raises the possibility that exogenous rHuEPO may 
directly influence tumor growth or sensitivity to chemo-radiation therapy. In addition, EPOR expression in endo-
thelial cells suggests what potential effects EPO may have on tumor capillaries, such as the stimulation of an-
giogenesis. However, as experimental studies reveal, the overall direct effect of EPO-EPOR signaling on can-
cer progression and therapy is not a straightforward one. The current paper provides an update on the biology 
of EPO, and discusses its utility in the treatment of cancer patients.
Keywords: Erythropoietin, hypoxia, anemia, cancer. 
INTRODUCTION  
Anemia frequently occurs in patients with cancer [1, 
2]. The degree of anemia depends on cancer type, tu-
mor stage, duration of the disease, treatment status, 
patient age and bone marrow reserve. In the European 
Cancer Anemia Survey, the prevalence of anemia was 
39% at enrollment and increased to 67% during the 
survey [3]. The incidence of anemia was 63% in pa-
tients receiving chemotherapy, 42% in those receiving 
concurrent chemoradiotherapy, and only 19.5% in 
those receiving radiotherapy alone [3]. The incidences 
were highest in patients receiving platinum- or anthra-
cycline-based chemotherapy to treat lung cancer, gy-
necological malignancies, genitourinary cancer and 
lymphomas [1, 3]. 
The etiology of cancer-related anemia includes 
myelosuppressive therapy, tumor infiltration of the bone 
marrow, bleeding, hemolysis, relative deficiency of 
erythropoietin, inappropriate response of the bone mar-
row, functional iron deficiency, and anemia associated 
with chronic disease, the most common type of non-
treatment-induced anemia in patients with cancer. 
Anemia has been shown to be a prognostic factor in 
many cancers with an overall 65% increase in the rela-
tive risk of death [4], owing perhaps to anemia’s possi-
ble impact on the outcome of both chemotherapy and  
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radiotherapy as a result of hypoxia-induced treatment 
resistance [5]. The systemic hypoxia caused by anemia 
in cancer patients contributes significantly to tissue hy-
poxia, a common feature of growing cancer. However, 
the correction of anemia, and the increased oxygen 
level inside the tumor not only result in the improve-
ment of quality of life but also enhance the success of 
cancer therapy, leading to improved survival of patients 
[6]. Recombinant human erythropoietin (rHuEPO) is 
widely used for correction of hemoglobin level by in-
creasing the number of red blood cells [7, 8]. Recent 
studies initiate that, besides hematopoietic progenitor 
cells, numerous other cell types (endothelial- and can-
cer cells) express erythropoietin receptor (EPOR) and 
rHuEPO may affect their functions [9, 10]. However, 
new clinical and experimental data are contradictory on 
the way by which exogenous rHuEPO treatment can 
influence cancer growth and therapy [11-17]. Below, 
we will discuss the molecular consequences of cancer 
hypoxia, providing a solid basis for correction efforts in 
anemic cancer patients. We will also analyze the recent 
controversies over erythropoietins, pre-clinical findings 
and current usage guidelines. We firmly believe that 
only scientific and clinical evidences can resolve the 
controversies over clinical use of rHuEPOs.  
EPO IN THE HEMATOPOIETIC SYSTEM 
The glycoprotein hormone erythropoietin (EPO, MW 
30.4 kDa) belongs to the family of class I cytokines 
[18]. The peptide core, containing 165 amino acids, has 
a globular structure with 4 -helix bundles and two 
structure-stabilizing disulfide bonds and is attached by 
four carbohydrate chains including one O-linked acidic 
and three N-inked oligosaccharides [19]. The protein is 
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responsible for cytokine binding and the stimulation of 
erythropoiesis, while the carbohydrate parts are re-
quired for the production and secretion of the mature 
EPO and ensure the survival of the cytokine in the 
blood stream [20]. During embryogenesis, EPO is pro-
duced mainly by the liver, but after birth production is 
taken over by the peritubular fibroblast-like cells of the 
kidney cortex [21, 22]. However, in adults, several 
other tissues (i.e. liver, brain, spleen, testis, lung) and 
cell types (i.e. peripheral endothelial cells, vascular 
smooth muscle cells, pancreatic islets) express EPO 
mRNA, although these EPOs have no role in normal 
erythropoiesis [23-26].  
The EPO gene is located on the long arm of chro-
mosome 7, exists as a single copy in a 5.4-kb region of 
the genomic DNA, is composed of five exons and four 
introns, and is under the control of the hypoxia-
inducible factor-1 (HIF-1) pathway [27-30]. Interest-
ingly, although EPO is the main modulator of erythro-
poiesis, the decreasing red blood cell number does not 
induce EPO production; only the diminished tissue 
oxygen concentration turns on gene expression and 
protein secretion [31]. The O2-sensor controls several 
hypoxia-related genes through the hypoxia-responsible 
elements (HRE) sequence located in the regulatory site 
of these genes [32], which bind the hypoxia-inducible 
transcription factors (HIFs). HIFs are dimers containing 
one - and one -subunit and belong to the family of 
basic helix-loop-helix (bHLH) proteins. Three types of 
-subunits are known (1, 2, 3), but only the HIF-
1/ is described as the regulator of hypoxia-related 
genes [33]. Both subunits are constitutively produced 
and in normoxic conditions HIF-1 is hydroxylated at 
two proline residues by an enzyme containing specific 
prolyl-hydroxylase domain (PHD) [34]. Prolyl-
Fig. (1). Theoretical effect of EPO treatment on hypoxia signaling in cancer. 
HIF-1 levels are mainly regulated post-transcriptionally, by the rate of HIF-1 production and degradation. Under normoxia, 
HIF-1 is hydroxylated at specific proline residues (proline 402 and 564) via prolyl hydroxylases (PHDs 1–3). This HIF- modifi-
cation allows binding to the tumor-suppressor protein von Hippel–Lindau (VHL), a recognition component of an E3 ubiquitin li-
gase complex. Subsequently, HIF-1 subunits become ubiquitylated that drive them to degradation in the proteasomal system. 
Under hypoxia, HIF-1 remains unhydroxylated, slowing the HIF-1 destruction rate and allowing large HIF-1 quantities to ac-
cumulate in the cytoplasm. The hypoxic stabilization of HIF-1 also allows its translocation to the nucleus where it heterodimer-
izes with HIF-1ß to bind to the “hypoxia-response elements” (HREs) in the promoter and enhancer regions of target genes. Be-
cause, as demonstrated in various anemic animal models, the oxygen tension of tumors tends to rise with increasing Hb levels, 
and EPO treatment has recently demonstrated to be associated with increased tumor perfusion, EPO may have the potential to 
block HIF signaling and to improve sensitivity of tumors to chemo- and/or radiotherapy.  
AH= asparagine hydroxylase; ARNT= aryl hydrocarbon receptor nuclear translocator; bFGF= basic fibroblast growth factor; 
EPO= erythropoietin; ET-1= endothelin-1; HRE= hypoxia response element; HSP90= heat shock protein 90; LDH-A= lactate 
dehydrogenase-A; NOS= nitric-oxide synthase; PDGF= platelet derived growth factor; PRH= prolyl hydroxylase; U= ubiquitin; 
VEGF= vascular endothelial growth factor; VEGFR= vascular endothelial growth factor receptor; VHL= von Hippel-Lindau pro-
tein. 
Erythropoietin in Cancer Current Molecular Medicine,  2008, Vol. 8, No. 6     483
hydroxylated HIF-1 is the target of the von Hippel-
Lindau protein (pVHL) and the E3 ubiqutin ligase com-
plex. Polyubiquitinated HIF-1 is degraded at the cellu-
lar proteosomes [35, 36]. Under hypoxic conditions, 
HIF-1 escapes from the degradation mechanism and 
forms a functionally active transcription factor complex 
with HIF-1 at the nucleus (Fig. 1).  
The main targets of endogenous EPO are the 
“burst-forming unit erythroid” (BFU-E) and the “colony-
forming unit erythroid” (CFU-E) stem cells in the bone 
marrow [37-39]. These stem cells produce erythroblast 
colonies whose number correlates with EPO concen-
trations [40]. It is well documented that the primary ef-
fects of EPO on the production of erythrocytes is the 
prevention of stem cell apoptosis [41, 42]. BFU-Es and 
even more CFU-Es express GATA-1 transcription fac-
tor [43], which can modulate the caspase system 
through activation of the bcl-XL anti-apoptotic protein 
[44]. The erythroid progenitors can produce a small 
amount of EPO to maintain a basal level of proliferation 
and erytropoiesis [45]. However, as the level of 
erythropoietin in the blood increases, a growing num-
ber of erythroid progenitors can survive, proliferate and 
differentiate into proerythroblasts and normoblasts. 
EPO regulates the stem cell proliferation and apop-
tosis through the specific erythropoietin receptor 
(EPOR). This glycosylated cell surface protein consists 
of 484 amino acids in a single chain and is a member 
of the cytokine class I receptor superfamily [46]. One 
EPO molecule crosslinks two EPORs forming a func-
tionally active dimer through the extracellular ligand-
binding domains, which induce conformational change 
and start signal transduction. Since the intracellular 
domain has no catalytic activity, the signal is mediated 
by the tyrosine kinase JAK2 that is constitutively asso-
ciated to the receptor [47, 48]. After receptor activation 
by EPO, JAK2 phosphorylates several proteins (includ-
ing EPOR) and these tyrosine-phosphorylated mole-
cules can bind signal peptides containing Src homology 
2 domains (SH2) [49]. Accordingly, several signal 
transduction pathways can be activated, such as phos-
phatidyl-inositole 3-kinase (PI3K)/protein kinase B 
(Akt), Grb2/Ras/MAPK, protein-kinase C, Src-
homology phosphatases (SHP1,2) and STAT5 [50] 
(Fig. 2). The main downstream signal is the 
JAK2/STAT5 pathway: phosphorylated STAT5 mole-
cules form stable and functionally active dimers as 
transcription factors, which regulate target gene ex-
pression after translocation to the nucleus, resulting in 
erythroid differentiation [51]. EPO prevents apoptotic 
cell death by maintaining the mitochondrial membrane 
potential, which prevents the cellular release of cyto-
chrome C and modulates caspase activity using these 
different signaling pathways. Signaling terminates with 
the dephosphorylation of the JAK2 and the EPOR fol-
lowing EPO/EPOR internalization and degradation in 
proteosomes [52]. In addition to these full-length forms 
of EPOR (F-EPOR), there are two other isoformes ex-
pressed by different erythroid cells. The truncated form 
Fig. (2). EPOR signaling pathways. 
ERK= extracellular signal-related kinase; Grb2= Growth factor receptor-bound protein 2; JAK2= Janus kinase-2; MEK= mitogen 
extracellular kinase; NFkB= nuclear factor-kappa B; Raf= MAP3K= mitogen-activated protein kinase kinase kinase; Ras= Rat 
sarcoma viral oncogen homolog; STAT5= Signal transducer and activator of transcription-5. 
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(T-EPOR) plays a role in the survival of erythroid pro-
genitors in low EPO concentration, while the soluble 
form (S-EPOR) is an antagonist of F-EPOR in neuronal 
tissues [53, 54]. 
EPOR EXPRESSION ON NON-HEMATOPOIE-
TIC CELLS 
Until recently it was generally accepted that EPO 
plays a role solely in erythropoiesis. However, several 
data indicate that the EPO-receptor is expressed by a 
variety of non-hematopoietic cells. EPOR can be de-
tected on neurons, microglias, astrocytes, megakario-
cytes, cardiomyocytes, epithelial-, insulin producing-, 
vascular smooth muscle- and endothelial cells (re-
viewed in ref. [55]). Molecular (RT-PCR, nested PCR) 
and immuntechniques (Western-blot, histochemistry) 
can be used to detect EPOR, but it should be empha-
sized that using antibodies to detect EPO receptor pro-
tein often has questionable results. Elliot et al. [56] 
tested four commercially available rabbit polyclonal 
antipeptide anti-EPOR antibodies, including C-20 (sc-
695; anti-human EPOR), M-20 (sc-697; anti-mouse 
EpoR), H-194 (sc-5624; anti-human EPOR) from Santa 
Cruz Biotechnology (Santa Cruz, CA), and 07-311 
(anti-mouse EPOR) from Upstate Biotech (Waltham, 
MA) using immunoblotting and immunohistochemistry 
techniques. They found that none of the investigated 
antibodies were suitable for detecting EPOR by immu-
nohistochemistry (because of a cross-reaction with 
other proteins), and only M-20 gave an adequate result 
in detecting EPOR by immunoblotting. 
TUMOR HYPOXIA AND ADAPTATION MECHA-
NISMS 
Hypoxia arises due to a critical imbalance between 
the tissue’s supply of O2 and its consumption rate. In 
solid tumors, there are several basic mechanisms lead-
ing to hypoxia: structural/functional abnormalities of the 
tumoral blood vessels [57] (perfusion caused de-
creased O2 delivery), diffusion abnormalities (poor dif-
fusion of O2) and tumor- or therapy-induced anemia 
(anemic hypoxia).  
Poor perfusion of cancer tissue usually leads to 
acute ischemic hypoxia. In malignant tumor tissues, the 
diffusion distance of O2 usually increases above 70 m
from the supplying blood vessel, which results in 
chronic hypoxia in the supplied area (Table 1). The 
irregular development and structure of tumoral vessels 
causes this condition to further deteriorate.  
Systemic anemia, a common phenomenon in can-
cer, significantly reinforces the negative consequences 
of both the perfusion- and diffusion-limited hypoxia in 
cancer tissues. Because it is increasingly clear that 
tumor hypoxia fundamentally affects not only the prog-
nosis of the disease but the therapeutic responses as 
well, it is important to summarize here our growing 
knowledge on the molecular and physiological conse-
quences of hypoxia in cancer cells.  
There are two oxygen sensors in mammalian (and 
cancer) cells: the PHD (prolyly-hydroxylase domain) 
proteins, belonging to the family of non-haem oxidizing 
enzymes, and the asparaginyl hydroxylase FIH (factor 
inhibiting HIF [58]). Both proteins target (and regulate) 
the transcription factor HIF-1 [59]. In a well-
oxygenated milieu (~20% O2) the half life of HIF-1 is 
less than 5 min due to proteasomal degradation 
caused by VHL protein and E3 ubiquitin ligase com-
plex. Although there are three isoforms of PHD, in can-
cer cells PHD1 function predominates in regulating 
HIF-1 degradation. On the other hand, in normoxic 
conditions, FIH hydroxylates the C-terminal asparagin-
containing transcriptional activation domain of HIF-1
inhibiting its interaction with its co-activators p300 and 
CBP. This results in repression of the transcriptional 
activity of HIF-1 already associated with the DNA [58-
60]. 
HIF1 is a family of transcription factors, where HIF-
1 is constitutively expressed and HIF1, HIF2 and 
HIF3 are regulated by the level of O2 [58, 59, 61]. The 
 and  subunits must heterodimerize in order to rec-
ognize the HRE elements (RCGTG) in the promoter 
regions of several genes. HIF is activated at 5% O2 (40 
mmHg) level in vitro with a progressive increase in its 
activity to near anoxia (0.1-0.2%). This activation proc-
ess is initiated by stabilization of the cytoplasmic pro-
tein (escape from proteasomal degradation), nuclear 
translocation, heterodimerization and transcriptional 
activation. Knowing the approximately 100 genes con-
trolled by HIF under hypoxic conditions is critical. Ac-
cording to our current knowledge these genes can be 
divided into the following categories: genes involved in 
angio- and erythrogenesis, glucose metabolism, and 
metastasis.  
Promoters of the key angiogenic cytokines VEGFs, 
bFGF, HGF as well as EPO all contain HRE and their 
gene expression are regulated by hypoxia through HIF. 
Furthermore, the expression of the receptors of VEGFs 
as well as of HGF (c-met) is also regulated by the HIF 
Table 1. Oxygenation Status and Expression of HIF1 in Human Cancers. [See in Ref: 122] 
Cancer type Hypoxic fraction in % (pO2<2.5 mmHg) Incidence of HIF1 protein (%) 
Breast cancer 25-40 40-100 
Cervical cancer (uterine) 11-47 72-100 
Head and neck cancer 0-25 64-94 
Various cancers NA 53 [Ref. 61]  
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system. HIF controls the expression of (i)NOS, a sur-
vival enzyme of the endothelial cells, too [62].  
HIF may also control enzymes involved in glucose 
metabolism under hypoxia. These include glucose 
transporters (GLUT1/GLUT3), glycolytic enzymes, 
LDH-A, pyruvate dehydrogenase kinase-1 and cyto-
chrome C oxidase subunit COX4-2. HIF regulates en-
zymes involved in intracellular pH regulation as well, 
such as MCT (monocarboxylate transporter), 
hexokinase-1/2 and carbonic anhydrase-9 (CAIX [63, 
64]).  
Hypoxia (and HIF) has been shown to be capable of 
modulating the expression of several genes involved in 
tumor progression, while HIF2 is known to regulate 
the expression of OCT4 and ID2 stem cell marker 
genes, as well as the expression of MYC, TGF and 
CCND1 responsible for the regulation of cell prolifera-
tion [65]. HIF1 may interact with -catenin as well. HIF 
(1 in particular) is also involved in regulating the ex-
pression of several genes involved in tumor metastasis, 
including intermediate filaments, vimentin, cytokeratins 
(14,18,19), the matrix protein fibronectin, proteases 
such as MMP2, uPA, cathepsin D, lysyloxydase, the 
autocrine motility factor (AMF, phosphoglucose 
isomerase), the AMF receptor gp78 and the chemokine 
receptor CXCR4 [66, 67]. One of the hallmarks of the 
invasive phenotype of epithelial cancer cells is epithe-
lial-mesenchymal transition characterized by de-
creased expression of E-cadherin and cytokeratins and 
increased expression of vimentin and c-met. It was 
found that through LOX (and LOXL2 in particular), HIF 
can modulate the activity of Snail/slug resulting in the 
repression of E-cadherin. On the other hand HIF also 
targets E-cadherin repressors resulting in the repres-
sion of E-cadherin gene expression too [65, 66]. 
As summarized above, cellular hypoxia in tumor 
cells initiates a cascade of events which leads to the 
reprogramming of hypoxic cancer cells and promotes 
the development of aggressive cancer cell clones with 
a more aggressive, irradiation-[68] and therapy-
resistant geno-/phenotype. This angiogenic phenotype 
of cancer cells is characterized by the overexpression 
of various angiogenic cytokines, which initiates and 
maintains the increased activity of neoangiogenesis in 
tumors, stimulates postnatal vasculogenesis in the 
bone marrow, and promotes vascular remodeling [57].  
Hypoxia in tumor tissue acts as a double-edged 
sword. On the one hand, hypoxia induces cell cycle 
arrest and apoptosis of cancer cells through a p53- and 
BCL-2-dependent mechanism [59]. On the other hand, 
hypoxia triggers adaptation mechanisms to overcome 
nutrient deprivation and lack of O2 resulting in a tumor 
cell population chronically adapted to a hypoxic envi-
ronment. By virtue of clonal selection, hypoxia pro-
motes the accumulation of cancer cells that are geneti-
cally resistant to hypoxic conditions. Furthermore, hy-
poxia through HIF-activation induces genetic mecha-
nisms that help cancer cells to escape the hypoxic en-
Fig. (3). Example for perivascular tumor growth. 
Confocal image of mouse brain microvessels labeled for the endothelial cell marker CD31 (green) and the basal membrane 
component laminin (red). Hypoxia, through the activation of genetic mechanisms that help pigment containing B16 melanoma 
cells to escape the hypoxic environment, forces tumor cells to migrate toward host vasculature without the onset of angiogene-
sis. 
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vironment (through migration to better perfused areas 
[66, 67], usually to an area around the intratumoral 
blood vessels (Fig. 3). Unfortunately, these activated 
genes are just what are needed for local invasion and 
intravasation of cancer cells, leading to systemic dis-
semination and metastasis.  
Hypoxia results in a relative resistance to irradiation 
caused by the oxygen enhancement effect (increased 
DNA-damage caused by irradiation in the presence of 
O2 [68]. However, it seems that acute and chronic hy-
poxia differentially affects radiosensitivity: while acute 
hypoxia/anoxia results in radioresistance, chronic hy-
poxia seems to increase the radiosensitivity of cancer 
cells. However, tumor stroma may respond differently 
to hypoxia than cancer cells do, which may also influ-
ence radiosensitivity of tumor tissue. The effectiveness 
of irradiating tumor tissue critically depends on the ef-
fect on tumoral vasculature, where the sensitivity of the 
blood vessels depends on angiogenic survival factors 
(cytokines) produced by hypoxic cancer cells [69-72]. 
At this point it is difficult to calculate the net outcome of 
those processes, but more data suggest that hypoxia of 
tumor tissue decreases the sensitivity to irradiation.  
Novel data has revealed the molecular background, 
showing how hypoxia induces genetic instability in the 
tumor cell population, leading to clonal selection for 
therapy resistance and progression. Hypoxia represses 
the expression of miss-matched repair genes and 
homologue recombination repair as well. This is due to 
HIF-independent mechanisms that involve the phos-
phorylation of the E2F4/p130 repressor complex result-
ing in a decrease in BRCA1 and RAD51, the posttrans-
lational modulation of H3K9, and the activation of 
Mnt/Max resulting in a decrease in MLH1 and activa-
tion of Mad1/max to depress MSH2 expressions [73]. 
All these genetic alterations can also be regarded as 
paving the path for a more chemotherapy-resistant 
genotype.  
These molecular scenarios can be significantly al-
tered in cancer cells. In various cancers, HIF genes 
can be constitutively active for various reasons inde-
pendent of oxygenation status [61]. One rare possibility 
is the activating mutation of HIF genes themselves. 
More frequently, mutations of other regulating genes, 
such as of the p53 or VHL, result in HIF activation. Last 
but not least, activation of various oncogenic signaling 
pathways characteristic of various cancers such as 
breast, lung or pancreas and involving HER-2, EGFR 
or K-RAS maintains the sustained activity of HIFs [57, 
59, 65]. In such conditions hypoxia of cancer tissue 
induces adaptive molecular responses in stromal cells 
exclusively. 
DIRECT EFFECTS OF EPO ON TUMOR CELLS: 
FACTS AND UNANSWERED QUESTIONS 
EPOR has been detected in growing numbers on 
non-hematopoietic cell types including different tumor 
cell lines and primary tumors, raising the question of 
weather EPO can modulate the biology of these cells. 
At the same time, it is well documented that anemia 
and tissue hypoxia negatively influence the tumor ther-
apy and the patient’s quality of life [74, 75]. Hence, 
various rHuEPOs are frequently used for correction of 
the decreased hemoglobin level in cancer patients, 
potentially increasing progression of the EPOR-
expressing tumors [76]. 
Several in vitro and in vivo preclinical experiments 
have demonstrated that rHuEPO treatment modulates 
tumor growth and the efficacy of cancer therapy; how-
ever, these data are controversial and unexplained. A 
broad variety of tumor types express EPO and EPOR 
mRNA, particularly under hypoxic conditions [77]. 
Moreover, research has demonstrated that different 
splice variants of EPOR are expressed in tumor cell 
lines [14]. Administration of exogenous rHuEPO in-
creased the in vitro proliferation of breast [77] and renal 
cell carcinoma cells [78]. Similar results, but lower in-
duction effects of proliferation and invasion, were re-
ported in head and neck squamous cell carcinoma cell 
lines [79]. The inhibition of erythropoietin signaling sys-
tem by soluble EPOR or anti-EPO antibody destroyed 
xenografts of ovarian and uterine cancers in nude 
mice, as a result of increased apoptosis of tumor cells 
[80]. In other studies, administration of EPOR antago-
nist inhibited melanoma and stomach choriocarcinoma 
tumor cell survival [81] and rat mammary adenocarci-
noma tumor growth [82]. 
In contrast, however, Berdel et al. showed that ex-
ogenous rHuEPO has no growth-modulating effect on 
22 non-hematopoietic tumor cell lines [83]. Other re-
search has similarly found that EPOR+ melanoma [84] 
and breast carcinoma cell lines [85], as well as six 
other EPOR-positive tumor cell lines [86] did not prolif-
erate in the presence of rHuEPO. Moreover, rHuEPO 
enhanced the antitumor efficacy of photodynamic ther-
apy in mice [87] and restored the anemia-induced re-
duction of cyclophosphamide cytotoxicity in rat tumors 
[88] and the radiosensitivity of experimental tumors 
[89]. rHuEPO alone induced tumor regression and anti-
tumor immune response in murine myeloma models 
[90]. 
Worth mentioning is another interesting side effect 
of EPO that can influence exogenous rHuEPO admini-
stration in cancer patients. It is well documented that 
endothelial cells also express EPO receptors, and sev-
eral data indicated that EPO inhibits apoptosis and in-
duces proliferation and migration of these cells [91, 92]. 
EPO is a potent angiogenic factor comparable in its 
effect to VEGF [93], while rHuEPO has been shown to 
stimulate the in vitro endothelial tube formation and in 
vivo angiogenesis in chicken chorioallantois membrane 
assay [94]. Furthermore, it is also known that normoxic 
conditions (i.e. appropriate level of tissue oxygen) have 
a positive effect on the efficacy of chemo- and/or radio-
therapy, verifying the important role of the tumor vascu-
lature. Blackwell et al. demonstrated that administration 
of rHuEPO improved the oxygenation inside the living 
tumor mass independent of the hemoglobin level [95], 
suggesting that tumor oxygenation may be increased 
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by enhanced tumor perfusion. In human squamous cell 
and colorectal carcinoma xenograft models, rHuEPO 
administration significantly increased the proliferation 
index of tumor-associated endothelial cells, but without 
stimulation of tumor cell proliferation, leading to larger 
intratumoral blood vessels. The increased vessel sur-
face resulted in improved drug delivery to tumor cells 
and augmented its antitumor effects [96]. 
On the other hand, as described previously, one of 
the key factors in the antitumor action of irradiation is 
its anti-angiogenic effect [69, 70]. Exogenous rHuEPOs 
enhanced the radiation sensitivity of intratumoral endo-
thelial cells increasing their apoptosis inducing capacity 
[71, 72] resulting in effective tumor control. Exogenous 
EPO decreased both the host- and tumor-derived 
VEGF expression suggesting the proliferation-
promoting effect of rHuEPO on tumoral endothelial 
cells is independent of VEGF production [95]. Data in-
dicate that HIF-1 could be responsible for decreased 
VEGF expression, since HIF-1 gene expression was 
also decreased in rHuEPO-treated animals before ra-
diotherapy [97]. The underlying molecular conse-
quences of hypoxia correction are illustrated on Fig. 
(1). Some data suggest there is a tight correlation be-
tween HIF-1 expression and tumor progression [98], 
and HIF-1-regulated cytokines enhance the radioresis-
tance of endothelial cells. Moreover, inhibition of postir-
radiation HIF-1 activation significantly increased tumor 
radiosensitivity through vessel destruction [70].  
These results suggest that rHuEPO treatment has 
at least two different effects on tumors: first, it can de-
crease hypoxia, which is well-known as one of the 
markers of poor prognosis; second, it increases endo-
thelial cell proliferation, causing enhanced radiosensi-
tivity of the vessels and tumor perfusion by oxygen and 
chemotherapeutic agents. 
rHuEPOs IN CANCER PATIENTS 
Cancer-related anemia leads to cancer-related fa-
tigue and many other symptoms [99, 100]. Patients 
with fatigue complain of generalized weakness, easy 
tiring, diminished concentration, sleep disturbances, 
memory loss and emotional instability. Fatigue, often 
associated with anxiety and depression, has a major 
impact on the social and occupational life of these pa-
tients. Absolute Hb levels, rapid onset of anemia, com-
pensatory mechanisms and co-morbidity all influence 
anemia-related symptoms. Diagnosis of anemia should 
focus on symptoms, ability to perform daily activities, 
blood cell counts and laboratory parameters (e.g. iron 
status, vitamin levels). Determining the possible causes 
of the anemia is also essential. In making the diagno-
sis, quality of life instruments should be used, as they 
allow for a more detailed evaluation [101]. 
TREATMENT OF TUMOR- OR THERAPY-
INDUCED ANEMIA 
Treatment of cancer-related anemia should primar-
ily aim at correcting potential causes. Red blood cell 
transfusion and the administration of recombinant hu-
man erythropoietins are important symptomatic treat-
ments.  
Red Blood Cell Transfusions 
Red blood cell transfusions are usually given only to 
patients with Hb levels approaching 8 g/dl and/or highly 
symptomatic patients. Approximately one third of can-
cer patients require at least one transfusion and 16% 
need multiple transfusions [102]. Patients at risk for 
transfusions are those with low baseline Hb levels, ad-
vanced age, advanced disease, reduced performance 
status, weight loss, and platinum- or anthracycline-
based chemotherapy. Patients with lung cancer, ovar-
ian cancer or genitourinary cancer have the highest 
transfusion rates. Transfusions result in immediate but 
often only transient relief. Side effects of transfusions 
are hemolysis, iron overload and transmission of infec-
tious agents [103, 104]. 
Erythropoietic Proteins  
The erythropoietic proteins in clinical use are epo-
etin alfa, epoetin beta and darbepoetin alfa. Continuous 
erythropoiesis receptor activator (CERA) is in clinical 
development and biosimilars are expected to be avail-
able in the future.  
Erythropoietic proteins increase Hb levels and de-
crease RBC transfusions in patients either receiving 
chemotherapy, chemoradiotherapy, radiotherapy or not 
receiving chemotherapy [105-108], for review see ref. 
[2]). Erythropoietic proteins decrease the relative odds 
of receiving a RBC transfusion by an average of 62% 
[109]. Erythropoietic proteins improve anemia-related 
symptoms and quality of life and these improvements 
correlate with Hb increases [107].  
PRACTICE GUIDELINES 
Practice guidelines on the use of erythropoietic pro-
teins are available from the American Society of Clini-
cal Oncology and the American Society of Hematology 
[109, 110], the EORTC [111] and other organizations. 
Currently, erythropoietic proteins are only recom-
Table 2. Guidelines for Chemotherapy-Induced Anemia [119] 
Trigger Hb <10 g/dl  
 >10 but < 12 g/dl elderly patients with limited cardiopulmonary reserve coronary artery disease reduced ability to carry out 
daily life 
Target Hb near to 12 g/dl  
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mended for patients with chemotherapy-induced ane-
mia (Table 2).  
ASCO/ASH Guidelines 
The previously published guidelines were recently 
updated [109, 110]. Epoetins are recommended for 
patients with chemotherapy-induced anemia and a Hb 
level of 10 g/dl or less. For patients with less severe 
anemia epoetins might be considered dependent on 
clinical circumstances. A target level of 12 g/dl is rec-
ommended.  
Starting dose and dose modifications should be pre-
scribed according to the package insert (Table 3). Non-
responders should be considered for a dose escalation 
for an additional 4-6 weeks. Continuing treatment 
beyond 6-8 weeks in the absence of response is not 
recommended. Iron stores should be monitored. How-
ever, more studies on optimal iron supplementation are 
warranted. 
The prophylactic use of erythropoietic proteins is not 
recommended. The guidelines also caution against the 
use of erythropoietic proteins in patients not receiving 
chemotherapy.  
EORTC Guidelines 
Initiation of treatment with erythropoietic proteins is 
recommended at Hb levels of 9-11 g/dl based on ane-
mia-related symptoms in patients with chemotherapy-
induced anemia [111]. Based on individual factors and 
clinical circumstances, the erythropoietic proteins may 
also be considered in asymptomatic patients with ane-
mia and in patients with only mild anemia. A target Hb 
level of about 12 g/dl is recommended. 
SAFETY OF ERYTHROPOIETIC PROTEINS 
Erythropoietic proteins are usually well tolerated. 
Clinically relevant side effects are hypertension and 
thrombo-embolic events (transient ischemic attacks, 
stroke, pulmonary emboli, deep vein thrombosis and 
myocardial infarction). The risks are increased by 1.25-
fold for hypertension and by 1.67-fold for thrombo-
embolic events [112,113]. Skin reactions, cephalea and 
influenza-like symptoms are also occasionally seen. 
ERYTHROPOIETIC PROTEINS AND SURVIVAL 
OF CANCER PATIENTS  
Because anemia contributes to tumor hypoxia, 
which is associated with resistance to cytotoxic drugs 
and radiotherapy, control of anemia by erythropoietic 
proteins could improve response to anticancer therapy 
and, thereby, also prolong survival.  
Initial trials suggested that epoetins administered to 
patients with chemotherapy-induced anemia might im-
prove survival in patients undergoing non-platinum 
chemotherapy for breast cancer [105] or platinum-
based chemotherapy for small cell lung cancer, [106] 
but both trials lacked statistical power to exactly deter-
mine the association between treatment with erythro-
poietic proteins and survival. A potentially positive im-
pact of erythropoietic proteins on survival was further 
supported by a meta-analysis of controlled trials, which 
found a survival benefit with an adjusted HR of 0.81 
(95% CI 0,67-0,99) and an unadjusted HR of 0,84 
(95% CI 0,69-1,02) [112].  
However, two subsequent trials raised concerns 
about the safety of erythropoietic proteins with regard 
to survival [17, 114, 115]. In patients undergoing che-
motherapy for metastatic breast cancer, the 1-year sur-
vival rate was 70% in the epoetin alfa group but 76% in 
the placebo group [17, 114]. In patients undergoing 
radiotherapy for head and neck cancer, survival was 
shorter in the epoetin group in the intent-to-treat analy-
sis but no survival difference was seen in the per pro-
tocol analysis [115]. The percentage of patients achiev-
ing Hb levels greater than 14 g/dl (women) or 15 g/dl 
(men) was much higher in the epoetin beta group than 
in the placebo group (82% versus 15%). This high tar-
get Hb level achieved in most epoetin-treated patients 
could have had a detrimental impact on oxygen deliv-
ery to the tumor and, thereby, could have decreased 
the efficacy of radiotherapy in these patients. Other 
shortcomings of the trial were a heterogeneous patient 
population, imbalances between the groups, inappro-
priate treatment (radiotherapy instead of radioche-
motherapy), protocol violations, and poor overall out-
come.  
A renewed meta-analysis on 8167 patients from 42 
trials revealed a HR of 1.08 (95% CI 0.99-1.18) [113]. 
This meta-analysis did not include two recent trials 
which demonstrated a neutral effect of erythropoietic 
proteins on survival in patients undergoing chemother-
apy for either breast cancer [116] or small-cell lung 
cancer [117]. A prematurely closed trial in small cell 
lung cancer also found no effect of epoetin alfa on sur-
vival [118]. Thus erythropoietic proteins appear to be 
safe in patients with chemotherapy-associated anemia. 
The situation might be different for patients with 
cancer-related anemia in the absence of chemother-
Table 3. Recommendations for Dose Modifications 
Initial dose Epoetin alfa 150 U/kg subcutaneous 3-times weekly
Epoetin beta 30 000 U subcutaneously weekly
Darbepoetin alfa 2.25 g/kg weekly or 500 g every 3 weeks
Dose reduction decrease dose by 25% when Hb approaches 12 g/dl or increase >1 g/dl in 2 weeks
Dose withholding if Hb exceeds 12 g/dl and withhold until Hb <11 g/dl, restart dose at 25% below
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apy. Three trials in which patients received either radio-
therapy or best supportive care only reported a detri-
mental impact of erythropoietic proteins on survival. 
One of these trials was prematurely closed due to an 
unplanned safety analysis and included only 70 pa-
tients with non-small cell lung cancer [119]. The second 
trial was in patients with head and neck cancer under-
going radiotherapy [120]. The third trial included pa-
tients with cancer-related anemia without chemother-
apy [121]. All these trials were criticized for epoetin use 
outside the approved indications, heterogeneous pa-
tient populations, and target Hb levels above the ap-
proved target levels. Based on the results from these 
trials, the up-dated ASCO guidelines caution against 
the use of erythropoietic proteins in these patients.  
SUMMARY AND FUTURE DIRECTIONS 
Cancer hypoxia has emerged as one of the key is-
sues in tumor progression, angiogenesis and therapy 
resistance because of its profound effect on gene ex-
pressions of cancer cells. At the same time, cancer-
related anemia is one of the most common complica-
tions of advanced disease and chemotherapy resulting 
in systemic (as well as local) hypoxia. Accordingly, at-
tempts are justified to correct both the systemic as well 
as local (intratumoral) oxygen status of cancer patients. 
Although erythropoietins are powerful drugs for correct-
ing anemia (and systemic hypoxia), they may have di-
rect or indirect side effects due to their effects on bone 
marrow, tumor stroma, or the tumor cells themselves. 
Although preclinical data are available for the broad 
range of effects of EPOs on various cell types, includ-
ing cancer cells, clinical data are lacking on whether 
this has detrimental effects in cancer patients. Most of 
the preclinical data have indicated that EPOs are at 
least neutral in relation of the efficacy of various anti-
cancer modalities. Furthermore, most of the clinical trial 
data suggest that EPOs do not decrease the efficacy of 
anticancer therapies, although recently there have 
been a few disturbing exceptions. Therefore, further 
preclinical and clinical research on EPO biology and 
the association between erythropoietic proteins and 
disease outcome, including survival, are warranted. 
These trials should be based on homogeneous patient 
populations with homogeneous treatment and should 
have sufficient statistical power, otherwise they cannot 
provide enough strong clinical evidence to support any 
changes in the guideline for the use erythropoietins in 
cancer patients. 
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Abstract
Several in vitro and in vivo studies have examined the positive and negative effects of retinoids
(vitamin A analogs) in premalignant and malignant lesions. Retinoids have been used as
chemopreventive and anticancer agents because of their pleiotropic regulator function in cell
differentiation, growth, proliferation and apoptosis through interaction with two types of nuclear
receptors: retinoic acid receptors and retinoid X receptors. Recent investigations have gradually
elucidated the function of retinoids and their signaling pathways and may explain the failure of
earlier chemopreventive studies.
In this review we have compiled basic and recent knowledge regarding the role of retinoid
receptors in lung carcinogenesis. Sensitive and appropriate biological tools are necessary for
screening the risk population and monitoring the efficacy of chemoprevention. Investigation of
retinoid receptors is important and may contribute to the establishment of new strategies in
chemoprevention for high-risk patients and in the treatment of lung cancer.
Background
Despite antismoking efforts and advances in therapy, lung
cancer remains the leading cause of cancer-related death
worldwide [1].
Multi-step carcinogenesis has been described as "a gradual
accumulation of genetic and epigenetic aberrations result-
ing in the deregulation of cellular homeostasis" [2]. There
is a similarity between bronchial lesions found in carcin-
ogen-treated animals (squamous metaplasia) and the his-
tological changes affecting the bronchial epithelia of
humans or animals deficient in vitamin A. Restoration to
a normal histological state occurs after vitamin A reple-
tion, which in experimental models has also been shown
to confer protection against pro-carcinogens.
The term retinoid (first coined by Sporn in 1976) gener-
ally refers to naturally occurring and synthetic vitamin A
(retinol) metabolites and analogs [3].
Several studies have shown that vitamin A/retinoids are
physiological regulators of embryonic development,
vision, reproduction, bone formation, haematopoesis,
differentiation, proliferation and apoptosis. Pharmaco-
logically, they have been recognized as modulators of cell
growth, differentiation and apoptosis. Furthermore they
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organs (e.g. oral cancer, skin, bladder, lung, prostate and
breast cancers) in experimental animals [4]. Clinically,
retinoids reverse premalignant human epithelial lesions
and prevent lung, liver and breast cancer and second pri-
mary tumors in the head and neck [5].
It is now generally thought that the effects of retinoids are
mainly mediated by the nuclear retinoid receptors, which
are members of the steroid and thyroid hormone receptor
superfamily [6,7]. Two families of retinoic receptors have
been identified, namely RARs and RXRs with three sub-
types for each (α; β, γ) and several isoforms arising from
promoter usage and alternate splicing. The retinoid recep-
tors are ligand-activated, DNA binding trans-acting, tran-
scription-modulating proteins. The three RAR types have
a strong affinity for all-trans and 9-cis isomers of retinoic
acid. The three RXR types, on the other hand, have dem-
onstrated an especially strong specificity for only the 9-cis
isomers. Studies have shown that RXR/RAR heterodimers
are responsible for transducing the retinoid signal in vivo
[8]. These heterodimers bind to retinoic acid response ele-
ments found in the promoter region of retinoic acid-
inducible target genes thereby activating transcription
[8,9]. Without ligand RAR-RXR, heterodimers bind to co-
repressors, which play an active role in repressing the tran-
scription of targeted genes. The recruitment of histone
deacetylases (HDACs) brings about transcriptional repres-
sion by preventing the opening of chromatin, which is
linked to deacetylation of nucleosomes [10]. Several of
the co-activators and co-repressors are shared by multiple
signaling pathways, e.g. CBP (cAMP response element
binding protein) has been implicated in AP-1 (activator
protein 1) and p53 signaling. Meanwhile STAT signaling,
Sin3 and HDAC-1 seem to have a role in what Ayer, et. al.
call "Mad-Max signaling" [4].
Dawson lists a series of nuclear receptors such as thyroid
hormone receptors, vitamin D3 receptors (VDRs), peroxi-
some proliferator activated receptors (PPARs), and several
orphan receptors in which RXR is important as a "het-
erodimeric partner" [11].
The RARs and RXRs exhibit the conserved module struc-
ture of nuclear receptors and their amino acid sequence
can be divided into six regions (A-F) based on homology
among themselves and with other members of the nuclear
superfamily.
The central region C consists of 66 amino acids and has
two zinc-binding motifs very much like the core of the
DNA binding domain (DBD) which enables cognate
response elements to be recognized specifically. Both this
central C region and the functionally complex E region are
highly conserved between RARs and RXRs. Region E gains
its complexity from the ligand binding domain (LBD), the
ligand-dependent transcriptional activation function AF-
2, and a dimerization surface contained within it. The
name AF-1 has been given to a second transcriptional acti-
vation function found in both the amino-terminal A/B
regions.
In humans, the genes encoding RAR α, β and γ are respec-
tively located on chromosomes 17q21.1, 3p24 and
12q13. Those for RXR α, β and γ lie on chromosomes
9q34.3, 6p21.3, and 1q22. The physiological importance
of the multiple isoforms of RARs is not known precisely,
but these isoforms may explain why RARs have pleio-
tropic biological effects.
There are two major isoforms for RARα (α1 and α2) and
for RAR γ (γ1 and γ2), and four major isoforms for RARβ
(β1–β4) and the recently described RARβ1' [12], whose
absence seems to be responsible for retinoid resistance in
lung carcinognesis. RAR isoforms can be classified as
those which are transcribed from either the P1 (class I:
RAR α1, β1, and β3, γ1) or P2 (class II: RARα2, β2 and β4,
γ2) promoter. All class II isoform P2 promoters contain an
RA response element and are RA-inducible to varying
degrees [13].
Similarly, several isoforms differing from one another in
their amino-terminal region have been identified for
RXRα (α1, α2), RXRβ (β1 and β2), and RXRγ (γ1, γ2) [14].
Epigenetic and genetic changes
Respiratory epithelium carcinogenesis is a multifactorial
process which includes inherited and acquired genetic
changes, chromosomal rearrangements, epigenetic phe-
nomena and chemical carcinogenesis.
Vitamin A deficiency has been associated with bronchial
metaplasia and increased lung cancer development. Many
other factors contribute to dysfunction of retinoids and
their cognate receptors [2].
The first cytogenetic reports connecting chromosome 3 to
lung cancers were those of Whang-Peng et al. [15,16], who
reported that 100% of small cell lung cancer (SCLC) cases
examined showed specific 3p deletions by Giemsa band-
ing. These changes were observed in 12/12 cell lines and
three fresh tumors after a two-day culture period. The
minimal region of common deletion was 3p14-p25. A
number of studies have since been undertaken that
obtained similar results that were extended to non small
cell lung cancer (NSCLC).
Houle et al. mapped the RARβ2 at 3p24 and demon-
strated that expression was decreased or even suppressed
in lung cancer cell lines, suggesting that its re-expressionPage 2 of 7
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2008, 27:18 http://www.jeccr.com/content/27/1/18could suppress malignity [17]. Frequent loss of RARβ
mRNA expression has been described in both primary
NSCLCs and bronchial biopsy specimens from heavy
smokers [18,19]. Furthermore, in addition to lung cancer
[18,20], decreased RARβ2 mRNA expression has been
demonstrated in a variety of solid tumors including head
and neck [21]and breast carcinomas [22]. Xu et al. [18]
also reported that all RARs and RXRs were expressed in at
least 89% of control normal bronchial tissue specimens
from patients without a primary lung cancer and that in
distant normal bronchus specimens from patients with
NSCLC RARα, RXRα and γ were expressed in more than
95% of the tumor-free specimens. In contrast, RARβ, RARγ
and RXRβ expression was decreased, detected in only 76%
of NSCLC specimens. Picard et. al similarly showed
diminished or absent RARβ protein expression in ~50% of
resected NSCLCs [23]. Furthermore, these authors
observed normal or elevated RARα and RXRα expression
in NSCLCs. The expression of RARβ, RARγ, and RXRβ was
found to be decreased, however, in many tumors, while
LOH at 3p24 occurred at a high frequency. This phenom-
enon was also seen in non-neoplastic lesions. The authors
concluded that altered retinoid receptor expression might
be involved in lung carcinogenesis. Martinet et al.
extended the above study investigating RARs and RXRs
alteration in lung cancer precursor lesions. They per-
formed allelotyping for microsatellites located near the
RAR/RXR gene loci and immunohistochemistry was addi-
tionally carried out to evaluate P53 and RARβ expression.
Microsatellite changes occurred frequently in all samples,
but without specificity for any group. RARβ marker losses
were found in all examined groups, with a concomitant
RARβ protein expression [24].
Aberrant methylation of the promoter regions of genes is
a major mechanism of gene silencing in tumors [25]. Vir-
many et al. [26] identified hypermethylation as the under-
lying mechanism for this frequent loss of RARβ
expression. Twenty-one of 49 (43%) primary resected
NSCLC samples showed RARβ hypermethylation. In addi-
tion, it was demonstrated that RARβ hypermethylation
was also important in the pathogenesis of SCLCs, with
62% of SCLCs methylated for RARβ. In the same study, it
was also demonstrated that treatment of lung cancer cell
lines with the demethylation agent 5-aza-2'-deoxycytidine
(5-AZA-CdR) can restore RARβ expression. Moreover, a
phase I-II trial in patients with stage IV NSCLC suggests
that 5-AZA-CdR may have some clinical activity against
metastatic NSCLC [27]. The loss of RARβ mRNA expres-
sion has been observed in many lung cancer cell lines also
suggesting that to function as a tumor suppressor gene,
RARβ expression is contingent on the intracellular con-
centration of retinoids [28]. The effects of retinol (vitamin
A) depend on its intracellular metabolism including its
transport by specialized proteins such as Cellular Retinol
Binding Proteins (CRBP) and on its binding as retinoic
acid to specific nuclear receptors: the Retinoic Acid Recep-
tors (RARs) and the Retinoid X Receptors (RXRs) [7]. The
CRBP I and II transport retinol in the cell and serve as
chaperon proteins to prevent unscheduled retinol catabo-
lism. It is the first building block in retinoic acid synthesis.
Retinoid signaling
The mechanisms through which retinoids suppress car-
cinogenesis, although complex, are gradually being eluci-
dated. Their complexity results from the large number of
genes involved in tumor cell differentiation and prolifera-
tion that include retinoic acid response elements in their
promoters. Retinoids also inhibit tumorigenesis and
tumor growth through their ability to induce either apop-
tosis (programmed cell death) or terminal differentiation.
Interestingly, it has been established that the apoptotic
process triggered by Retinoid Related Molecules is inde-
pendent of p53 activation and proceeds through a novel
pathway in which the mitochondrion seems to play a piv-
otal role [29].
As Karamouzis et al. stated in a recent publication [2], a
'switch on/off' model determines the relationship
between retinoid receptors and other signaling pathways
during bronchial carcinogenesis. According to this model,
RXR selective compounds specifically inhibit AP-1 (activa-
tor protein 1) activity resulting in inhibited cell prolifera-
tion in normal respiratory epithelium, RARβ and RXRα
AP-1-dependent interaction with other nuclear receptors,
such as PPARγ with contribution cofactors (CBP/
p300cAMP response element binding protein), ensures
cyclin D1 mediated cell cycle inhibition, hence favoring
apoptosis or differentiation. Down-regulation of the
RARβ mechanism (as detailed above) combined with CBP
and AP-1 up-regulation triggers tumor progression and
proliferation. Concurrently the inability of RXRα to form
heterodimers with PPARγ enables an AP1/CBP-dependent
up-regulation of Cox2, resulting in the inhibition of apop-
tosis. This crucial role of RXRs may explain the observa-
tion of Brabender et. al as well. They observed suppressed
mRNA expression of all subtypes of RXRs in curatively
resected NSCLC that is followed by statistically worse
overall survival [30].
In addition, retinoids play a central role in tumor stroma
production and thus in the control of tumor progression
and invasion through their ability to regulate the expres-
sion of matrix metalloproteinases, transforming growth
factor-β, and cell cycle regulator proteins, such as cyclin
dependent kinase I, such as p16, or p21 [31,32].
Up to now, the use of retinoids in clinical trials has been
limited because of their pharmacologic effects and side
effects. Furthermore a majority of human or experimentalPage 3 of 7
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mechanism of retinoic acid resistance has not been totally
elucidated. The absence of the newly recognized RARβ1'
(alternatively spliced from RARβ1 isoform) could be one
reason for retinoid resistance in lung carcinogenesis [12].
In that study RARβ1' expression was repressed in RA-
resistant BEAS-2B-R1 cells in lung cancer, compared with
adjacent normal lung tissues. In H358 lung cancer cells
that were transiently transfected with RARβ1', RA treat-
ment was able to restore target gene expression. In order
to better understand the mechanism of RARβ1' repression
more studies are needed, and the authors note that
"potential reexpression in lung cancer may be important
to future approaches to lung cancer chemoprevention"
[33].
Chemoprevention
Chemoprevention has been defined as: the application of
natural or synthetic molecules to prevent, inhibit or
reverse the carcinogenic machinery [34].
For the respiratory tract there are two major classes of
agents which appear to prevent damage induced by
inhaled carcinogens: retinoids and antioxidants. (In addi-
tion to those mentioned above, new classes of chemopre-
ventive agents are under investigation, such as EGFR
inhibitors, farnesyl transferase inhibitors, Cyclooxygen-
ase-2 inhibitors etc., but presently we are focused on retin-
oids and synthetic Retinoid Related Molecules (RRMs).
Clinical trials have shown how complex the chemopre-
vention approach is. Nevertheless, large primary preven-
tion trials in volunteers (physicians and nurses in the
Physicians Health Study) and in high-risk populations
(smokers, ex smokers and asbestos workers in the CARET
and ATBC studies, and in the more recent EUROSCAN
trial) using either beta-carotene, or the combination of
beta-carotene and retinyl palmitate and the combination
of beta-carotene and alpha-tocopherol have documented
a higher incidence of lung cancer among smoking partici-
pants who received beta-carotene [35,36]. Interestingly a
negative effect of beta-carotene supplementation has also
been observed in experimental animals exposed to ciga-
rette smoke [37]. In the EUROSCAN study, where retinyl
palmitate and/or N-acetylcisteine supplementation were
used, no beneficial effects on the incidence of second pri-
mary cancer and survival were observed. There was one
exception for retinal given to workers exposed to asbesto-
sis, which seemed almost protective against mesotheli-
oma development [38]. One possible explanation for the
failure and harm seen in the chemoprevention trials could
be the procarcinogenic effect of the toxic oxidative caro-
tene metabolites. The oxidative metabolites induce cyto-
chrome P450 enzymes, lowering the serum levels of
retinoid acid and down regulating RXR and RARβ. Nico-
tine by itself inhibits RARβ expression via methylation.
Further randomized, controlled chemoprevention trials
designed to test retinoids, β-carotenes or α-tocopherol
defined their target population based on smoking history,
preneoplastic changes of the bronchial epithelium, or
cancer history [39] (Table 1).
In a recent study Lam S. et al. observed that retinol was not
effective in the up-regulation of RARβ in lesions with
bronchial dysplasia among individuals who continued to
smoke [40].
In addition Khurie FR. et al. reported worse prognosis in
stage I. lung cancer, which indicated maintenance of
RARβ expression and overexpression of RARβ correlated
with increased expression of cyclooxygenase-2, an enzyme
that contributes to progressive carcinogenesis and is a
marker of poor prognosis [41,42].
The gene promoter hypermethylation is a leading cause of
gene silencing. The loss of RARβ expression due to hyper-
methylation is of interest as are bronchial premalignant
Table 1: Lung cancer chemoprevention trials on retinoic acid analogs
Study Drug Number of patients End point Result Reference
ATBC β-Carotene 29,133 Lung cancer Negative/harmful [57]
α-Tocoferol
CARET β-Carotene 18,314 Lung cancer Negative/harmful [58]
Retinol
EUROSCAN Retinyl-palmitate 2,592 Second primary tumor Negative [38]
N-Acetycystein
Physician's Health Study β-Carotene 22,071 Lung cancer Negative [59]
Pastorino et al. Retinyl-palmitate 307 Second primary tumor Positive [35]
Lam et al. ADT 112 Bronchial dysplasia Positive [40]
Kurie et al. Fenretinide 82 Metaplasia Negative [60]
Lippman et al. 13cRA 1,304 Second primary tumor Negative [61]
ATBC, α-Tocoferol, β-Carotene Cancer Prevention Study; CARET, Carotene and Retinol Efficacy Test; ADT, anethole dithioethione (5-[p-
methoxyphenyl]-1,2-dithiole-3-thione; 13cRA, 13 cis retinoic acidPage 4 of 7
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show that hypermethylation of RARβ2 genes has a differ-
ent effect on the development of second primary lung can-
cers (SPLCs) in NSCLCs depending on smoking status. In
current smokers, SPLCs developed more frequently when
RARβ was unmethylated than when it was hypermethyl-
ated. In the case of former smokers it was the opposite.
SPLCs were more prevalent in patients with hypermethyl-
ated RARβ. Thus, in active smokers, silencing RARβ
expression by hypermethylation has a protective effect
against the development of SPLCs, whereas in former
smokers RARβ expression (unmethylated) appears to be
protective. The authors suggested that in current smokers,
the continuous high oxygen tension and free radicals
induce apoptosis and offer protection from the SPLCs.
This apoptosis may be inhibited by retinoic acid if RARβ
is expressed on a normal level [43]. These findings explain
in part the previous observation that RARβ expression is
associated with poor prognosis among patients who are
active smokers [44].
Now available are stronger synthetic retinoids that select
for an RAR and RXR type without exposing patients to the
kind of retinoid toxicity that had previously been
observed [45,46]. Aerosolized early on site, these retin-
oids have been able to reverse the RR deficiency in stabi-
lizing RAR/RXR expression for increased ligand binding to
restore normal cellular differentiation [47]. The authors,
collaborating with a French research group, conceived and
designed an appropriate RR assay in order to measure effi-
ciently the normal bronchial mucosa level of each Retin-
oid Receptor's mRNA by real time quantitative relative RT-
PCR. This method could be useful for screening the RR's
status in the damaged bronchial epithelia of the high-risk
patient and for monitoring the efficacy of the different
Retinoids used as chemopreventive agents [48].
Summary
There is a large body of literature on clinical and preclini-
cal studies using natural retinoids and related compounds
for the prevention and the treatment of cancer [49]. The
field of lung cancer chemoprevention has been controver-
sial until now. However, there has also been disappoint-
ment in extending the therapeutic use of bexarotene
(selective RXR agonist) to patients with NSCLC. Although
preclinical data and a phase II clinical trial suggested that
bexarotene added to platinum based chemotherapy may
improve overall survival [50], a subsequent Phase III clin-
ical trial did not bear this out [51,52]. One possible rea-
son is that solid tumors can acquire and develop intrinsic
resistance to retinoids during carcinogenesis. The effects
of receptor selective retinoids on NSCLC cell lines were
examined by Sun et al. According to their findings 8 of the
37 retinoids showed growth-inhibitory activity (IC50, <10
μM) against at least two of the eight NSCLC cell lines [53].
CD437, a retinoid with some selectivity toward RARγ, was
highly effective [54]. The RXR selective compounds did
show growth inhibitory effects when combined with the
RAR retinoids. These results indicated that human lung
cancer cell lines have a high degree of resistance to syn-
thetic retinoids [55]. Freemantle et al. have summarized
the potential mechanisms of Retinoic Acid resistance.
Increased P450 catabolism, drug export (P glycoprotein
mediated), sequestration of retinoids by CRABs or other
proteins, decreased expression of RARs through promoter
methylation, persistent histone deacethylation, RAR rear-
rangement or mutation in the RAR ligand binding
domain, and coactivator alteration or alterations down-
stream of target gene expression may lead to cellular retin-
oid resistance. This knowledge should aid in predicting
those most likely to benefit from retinoid therapy and in
developing strategies to optimize single agent or combi-
nation retinoid regimens to overcome resistance [56]. The
generation of retinoids and rexinoids with restricted selec-
tivity has opened new possibilities for cancer therapy and
chemoprevention. It is probable that demethylating and
chromatin remodeling agents currently under clinical
investigation could be combined with these new retinoids
for a better restoration of RR expression.
Authors' contributions
KB and BD conceived of the study and co-wrote the man-
uscript. FR, GK and JT provided helpful comments and
helped write the paper. All authors read and approved the
final manuscript.
Acknowledgements
Grant support: Krisztina Bogos was a recepient of the NATO Fellowship 
(Le Comité Scientifique de l'OTAN, Organisation du Traité de l'Atlantique 
Nord) in 2003. Balazs Dome is a recipient of the Bolyai Janos Scholarship 
of the Hungarian Academy of Sciences. Jozsef Tovari is a recipient of the 
Eotvos Hungarian State Fellowship. Further support: GVOP-2004-3.2.1., 
KFIIF 2005, OTKA-F68916, OTKA-NK-73082 (B.D.); Hungarian Ministry 
of Education, NKFP1a-0024-05 (B.D.); OTKA-D048519, OTKA-F046501, 
OTKA-K76293 (J.To.);. Oveges Jozsef Program"of the Hungarian Agency 
for Research Fund Management and Research Exploitation (B.D.).
References
1. Smith W, Khuri FR: The care of the lung cancer patient in the
21st century: a new age.  Semin Oncol 2004, 31:11-15.
2. Karamouzis MV, Papavassiliou AG: Retinoid receptor cross-talk-
ing respiratory epithelium cancer chemoprevention.  Trends
Molecular Medecine 2005, 1:10-16.
3. Sporn MB, Dunlop NM, Newton DL, Smith JM: Prevention of
chemical carcinogenesis by vitamin A and its synthetic ana-
logs (retinoids).   Fed Proc 1976, 35(6):1332-1338.
4. Lotan R: Retinoids and apoptosis: implications for cancer che-
moprevention and therapy.  J Natl Cancer Inst 1995,
87:1655-1657.
5. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM:
Retinoids in chemoprevention and differentiation therapy.
Carcinogenesis 2000, 7:1271-1279.
6. Evans RM: The steroid and thyroid hormone receptor super-
family.  Science 1988, 240:889-895.
7. Chambon P: A decade of molecular biology of Retinoic Acid.
Faseb J 1996, 10:940-954.Page 5 of 7
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2008, 27:18 http://www.jeccr.com/content/27/1/188. Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger
M, Lovey A, Kastner P, Grippo JF, Chambon P, AA Levin: Retinoic
acid receptors and retinoid X receptors: interactions with
endogenous retinoic acids.  Proc Natl Acad Sci USA 1993, 90:30-34.
9. Sun SY, Lotan R: Retinoids and their receptors in cancer devel-
opment and chemoprevention.  Critical Reviews in Oncology/Hema-
tology 2002, 41:41-55.
10. Vigushin DM, Coombes RC: Targeted histone deacetylase inhi-
bition for cancer therapy.  Curr Cancer Drug Targets 2004,
2:205-218.
11. Dawson MI: Synthetic retinoids and their nuclear receptors.
Curr Med Chem Anticancer Agents 2004, 3:199-230.
12. Petty WJ, Li N, Biddle A: A novel retinoic acid receptor beta iso-
form and retinoid resistance in lung carcinogenesis.  J Natl
Cancer Inst 2005, 97(22):1645-1651.
13. Evans TR, Kaye SB: Retinoids: present role and future poten-
tial.  Br J Cancer 1999, 80:1-8.
14. Leid M, Kastner P, Chambon P: Multiplicity generates diversity in
the retinoic acid signalling pathways.  Trends Biochem Sci 1992,
10:427-433.
15. Whang-Peng J, Bunn PA Jr, Kao-Shan C, Lee C, Carney DN, Gazdar
A, Minna JD: A nonrandom chromosomal abnormality, del
3p(14-23), in human small cell lung cancer (SCLC).  Cancer
Genet Cytogenet 1982, 2:119-134.
16. Whang-Peng J, Kao-Shan CS, Lee EC, Bunn PA, Carney DN, Gazdar
AF, Minna JD: Specific chromosome defect associated with
human small-cell lung cancer; deletion 3p(14-23).  Science
1982, 215:181-182.
17. Houle B, Leduc F, Bradley WE: Implication of RARB in epider-
moid (Squamous) lung cancer.  Genes Chromosomes Cancer 1991,
5:358-366.
18. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong
WK, Lotan R: Suppression of retinoic acid receptor beta in
non-small-cell lung cancer in vivo:implications for lung can-
cer development.  J Natl Cancer Inst 1997, 89:624-629.
19. Ayoub J, Jean-François R, Cormier Y, Meyer D, Ying Y, Major P,
Desjardins C, Bradley WE: Placebo-controlled trial of 13-cis-
retinoic acid activity on retinoic acidreceptor-beta expres-
sion in a population at high risk: implications for chemopre-
vention of lung cancer.  J Clin Oncol 1999, 17(11):3546-3552.
20. Gebert JF, Moghal N, Frangioni JV, Sugarbaker DJ, Neel BG: High
frequency of retinoic acid receptor beta abnormalities in
human lung cancer.  Oncogene 1991, 6:1859-6.
21. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R: Differential
expression of nuclear retinoid receptors in normal, prema-
lignant, and malignant head and neck tissues.  Cancer Res 1994,
54:3580-7.
22. Widschwendter M, Berger J, Daxenbichler G, Müller-Holzner E, Wid-
schwendter A, Mayr A, Marth C, Zeimet AG: Loss of retinoic acid
receptor beta expression in breast cancer and morphologi-
cally normal adjacent tissue but not in the normal breast tis-
sue distant from the cancer.  Cancer Res 1997, 57:4158-61.
23. Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J,
Martinet Y, Martinet N, Vignaud JM: Expression of retinoid recep-
tor genes and proteins in non-small-cell lung cancer.  J Natl
Cancer Inst 1999, 91:1059-66.
24. Martinet N, Alla F, Farré G, Labib T, Drouot H, Vidili R, Picard E,
Gaube MP, Le Faou D, Siat J, Borelly J, Vermylen P, Bazarbachi T, Vig-
naud JM, Martinet Y: Retinoic acid receptor and retinoid X
receptor alterations in lung cancerprecursor lesions.  Cancer
Res 2000, 60:2869-2875.
25. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Her-
man JG: Aberrant patterns of DNA methylation, chromatin
formation and gene expression in cancer.  Hum Mol Genet 2001,
10:687-92.
26. Virmani AK, Rathi A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bry-
ant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar
AF: Promoter methylation and silencing of the retinoic acid
receptor-beta gene in lung carcinomas.  J Natl Cancer Inst 2000,
92:1303-1307.
27. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K,
Ayoub J: Pilot phase I-II study on 5-aza-2'-deoxycytidine
(Decitabine) in patients with metastatic lung cancer.  Antican-
cer Drugs 1997, 8:358-68.
28. Toma S, Emionite L, Fabia G, Spadini N, Vergani L: Chemopreven-
tion of tumors: the role of RAR-beta.  Int J Biol Markers 2003,
18:78-81.
29. Garattini E, Gianni M, Terao M: Retinoid related molecules an
emerging class of apoptotic agents with promising therapeu-
tic potential in oncology: pharmacological activity and mech-
anisms of action.  Curr Pharm Des 2004, 10:433-448.
30. Brabender J, Danenberg KD, Metzger R, Schneider PM, Lord RV,
Groshen S, Tsao-Wei DD, Park J, Salonga D, Hölscher AH, Danen-
berg PV: The role of retinoid X receptor messenger RNA
expression in curatively resected non-small cell lung cancer.
Clin Cancer Res 2002, 8:438-443.
31. Ayer DE, Lawrence QA, Eisenman RN: Mad-Max transcriptional
repression is mediated by ternary complex formation with
mammalian homologs of yeast repressor Sin3.  Cell 1995,
80:767-776.
32. Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE: Histone
deacetylase activity is required for full transcriptional
repression by mSin3A.  Cell 1997, 89:341-347.
33. Sabichi AL, Xu X, Lippman SM: RARbeta1': primed to fight retin-
oid resistance in lung carcinogenesis.  J Natl Cancer Inst 2005,
97:1632-1633.
34. Krishnan K, Campbell S, Abdel-Rahman F, Whaley S, Stone WL: Can-
cer chemoprevention drug targets.  Curr Drug Targets 2003,
4:45-54.
35. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, Ros-
mentz N, Clerici M, Soresi E, Valente M: Adjuvant treatment of
stage I lung cancer with high-dose vitamin A.  J Clin Oncol 1993,
7:1216-1222.
36. Pastorini U: Beta-carotene and the higher risk of lung cancer.
J Natl Cancer Inst 1997, 89:456-457.
37. Wang XD, Liu C, Bronson RT, Smith DE, Krinsky NI, Russell M:
Retinoid signaling and activator protein-1 expression in fer-
rets given beta-carotene supplements and exposed to
tobacco smoke.  J Natl Cancer Inst 1999, 91:60-66.
38. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren :
EUROSCAN, a randomized trial of vitamin A and N-acetyl-
cysteine in patients with head and neck cancer or lung can-
cer.  J Natl Cancer Inst 2000, 92:977-986.
39. Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn
PA: Chemoprevention of lung cancer-from biology to clinical
reality.  Ann Oncol 2004, 2:185-196.
40. Lam S, Xu X, Parker-Klein H, Le Riche JC, Macaulay C, Guillaud M,
Coldman A, Gazdar AF, Lotan R: Surrogate end-point biomarker
analysis in a retinol chemoprevention trial in current and
former smokers with bronchial dysplasia.  Int J Oncol 2003,
23(6):1607-1613.
41. Khuri FR, Lotan R, Kemp BL, Lippman SM, Wu H, Feng L, Lee JJ,
Cooksley CS, Parr B, Chang E, Walsh GL, Lee JS, Hong WK, Xu XC:
Retinoic acid receptor-beta as a prognostic indicator in stage
I non-small-cell lung cancer.  J Clin Oncol 2000, 15:2798-2804.
42. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong
WK, Xu XC: Cyclooxygenase-2 overexpression is a marker of
poor prognosis in stage I non-small cell lung cancer.  Clin Can-
cer Res 2001, 4:861-867.
43. Kim JS, Lee H, Kim H, Shim YM, Han J, Park J, Kim DH: Promoter
methylation of retinoic acid receptor beta 2 and the devel-
opment of second primary lung cancers in non-small-cell
lung cancer.  J Clin Oncol 2004, 22:3443-3450.
44. Khuri FR, Lotan R: Retinoids in lung cancer: friend, foe, or fel-
low traveler?  J Clin Oncol 2004, 22:3435-3437.
45. Zusi FC, Lorenzi MV, Vivat-Hannah V: Selective retinoids and rex-
inoids in cancer therapy and chemoprevention.  Drug Discov
Today 2002, 7:1165-1174.
46. Dahl AR, Grossi IM, Houchens DP, Scovell LJ, Placke ME, Imondi AR,
Stoner GD, De Luca LM, Wang D, Mulshine JL: Inhaled isotretinoin
(13-cis retinoic acid) is an effective lung cancer chemopre-
ventive agent in A/J mice at low doses: a pilot study in A/J
mice at low doses: a pilot study.  Clin Cancer Res 2000,
6(8):3015-3024.
47. Spinella MJ, Dmitrovsky E: Aerosolized delivery and lung cancer
prevention: pre-clinical models showpromise.  Clin Cancer Res
2000, 8:2963-2964.
48. Bogos K, Bonnard L, Noel N, Claudot F, Grosdidier G, Siat J, Vignaud
JM, Martinet Y, Martinet M: Retinoid receptors mRNA levels inPage 6 of 7
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2008, 27:18 http://www.jeccr.com/content/27/1/18Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
normal bronchial mucosa and in lung cancer cell lines.  Lung
Cancer 2004, 45(Suppl 3):. abstract
49. Ortiz MA, Bayon Y, Lopez-Hernandez FJ, Piedrafita FJ: Retinoids in
combination therapies for the treatment of cancer: mecha-
nisms and perspectives.  Drug Resist Updat 2002, 5:162-175.
50. Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor
M, Bisaccia S: Phase II trial of the novel retinoid, bexarotene,
and gemcitabine plus carboplatin in advanced non-small-cell
lung cancer.  J Clin Oncol 2005, 23:5774-5778.
51. Tyagi P: Bexarotene in combination with chemotherapy fails
to prolong survival in patients with advanced non-small-cell
lung cancer: results from the SPIRIT I and II trials.  Clin Lung
Cancer 2005, 7(1):17-9.
52. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H:
RAR and RXR modulation in cancer and metabolic disease.
Nat Rev Drug Discov 2007, 10:793-810.
53. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman
RA, Teng M, Chandraratna RA, Shudo K, Hong WK, Lotan R: Differ-
ential effects of synthetic nuclear retinoid receptor-selective
retinoids on the growth of human non-small cell lung carci-
noma cells.  Cancer Res 1997, 57:4931-4939.
54. Sun SY, Yue P, Chen X, Hong WK, Lotan R: The synthetic retinoid
CD437 selectively induces apoptosis in human lung cancer
cells while sparing normal human lung epithelial cells.  Cancer
Res 2002, 62:2430-2436.
55. Crowe DL: Receptor selective synthetic retinoids as potential
cancer chemotherapy agents.  Curr Cancer Drug Targets 2002,
2:77-86.
56. Freemantle SJ, Spinella MJ, Dmitrovsky E: Retinoids in cancer ther-
apy and chemoprevention: promise meets resistance.  Onco-
gene 2003, 22:7305-7315.
57. Alpha-tocopherol, Beta-Carotene Cancer Prevention Study Group:
The effect of vitamin E and beta carotene on the incidence
of lung cancer and other cancers in male smokers.  N Engl J
Med 1994, 330:1029-35.
58. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR,
Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S,
Hammar S: Effects of a combination of beta-carotene and vita-
min A on lung cancer and cardiovascular disease.  N Engl J Med
1996, 334:1150-5.
59. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook
NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto
R: Lack of effect of long term supplementation with beta-car-
otene on the incidence of malignant neoplasms and cardio-
vascular disease.  N Engl J Med 1996, 334:1145-9.
60. Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Brox-
son A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan
R, Hong WK: N-(4-Hydroxyphenyl)retinamide in the chemo-
prevention of squamous metaplasia and dysplasia of the
bronchial epithelium.  Clin Cancer Res 2000, 6:2973-9.
61. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE,
Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Oka-
wara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R,
Roth JA, Hong WK: Randomized phase III intergroup trial of
isotertinoin to prevent second primary tumors in stage I
non-small-cell lung cancer.  J Natl Cancer Inst (Bethesda) 2001,
93:605-18.Page 7 of 7
(page number not for citation purposes)
392 Current Cancer Drug Targets, 2008, 8, 392-403  
 
 1568-0096/08 $55.00+.00 © 2008 Bentham Science Publishers Ltd. 
Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer 
Ethan Amir
1
, Sarah Hughes
1
, Fiona Blackhall
1
, Nick Thatcher
1
, Gyula Ostoros
3
, Jozsef Timar
4
, 
Jozsef Tovari
2,4
, Gabor Kovacs
3
 and Balazs Dome*
,2,3 
1
Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom; Departments of 
2
Tumor 
Biology and 
3
Thoracic Oncology, National Koranyi Institute of Pulmonology, Budapest, Hungary; 
4
Department of Tu-
mor Progression, National Institute of Oncology, Budapest, Hungary 
Absract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Although 
modest survival benefit has been observed with surgery, radiotherapy and platinum-based chemotherapy, an efficacy pla-
teau has been reached. It has become obvious, therefore, that additional treatments are needed in order to provide an im-
proved survival benefit for these patients. The use of molecular targeted therapies, particularly those against tumor capil-
laries, has the potential to improve outcomes for NSCLC patients. Bevacizumab, a recombinant humanized monoclonal 
antibody against vascular endothelial growth factor (VEGF), is the first targeted drug that has shown survival advantage 
when combined with chemotherapy in NSCLC. Other antivascular agents, including vascular disrupting agents (VDAs) 
and different small-molecule receptor tyrosine kinase inhibitors, have also shown promise in phase I and II trials in 
NSCLC. The aim of this study is to describe the clinical properties of these drugs and to discuss the evidence that supports 
their use in the treatment of NSCLC. Furthermore, we plan to review the main pitfalls of antivascular strategies in NSCLC 
cancer therapy as well as assess the future direction of these treatment methods with an emphasis on clarifying the mo-
lecular background of the effects of these drugs and defining the biomarkers. 
INTRODUCTION 
Lung cancer remains a major worldwide health problem 
accounting for 12.4% of cancer diagnoses and 17.6% of can-
cer deaths worldwide [1]. For treatment purposes, lung can-
cer is currently classified into two major groups: small-cell 
and non-small-cell cancer (NSCLC). The latter includes 
squamous-cell carcinoma, adenocarcinoma, and large-cell 
carcinoma. Bronchioloalveolar carcinoma is generally sub-
classified under adenocarcinoma. Overall, approximately 
85% of lung cancer patients have non-small-cell histology 
[2], and unfortunately, of these, a large proportion present 
with locally advanced or metastatic disease for which there is 
no curative treatment.  
The current standard palliative treatment for patients with 
NSCLC and a good performance status is double-agent cyto-
toxic chemotherapy consisting of a platinum combined with 
a third generation agent such as gemcitabine, vinorelbine or 
a taxane [3]. This treatment has been shown to provide pal-
liation of symptoms, improved quality of life and an increase 
in life expectancy from a median survival of approximately 
4-5 months to 8–10 months; and a corresponding increase in 
the 1-year survival rate from 10% to 30-40% [4]. Despite 
multiple studies to evaluate different schedules, doses and 
combinations of cytotoxic agents, it appears that a therapeu-
tic plateau has now been reached with cytotoxic therapy [5]. 
Consequently, attention over recent years has focused on 
targeted and novel therapies with notable success in the de-
velopment of antivascular drugs [6, 7]. These agents have 
shown particular promise in preclinical NSCLC models and 
in clinical studies and are the focus of this review. 
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VASCULARIZATION OF NON-SMALL CELL LUNG 
CANCER 
In order to develop and metastasize, growing tumors re-
quire an adequate blood supply. Similar to other solid tu-
mors, NSCLCs achieve this by secreting a range of angio-
genic factors that coordinate the complex series of events of 
new capillary growth. Among these angiogenic molecules, 
vascular endothelial growth factor (VEGF) has been identi-
fied as the key cytokine for endothelial sprouting (defined as 
the in situ proliferation and budding of endothelial cells) in 
NSCLC [8-10]. Although the hypoxia inducible factor (HIF) 
- von Hippel–Lindau (VHL) protein system has a major role 
in the regulation of VEGF expression, a variety of oncogenes 
can also enhance VEGF production, including activated epi-
dermal growth factor receptor (EGFR), mutant Ras and 
erbB-2/Her2. All are known to have influence on NSCLC 
progression. In addition to VEGF, however, many other 
molecules have been implicated as positive regulators of 
NSCLC induced endothelial sprouting, including platelet-
derived growth factor (PDGF) [11], basic fibroblast growth 
factor (bFGF) [12], matrix metalloproteinases (MMPs) [13], 
EGF [14], placental growth factor (PlGF) [15], interleukin-8 
(IL-8) [16], hepatocyte growth factor (HGF) [17] and angio-
poietins [18]. Interactions between these molecules initiate 
signaling cascades that regulate further processes such as 
expression of additional growth factors, alterations in cell-
cell and cell-matrix interactions, and activation of the mem-
bers of endothelial cell (EC) adhesion molecule families. 
These families of cell surface adhesion receptors include 
integrins, cadherins, cell membrane proteoglycans, selectins 
and the members of the immunoglobulin superfamily. Per-
haps the key adhesion molecules during EC sprouting are the 
members of the integrin family. A variety of integrins have 
been found to be expressed in migrating ECs, including 1ß1, 
 2ß1, 3ß1, 5ß1, vß5, and vß3. The most important among 
them is, perhaps, vß3, which mediates the migration of ECs 
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in the fibrin-containing tumor stroma and maintains the sol 
state of the basement membrane because of its ability to bind 
to MMP-2 [19]. During the later steps of new capillary 
growth, PDGF-BB recruits pericytes and smooth muscle 
cells, whereas TGF-ß1 (transforming growth factor beta-1) 
and angiopoietin-1/Tie-2 stabilize the interaction between 
mural and ECs [20].  
Although the central role of EC sprouting in lung cancer 
vascularization makes it an attractive target for anticancer 
therapy, it is well established now that tumor capillaries are 
not necessarily derived from EC sprouting; instead, solid 
tumors can acquire their vasculature by intussusceptive mi-
crovascular growth, co-option of pre-existing vessels, post-
natal vasculogenesis, glomeruloid angiogenesis, or vasculo-
genic mimicry [20]. It could be argued that the most impor-
tant non-sprouting mechanism in NSCLC is vessel co-
option. During “nonangiogenic” or “alveolar type” of 
growth, NSCLC cells fill the alveoli, entrapping, but not 
destroying, the alveolar walls with the co-opted capillaries. 
In the tumor cell nests circumscribed by the alveolar walls 
no neoangiogenesis (i.e. EC proliferation or sprouting) is 
present [21]. Analysis of the vasculature of nonangiogenic 
NSCLCs has demonstrated that their vascular phenotype is 
the same as that of normal alveolar capillaries [22] and, fur-
thermore, that nonangiogenic tumors can be distinguished by 
their gene expression profiles from angiogenic ones [23].  
Another known vascularization mechanism in NSCLC is 
postnatal vasculogenesis, a process during which circulating 
bone marrow (BM)-derived endothelial progenitor cells 
(EPCs) incorporate into sites of new vessel growth and dif-
ferentiate into ECs [24]. EPCs therefore resemble embryonic 
angioblasts, which are anchorage-independent cells having 
the capacity to proliferate, migrate and differentiate into ma-
ture ECs. Although the molecular pathways involved in EPC 
release and homing are in the early stage of definition, 
VEGF and molecules that induce leukocyte or erythrocyte 
mobilization (i.e. granulocyte macrophage colony stimulat-
ing factor and erythropoietin) are thought to be the most sig-
nificant of the other molecules [24]. However, recent results 
indicate that PDGF-CC [25], PlGF [26], nitric oxide (NO) 
[27], angiopoietin-1 [28], 3-hydroxy-3-methylglutaryl coen-
zyme-A reductase inhibitors (statins) [29] and estrogens [30] 
stimulate EPC mobilization as well. In contrast, tumor ne-
crosis factor-alpha (TNF-) and C-reactive protein (CRP) 
induce apoptosis, inhibit the function and decrease the levels 
of EPCs [31, 32]. Since the first description of EPCs by 
Asahara et al. [33], these progenitors have been detected at 
increased frequency in the peripheral blood of patients with 
various malignancies including hepatocellular [34], breast 
[35] and colorectal [36] cancers, and myeloma multiplex 
[37], myelofibrosis [38], non-Hodgkin's lymphoma [39], 
acute myeloid leukaemia [40] and malignant gliomas [41]. In 
NSCLC, our group demonstrated recently that the levels of 
EPCs are significantly increased in the peripheral blood of 
patients, and that these levels correlate to tumor burden and 
to clinical behavior [42]. Accordingly, Hilbe and colleagues 
found a significant increase in incorporated CD133+ EPCs in 
tumor samples of NSCLC patients [43].  
In summary, as in other malignant tumors, vasculariza-
tion of NSCLC is an extremely complex process that re-
quires a perfectly organized interaction between a host of 
different molecular and morphological events.  
ANTIVASCULAR THERAPY FOR NSCLC 
Any categorization of antivascular strategies is difficult, 
with overlap in several features. However, the main classes 
of these therapies that have been developed are angiosup-
pressive (anti-angiogenic) and vascular-disrupting agents 
(VDAs) [44]. Because it is beyond the scope of this paper to 
review all agents that target the vasculature of NSCLC, we 
focus here on the drugs that are at a more advanced stage of 
clinical testing.  
Antiangiogenic (Angiosuppressive) Therapy 
This approach is motivated by the fact that new capillary 
growth in cancer requires the induction of EC proliferation 
by specific or nonspecific mitogens. By inhibiting the pro-
duction of endothelial mitogens, the mitogens themselves, 
their endothelial receptors, the associated signalling path-
ways, the endothelial integrins and the matrix metalloprote-
inases (MMPs), these agents specifically target endothelial 
sprouting and postnatal vasculogenesis (i.e. endothelial pro-
genitors) in cancer.  
Matrix Metalloproteinase Inhibitors (MMPIs) 
The MMPs are a family of zinc-containing proteolytic 
enzymes which have been shown to facilitate tumor angio-
genesis, invasion and the establishment of metastases in pre-
clinical studies [45]. However, the results from a large, ran-
domised, phase III study of the MMPI, BMS-275291 con-
ducted in advanced lung cancer in 774 patients demonstrated 
no benefit from addition of this MMPI to chemotherapy with 
carboplatin and paclitaxel. Moreover, the combination of the 
MMPI with chemotherapy did not cause the severe muscu-
loskeletal toxicity that has been seen with other MMPIs; it 
did however, increase the rate of hypersensitivity reactions, 
rash and febrile neutropenia, and patients in the experimental 
arm were more likely to stop therapy because of toxicity 
[46]. 
Bevacizumab 
Bevacizumab (Avastin
®
; Genentech/Roche, South San 
Francisco, California, USA), is a humanized monoclonal 
antibody that acts by binding and neutralizing the VEGF-A 
ligand. This agent has been studied in a variety of solid tu-
mors both as a single agent and in combination with cyto-
toxic chemotherapy. It is the first of the antiangiogenic class 
of drugs to be licensed for the treatment of NSCLC as well 
as metastatic cancer of the colon or rectum. 
Bevacizumab Monotherapy 
As a single agent, bevacizumab appears to be cytostatic. 
In a clinical phase I trial in patients with a variety of solid 
tumors, treatment with bevacizumab was associated with no 
responses in the 23 patients studied, although 12 of these 
patients achieved stable disease over the duration of the 
study [47]. When combined with cytotoxic chemotherapy, 
however, bevacizumab appears to have a synergistic effect. 
Studies carried out in patients with metastatic colorectal and 
lung cancers have all shown improvements in both progres-
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sion-free and overall survival with the addition of bevacizu-
mab to chemotherapy [48, 49].  
Bevacizumab in Combination with Cytotoxic Chemother-
apy 
In lung cancer, the first evidence showing a benefit from 
administration of bevacizumab came in a phase II random-
ized trial for patients with advanced or recurrent NSCLC 
[50]. In this trial subjects were randomized to either chemo-
therapy alone or chemotherapy with bevacizumab. Patients 
received up to six cycles of 3-weekly paclitaxel 200mg/m
2
 
and Carboplatin (area under the curve of 6) alone or in com-
bination with bevacizumab (7.5 or 15mg/m
2
). Patients who 
did not progress during chemotherapy were continued on 
bevacizumab alone for up to 18 cycles. Results showed that 
those treated with bevacizumab at a dose of 15mg/m
2
 had a 
significantly increased time to progression, (7.4 versus 4.2 
months, P = 0.023), compared with chemotherapy alone. 
Furthermore, there was a non-significant trend to improved 
overall survival (17.7 versus 14.9 months, P = 0.63). It 
should be stressed, however, that this trial lacked sufficient 
statistical power to detect between-arm differences in sur-
vival outcomes. When given at a dose of 7.5mg/m
2
, bevaci-
zumab was no different than chemotherapy alone with a time 
to progression of 4.3 months. In general, bevacizumab was 
well tolerated, although one unusual and unexpected toxic 
effect was the development of life-threatening haemoptysis, 
mainly in patients with central tumors and squamous cell 
histology. Subsequently, a multivariate analysis identified 
squamous cell histology as an independent risk factor for 
unexpected massive and life-threatening bleeding. 
Subsequent to this study, the Eastern Cooperative Oncol-
ogy Group (ECOG) E4599 trial was initiated [51]. This 
study, which is to date the only published phase III random-
ized trial of an anti-angiogenesis agent in combination with 
chemotherapy in patients with lung cancer, randomized 878 
chemotherapy-naive patients with predominantly non-
squamous cell histology and advanced NSCLC to receive 
paclitaxel (200 mg/m
2
) and carboplatin (area under the curve 
of 6) with or without bevacizumab (15 mg/kg). Treatment 
was administered every 3 weeks for six cycles. In the 
bevacizumab treatment arm, following completion of che-
motherapy, single-agent bevacizumab was continued until 
disease progression. The primary study end point was overall 
survival. Results showed that the addition of bevacizumab 
was associated with a significant improvement in the median 
overall survival (12.3 versus 10.3months, P=0.003) com-
pared to chemotherapy alone. Progression-free survival was 
also significantly improved (6.2 versus 4.5 months), corre-
sponding to a hazard ratio for progression of 0.66 (P<0.001). 
However, it is important to note that the total benefit in me-
dian survival was a modest 2 months and that an unplanned 
subgroup analysis demonstrated that the survival improve-
ment was confined to male patients.  
Treatment with bevacizumab was however, associated 
with higher rates of toxicities. There was a significantly 
higher frequency of National Cancer Institute (NCI) Com-
mon Terminology Criteria for Adverse Events (CTCAE) 
grade 4 neutropenia (25.5 versus 16.8%, respectively; 
P=0.002), thrombocytopenia (1.6 versus 0.2%, respectively; 
P=0.04), and febrile neutropenia (5.2 versus 2%, respec-
tively; P=0.02). The reasons for such hematological toxicity 
are unclear, although various mechanisms could be involved, 
such as enhanced delivery of the chemotherapeutic agents to 
the bone marrow as a result of vascular changes or direct 
interaction of bevacizumab with chemotherapy at the stem 
cell level. Non-haematological toxicities were also much 
higher including grade 3-5 hypertension (7.7 versus 0.7%, 
respectively; P<0.001), hemorrhage (4.4 versus 0.7%, re-
spectively; P<0.001) and proteinuria (3.1 versus 0%, respec-
tively; P<0.001). It was noted that the observed hypertension 
and proteinuria were generally manageable and that perma-
nent discontinuation of bevacizumab was not required. In 
total, there were 17 treatment-related deaths: 2 deaths (gas-
trointestinal hemorrhage and febrile neutropenia) occurred 
with chemotherapy alone (0.5%) and 15 deaths occurred on 
the bevacizumab arm (3.5%; P=0.001). Of the 15 bevacizu-
mab-related deaths, 5 were attributed to pulmonary hemor-
rhage, 5 to complications of neutropenic fever, two each to a 
cerebrovascular event or gastrointestinal hemorrhage, and 1 
due to a probable pulmonary embolus. 
As a result of the this study the United States (US) Food 
and Drug Administration (FDA) approved the use of bevaci-
zumab in combination with carboplatin and paclitaxel for the 
initial systemic treatment of patients with unresectable, lo-
cally advanced, recurrent or metastatic, non-squamous, 
NSCLC and this treatment has become the standard of care 
for these patients in the US.  
More recently, preliminary results from the phase III 
Avastin in Lung ("AVAiL", BO17704) trial were presented 
in abstract form at the 2007 American Society of Clinical 
Oncology meeting
1
. In this European trial, 1,044 patients 
with previously untreated, advanced, non-squamous, NSCLC 
were randomized to receive cisplatin (80 mg/m
2
 on Day 1) 
and gemcitabine (1,250 mg/m
2
 on Day 1 and Day 8) chemo-
therapy every three weeks for up to six cycles together with 
either bevacizumab 15 mg/kg, bevacizumab 7.5 mg/kg or 
placebo every three weeks until disease progression. Results 
showed a median progression free survival of 6.5 months in 
the 15 mg/kg bevacizumab plus chemotherapy arm, 6.7 
months in the 7.5 mg/kg bevacizumab plus chemotherapy 
arm and 6.1 months in the chemotherapy alone arm. This 
equated to 22 and 33 percent improvements in progression 
free survival respectively in the 15 mg/kg and 7.5 mg/kg 
bevacizumab treatment arms. Toxicities were similar to pre-
vious studies of bevacizumab in NSCLC. Although the exact 
overall survival data has not yet been published, in a recent 
press release, the developer of bevacizumab announced that 
it did not yield a statistically significant prolongation of 
overall survival, a secondary endpoint, with either dose [52].  
Bevacizumab is also currently being tested in the adju-
vant setting in the ECOG E1505 trial. This trial aims to re-
cruit 1,500 patients with completely resected stage IB-IIIA 
tumors and compare adjuvant chemotherapy using four cy-
cles of three-weekly cisplatin with vinorelbine, docetaxel or 
gemcitabine with or without bevacizumab. 
                                            
1 Manegold, C.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; 
Leighl, N.; Mezger, J.; Archer, V.; Reck, M.; the BO17704 study group. Randomised, 
double-blind multicentre phase III study of bevacizumab in combination with cisplatin 
and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-
squamous non-small cell lung cancer (NSCLC): BO17704. J. Clin. Oncol. 2007, 
ASCO Annual Meeting Proceedings Part I. Vol 25, (Suppl. 18), Abstract LBA7514. 
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A further study is currently in progress to evaluate the 
safety and efficacy of carboplatin and paclitaxel chemother-
apy with bevacizumab in subjects with locally advanced or 
metastatic squamous NSCLC. These studies will help to fur-
ther define the role for bevacizumab in NSCLC.  
Bevacizumab in Combination with EGFR Inhibiting 
Agents 
VEGFR and EGFR signaling is interrelated, as VEGF 
was demonstrated to be downregulated by anti-EGFR drugs 
through both HIF1-dependent and -independent mecha-
nisms [53, 54]. Furthermore, acquired resistance to EGFR 
inhibitors is associated with increased levels of VEGF [55]. 
Recent data also suggest that EGFR inhibition could have 
antitumor effects even in EGFR negative tumors, but when 
the cancer capillary ECs express the receptor [56]. Combin-
ing anti-EGFR and anti-VEGFR drugs might therefore pro-
vide more enhanced anti-cancer effects than either therapy 
alone. Accordingly, both pre-clinical and early phase clinical 
trials have been carried out to explore the role of simultane-
ous inhibition of the VEGF and EGFR cascades. The latest 
of these, a multicentre, randomized, phase II trial compared 
the use of bevacizumab in combination with either chemo-
therapy or erlotinib against chemotherapy alone in a cohort 
of pre-treated patients with non-squamous NSCLC [57]. Re-
sults showed that when compared with chemotherapy alone, 
the combination of bevacizumab with chemotherapy was 
associated with a 34% reduction in the risk of disease pro-
gression or death whilst there was a 28% risk reduction from 
chemotherapy and Erlotinib. Of note, however, neither of 
these risk reductions met statistical significance. A phase III 
trial comparing erlotinib alone versus erlotinib plus bevaci-
zumab is underway to clarify the benefit of the combination 
of these two agents. Due to the successful clinical develop-
ment of bevacizumab and erlotinib in NSCLC, a number of 
other agents that inhibit both VEGF and EGFR pathways are 
currently in development as outlined below. 
In summary, the recent success of bevacizumab in com-
bination with paclitaxel/carboplatin chemotherapy for first-
line treatment of advanced, nonsquamous NSCLC in the 
E4599 trial [51] has confirmed that targeting of angiogenesis 
in NSCLC might be a reasonable therapeutic approach. 
However, notwithstanding the considerable progress made 
by the above study, a number of questions and future chal-
lenges relating to the use of bevacizumab in NSCLC linger. 
The clinical use of bevacizumab is restricted to patients with 
non-squamous histology and to those without central nerv-
ous system metastases. Moreover, the absolute improvement 
in median survival from the addition of bevacizumab to pa-
clitaxel/carboplatin was modest and bevacizumab failed to 
improve the overall survival of NSCLC patients in combina-
tion with gemcitabine/cisplatin chemotherapy in the AVAil 
trial [52]. Thus, the pharmacological interactions of bevaci-
zumab with other anticancer agents are still not fully under-
stood. Furthermore, it is still uncertain what the optimal bio-
logical dose is and the most favourable schedule and dura-
tion of therapy as well as the ideal clinical setting have not 
yet been defined.  
Vandetanib 
Vandetanib (Zactima®, ZD6474; AstraZeneca, Maccles-
field, UK), is a potent small molecule inhibitor of the tyro-
sine kinase domain of the VEGF receptor-2 (VEGFR-2). It 
also has moderate anti-EGFR activity, with an inhibitory 
concentration (IC50) of 500nM, compared with 40nM for 
VEGFR-2 [58]. At this time it is unclear how much of its 
anti-tumor activity can be attributed to its action at EGFR. In 
addition, vandetanib potently inhibits ligand dependent RET 
kinase activity. Constitutive RET activity is associated with 
certain thyroid tumors [59]. Pre-clinical studies have shown 
that vandetanib inhibits tumor angiogenesis, growth and me-
tastasis in a wide range of models, across several tumor 
types, including lung, prostate, colon, breast and ovary [58]. 
Two phase I clinical trials of vandetanib in patients with 
refractory advanced solid tumors have been conducted in the 
USA, Australia and Japan. With the primary objective of 
evaluating the safety and tolerability of the agent, these stud-
ies have shown vandetanib to be well tolerated at a daily oral 
dose  300mg, with common adverse events including rash, 
diarrhoea and asymptomatic QTc prolongation. The Japanese 
study yielded tumor responses in 4 of 9 patients with 
NSCLC [60], prompting a series of randomised phase II 
studies. 
In a comparative two-part study of vandetanib and gefit-
inib, 168 patients with previously treated stage IIIB-IV 
NSCLC were randomised to receive either vandetanib 
(300mg po od) or gefitinib (250mg po od) in part A of the 
study. At disease progression or development of unaccept-
able toxicity, subjects were switched to the alternative treat-
ment (part B) after a washout period of four weeks. The re-
sponse rate was 8% in the vandetanib arm compared with 
1% in the gefitinib arm, and a longer progression-free sur-
vival (PFS) time for vandetanib followed by gefitinib (11.9 
weeks versus 8.1 weeks; HR=0.63, 95% CI: 0.44-0.90; 
P=0.011). No survival difference was seen
2
. 
The efficacy of vandetanib in combination with standard 
chemotherapy regimes, compared with chemotherapy alone, 
has been investigated in two further randomized trials. The 
first of these, a randomized, placebo-controlled study of 
vandetanib (100mg/day or 300mg/day) plus docetaxel in 127 
patients with NSCLC who have progressed after first-line 
platinum-based chemotherapy, has recently been published 
[61]. Median PFS was 18.7 weeks for vandetanib 100mg + 
docetaxel (HR versus docetaxel =0.64, 95% CI:0.38-1.05; 1-
sided P=0.037); 17 weeks for vandetanib 300mg + docetaxel 
(HR versus docetaxel = 0.83, 95% CI:0.5-1.36; 1-sided 
P=0.231); and 12 weeks for docetaxel. The combination of 
vandetanib and docetaxel was generally well tolerated and 
adverse events manageable, with the incidence of vande-
tanib-associated toxicities increased at the higher dose level 
(diarrhoea (grade3/4) – 50%; rash (grade 3) – 46%; QTc-
related events (grade 3/4) – 16%). Again, there was no statis-
tically significant difference in overall survival between the 
three treatment arms. It is not clear why the addition of the 
100 mg dose of vandetanib to docetaxel seemed to be more 
effective that the addition of the 300 mg dose in this trial. 
One possible explanation is that the anti-EGFR activity of 
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vandetanib at higher doses may cause G1 cell cycle arrest in 
tumor cells, thereby reducing the sensitivity of tumors to the 
cell cycle phase-dependent activity of chemotherapy. As 
discussed below, a further possibility is that high levels of 
vandetanib might reduce tumor blood flow and impede the 
delivery of chemotherapy.  
For first-line treatment, a trial investigating vandetanib 
alone or in combination with carboplatin-paclitaxel, versus 
chemotherapy alone has completed, with results presented 
recently
3
. The primary objective was to determine whether 
vandetanib +/- carboplatin-paclitaxel prolonged PFS com-
pared with chemotherapy alone. With a total of 181 subjects, 
the primary objective was met, with vandetanib + car-
boplatin-paclitaxel significantly prolonging PFS compared 
with carboplatin-paclitaxel alone (HR=0.76, 95%CI 0.50-
1.15; P=0.098). Given this encouraging phase II data, vande-
tanib is currently undergoing phase III development, both as 
monotherapy and in combination regimes for NSCLC. The 
potential for efficacy in squamous cell NSCLC, in addition 
to non-squamous NSCLC, is a definite advantage over 
bevacizumab.  
A number of other angiosuppressive agents are at a less 
advanced stage in clinical development compared to bevaci-
zumab and vandetanib.  
AMG 706 (AMGEN, USA) is a small organic molecule 
with potent kinase-inhibiting activity against all known 
VEGFRs, PDGF receptor (PDGFR) and Kit. Preliminary 
integrated analyses of clinical data on AMG 706 monother-
apy have shown that the most common treatment-related 
adverse events are hypertension (42%), diarrhea (41%), fa-
tigue (32%), headache (21%), nausea (21%), anorexia (13%) 
and vomiting (10%). It is currently undergoing phase III 
evaluation as first-line treatment in combination with pacli-
taxel and carboplatin for advanced NSCLC. This random-
ized, placebo-controlled study aims to recruit 1240 subjects, 
with the primary objective to determine if treatment with 
AMG706 in combination with chemotherapy improves over-
all survival compared with chemotherapy alone. 
Aflibercept (VEGF Trap; Sanofi-Aventis, France) is an 
engineered soluble receptor, made from the extracellular 
domains of VEGFR-1 and VEGFR-2. It binds all isoforms of 
VEGF, as well as placental growth factor. Hypertension and 
proteinuria were the main toxicities seen in phase I trials of 
aflibercept, administered subcutaneously and intravenously 
[62]. A phase III second-line study of aflibercept in combi-
nation with docetaxel for advanced NSCLC has recently 
commenced recruitment. 
AZD2171 (Recentin
TM
; AstraZeneca, UK) is an orally ac-
tive tyrosine kinase inhibitor (TKI) of all VEGFR subtypes. 
A phase I study of AZD2171 in combination with gemcit-
abine and cisplatin in patients with advanced NSCLC has 
recently reported the toxicities of this combination to be 
manageable and predictable (hypertension, fatigue and diar-
rhea)
4
. In addition, encouraging anti-tumor activity was ob-
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served, which did not appear dose dependent at the doses 
tested. The combination of AZD2171 with pemetrexed is 
currently undergoing phase II evaluation for relapsed 
NSCLC, and for first-line therapy, a phase III randomized 
study of carboplatin and paclitaxel with or without AZD2171 
for stage IIIB/IV NSCLC is currently in progress. 
Axitinib (AG-013736; Pfizer, USA) is a small molecule 
TKI of VEGFR 1,2 and 3, with activity also against PDGFR-
 and Kit. Single agent activity in patients with advanced 
NSCLC has been demonstrated in a phase II study, with 
three (9.4%) confirmed responses and median duration of 
response 9.4 months
5
. Treatment was well tolerated with 
manageable toxicity in this population. Most common grade 
3/4 toxicities were fatigue (22%), diarrhea (6%), hyperten-
sion (6%) and hyponatraemia (6%). 
Sorafenib (Nexavar
®
, BAY 43-9006; Bayer, Germany), 
an oral multitargeted TKI, inhibits the kinase activity of both 
C-RAF and B-RAF, VEGFR-2 and 3 and PDGFR- and Kit 
[63]. It was thought particularly active in NSCLC because 
the proliferation signaling of the Ras/Raf/MEK/ERK path-
way is increased in NSCLC due to an increase in K-ras mu-
tations [64]. However, the Phase III “ESCAPE” (Evaluation 
of Sorafenib, Carboplatin And Paclitaxel Efficacy in 
NSCLC) study was stopped early after a planned interim 
analysis demonstrated that the trial would not meet its pri-
mary endpoint of an improvement in overall survival. In this 
study, more than 900 therapy naïve NSCLC patients were 
randomized to receive either sorafenib or a placebo in com-
bination with carboplatin and paclitaxel. The interim analysis 
showed more deaths among squamous cell carcinoma pa-
tients who received Nexavar, carboplatin and paclitaxel, 
compared to those who received placebo, carboplatin and 
paclitaxel [65].  
Sunitinib (Sutent
®
, SU11248; Pfizer, USA), an oral, 
small-molecule, multi-targeted TKI that was approved by the 
FDA for the treatment of renal cell carcinoma and imatinib-
resistant gastrointestinal stromal tumor (GIST) in 2006, in-
hibits signaling through PDGFR, Kit, FLT-3 and VEGFR-2 
[66, 67].  
Phase II studies of both agents as single-agent therapy in 
relapsed/refractory NSCLC have demonstrated good toler-
ability, and level of activity similar to currently approved 
agents
6, 7, 8
. 
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Vascular Disrupting Agents (VDAs) 
Targeting of VEGF has been shown to result in apoptosis 
only in newly formed, immature tumor vessels and in the 
developing vasculature of the neonatal mouse, but not in the 
tumor vessels of adult mice or in quiescent tumor vascular 
networks [68]. Vascular targeting therapy (i.e. VDAs) rec-
ognizes the fact that clinical diagnosis of cancer commonly 
occurs when the tumor tissue has already established its vas-
culature. VDAs specifically target pre-existing tumor capil-
laries, resulting in rapid cancer tissue ischemia and secon-
dary tumor cell death in the central regions of tumors, al-
though they leave the perfusion in peripheral tumor regions 
relatively intact. An additional advantage of VDAs is that 
compared to angiosuppressive drugs, their effects do not 
depend on the type of vascularization [20] occurring in a 
given cancer. The two major categories of VDAs that are in 
clinical development are the small-molecule VDAs and 
ligand-directed VDAs [69]. While small-molecule VDAs 
achieve selective occlusion of tumor vessels by exploiting 
phenotypic differences between tumor and host tissue ECs 
(i.e. increased reliance on the tubulin cytoskeleton to main-
tain cell shape and accelerated proliferation), ligand-directed 
VDAs use toxins and pro-coagulant agents coupled to pep-
tides or antibodies that selectively bind to the endothelial 
tube. Although animal studies with ligand-directed VDAs 
have certainly been elegant, and, furthermore, several poten-
tial target molecules (such as integrin vß3 [70] or endoglin, 
an auxiliary receptor for TGF signaling which is controlled 
by the HIF-1 complex [71]) exist that are up-regulated on 
tumor versus host tissue capillaries, testing of ligand-based 
agents are still in the preclinical phase. For that reason, and 
because they are at a much more advanced stage of clinical 
development, only representatives of small molecule VDAs 
will be discussed here. 
5,6 dimethylxanthenone-4-acetic acid (DMXAA) (No-
vartis, Switzerland) is a flavonoid VDA that has been dem-
onstrated to augment the anticancer effects of radiation [72], 
paclitaxel [73] and cisplatin [74]. The combination of 
DMXAA with carboplatin and paclitaxel is currently under-
going phase II evaluation for IIIb or IV NSCLC previously 
untreated with chemotherapy. Preliminary results suggest 
that this combination could provide additional benefit com-
pared with carboplatin/paclitaxel alone
9
. 
Combrestatin A4 phosphate (CA4P) (Zybrestat, CA-4-P, 
OxiGene, USA) is a phosphate prodrug of the tubulin-
binding agent combrestatin A4. By inhibiting tubulin polym-
erization, CA4P caused selective endothelial damage in hu-
man tumor xenografts [75]. Based on the promising results 
of phase I studies, CA4P is currently being evaluated in sev-
eral phase II trials. For example, an ongoing study is evaluat-
ing the safety and effectiveness of CA4P combined with the 
chemotherapy drugs carboplatin and paclitaxel in advanced 
solid tumors, including NSCLC [76]. More interestingly, 
because the CA4P-bevacizumab combination has appeared 
safe, resulted in significantly decreased tumor blood-flows, 
and shown clinical activity without simultaneous chemother-
apy, OxiGene plans to initiate a controlled Phase II study of 
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Zybrestat plus bevacizumab and standard chemotherapy in 
NSCLC patients by the first quarter of 2008 [77].  
ABT-751 (Abbott Laboratories, Abbott Park, IL, USA) is 
a novel oral sulfonamide that binds to the colchicine binding 
site of ß-tubulin, inhibits polymerization of microtubules and 
has demonstrated significant antitumor activity in a variety 
of preclinical xenograft models [78]. Interestingly, however, 
it has not been demonstrated to provoke the typical tumor 
vascular shutdown of other VDAs. There have been three 
published phase I trials of ABT-751 in patients with hemato-
logical malignancies and in adult and pediatric solid tumors 
[79-81]. In advanced NSCLC, two phase II trials evaluating 
ABT-751 in combination with chemotherapy are currently in 
progress [82, 83]. Another phase II Study of ABT-751 in 
patients with NSCLC refractory to Taxane regimens has 
been completed, but the results have not yet been released 
[84].  
POTENTIAL BIOMARKERS OF RESPONSE TO AN-
TIVASCULAR AGENTS IN NSCLC 
Antivascular treatment represents a novel and exciting 
type of molecular-based antitumor therapies. Accordingly, 
there is a clinical need in this field to identify biomarkers 
that can help to recognize patients responsive to these thera-
pies, detect tumor resistance and predict the efficacy of anti-
vascular drugs cost-effectively.  
Some of the most promising biomarkers for antivascular 
treatments are the circulating populations of EPCs and ma-
ture, desquamated ECs (circulating endothelial cells; CECs). 
In murine tumor models, EPC/CEC levels have been demon-
strated to correlate with tumor burdens and, moreover, with 
the efficacy of anticancer/antiangiogenic therapies [24]. In 
other murine tumors systems, VDA treatments led to a rapid 
increase in the levels of circulating EPCs, which incorpo-
rated into the microvessels of viable peripheral tumor areas 
that characteristically survive after such treatment. Suppres-
sion of this EPC mobilization by antiangiogenic agents re-
sulted in marked reductions in viable tumor rim size and 
blood flow as well [85]. More importantly, techniques for 
EPC/CEC enumeration have also been tested clinically. Par-
ticularly encouraging in this regard is a phase 1 trial in which 
bevacizumab decreased the number of EPCs and CECs in 
colorectal cancer patients [86]. Although no studies have 
been undertaken to determine the levels of these cells in 
NSCLC patients treated with antivascular drugs, in a recent 
study, we assessed the number of circulating EPCs by flow 
cytometry from the peripheral blood of NSCLC patients be-
fore and after chemoradiotherapy and found significantly 
lower posttreatment levels of circulating EPCs in patients 
who achieved a partial/complete remission than in patients 
with stable or progressive disease [42]. 
Measuring the efficacy of antivascular therapy could also 
be achieved by imaging the tumor capillaries themselves (i.e. 
direct imaging by agents targeted at cytokines or receptors 
involved in tumor vascularization) or investigating the result 
of such treatments on the anatomic features and the blood 
supply of tumors (indirect imaging) [87]. Currently, almost 
all direct techniques are available solely in murine models, 
whereas indirect techniques are typically used in clinical 
settings. Accordingly, with a few exceptions [88], experience 
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with vascular imaging in human NSCLC has been gained 
primarily by indirect techniques. These include measure-
ments of contrast enhancement, blood volume and oxygen 
saturation with computed tomography (CT) [89, 90], mag-
netic resonance imaging (MRI) [91], positron emission to-
mography (PET) [92] and singlephoton emission computed 
tomography (SPECT) [93].  
No single predictive angiogenic molecule has been iden-
tified to date and the use of cytokines as biomarkers of angi-
ogenesis can be complicated by the release of angiogenic 
growth factors from platelets. Nevertheless, because of the 
relative simplicity of performing protein analyses, the clini-
cal value of peripheral blood angiogenic biomarker meas-
urements has also been investigated recently in many human 
studies. For example, plasma concentrations of total VEGF 
and PlGF were observed to be significantly elevated in 
bevacizumab-treated colon carcinoma patients [86]. In an-
other clinical study on patients with colorectal cancer, a 
dose-dependent elevation of plasma VEGF-A and bFGF was 
found following the first cycle of PTK787/ZK222584 (an 
angiogenesis inhibitor targeting all known VEGFR tyrosine 
kinases) treatment [94]. Similarly, the authors of a phase II 
trial study reported a progressive increase of total VEGF 
levels after initiation of treatment with bevacizumab in renal 
cancer [95]. In a phase II/III trial in which 878 patients with 
advanced NSCLC were randomized to receive carboplatin + 
paclitaxel or carboplatin + paclitaxel + bevacizumab, E-
Selectin and bFGF, but not VEGF, levels showed significant 
decreases from the baseline in both arms
10
. Because investi-
gators of the above trials did not separate the VEGF bound 
to bevacizumab from free VEGF, it is important to note that 
in a recent study, free VEGF levels assessed after immu-
nodepletion of plasma samples were found to be signifi-
cantly reduced following bevacizumab treatment confirming 
that this anti-VEGF antibody effectively decreases the 
plasma level of the biologically active VEGF [96].  
In summary, because antivascular treatments are devel-
oping at a rapid pace, there is an urgent need to identify reli-
able biomarkers for the efficacy of these therapies. However, 
although some pieces of the puzzle are already in place, 
monitoring techniques should be explored further to fully 
understand their possible implications in solid tumors, as 
well as in NSCLC. Accordingly, at present, the optimal 
technique for evaluating effects of antivascular treatments in 
cancer patients is a matter of active discussion among ex-
perts. 
CHALLENGES OF ANTIVASCULAR THERAPY OF 
NSCLC: LESSONS FROM PRECLINICAL DATA AND 
FROM CLINICAL TRIALS ON ANTIVASCULAR 
AGENTS 
Improved overall survival demonstrated in the ECOG 
E4599 trial has confirmed the clinical value of bevacizumab 
(i.e. anti-VEGF) treatment in human NSCLC [51]. However, 
the absolute increase in overall survival was only ~2 months 
in the above study and, more notably, bevacizumab failed to 
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show a statistically significant improvement in overall sur-
vival in the AVAil trial [52]. Thus, the exact mechanisms of 
different antivascular drugs (in combination with different 
chemotherapeutic agents) in NSCLC patients are still not 
completely understood.  
One of the key unresolved questions is how antiangio-
genic agents can be combined with chemo- and/or radiother-
apy. There has been some concern that a strategy developed 
primarily to reduce tumor blood flow could impede the de-
livery of chemotherapeutic agents and reduce the level of 
intratumoral oxygen essential for effective radiotherapy. 
However, in different preclinical models, a combination of 
cytotoxic agents with angiogenesis inhibitors resulted at least 
additive but in certain cases synergistic antitumoral effects 
[97-99]. More importantly, there are now clinical examples 
of the improved efficacy of chemotherapy in combination 
with an angiosuppressive agent. Bevacizumab in combina-
tion with chemotherapy improved progression-free survival 
in breast cancer patients [100] and, as mentioned above, 
overall survival in colorectal [49] and NSCLC patients [51].  
Among the several possible explanations for the im-
proved efficacy, one called “normalization of tumor vascula-
ture” was put forth by Jain and colleagues recently [101]. 
According to their hypothesis, blood vessel leakiness and 
tortuosity as well as increased interstitial pressure in cancer 
tissue may render cancer capillaries insufficient to provide 
adequate blood supply for tumor cells. By blockade of 
VEGF signaling, bevacizumab could potentially help in the 
“normalization” of tumor vasculature and in the improve-
ment of the delivery of chemotherapeutic agents. Accord-
ingly, recent animal studies demonstrated that anti-VEGF 
treatment induces rapid alterations in blood capillaries. 
Within a few hours, EC proliferation is halted, luminal sta-
bility vanishes, and blood flow ceases in microvessels. Some 
ECs undergo apoptosis and disappear. Remaining capillaries 
lack endothelial fenestrations and have reduced VEGFR-2 
and VEGFR-3 expression (reviewed in ref. [102]). Thus, 
inhibition of VEGF signaling devastates some tumor mi-
crovessels and transforms others into a more normal pheno-
type.  
In vitro experiments have shown that a variety of human 
cancer cell lines express both VEGF and VEGFRs and that 
inhibition of VEGF–VEGFR pathways inhibited the prolif-
eration of these cell lines. VEGF can, therefore, serve as an 
autocrine growth factor for cancer cells that express 
VEGFRs [103]. Along that line, human studies have demon-
strated that in NSCLCs expressing VEGFRs, VEGF is a part 
of autocrine loops that enhance the malignant potential of 
NSCLC cells [104, 105]. A further mechanism for the addi-
tional benefits experienced with combined chemo- and 
antiangiogenic treatments might therefore be the direct cyto-
toxic effects of VEGF blockers on (lung) cancer cells that 
aberrantly express VEGF receptors and depend to some ex-
tent on VEGF for their survival.  
Alternatively, because VEGF is a potent survival factor 
for activated ECs and, as demonstrated in experimental tu-
mor models [106, 107], because cytotoxic drugs could kill 
proliferating ECs during capillary sprouting, antiangiogenic 
and chemotherapeutic drugs might also be synergistic 
against proliferating tumor ECs.  
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Given the well-known myelosuppressive side effects of 
cytotoxic agents and because bone marrow-derived EPCs are 
mobilized into the circulation by angiogenic cytokines such 
as VEGF [24], an additional, indirect way for chemothera-
peutic and antiangiogenic treatment approaches to synergis-
tically control vascularization of NSCLCs might be the im-
pairment of the release and function of EPCs. This assump-
tion is supported by recent studies in which we and others 
have found an association between circulating EPC numbers 
and clinical behavior of NSCLCs [42, 108].  
Finally, a possible explanation for the synergistic effects 
of cytotoxic and angiosuppressive drugs on the tumor vascu-
lature could also be the observation that antiangiogenic 
agents prevent cancer cell repopulation during the break pe-
riods between courses of chemotherapy [109].  
However, recent experimental and clinical studies have 
suggested, the overall direct effect of combined 
chemo(radio)- and antivascular therapy on tumor blood sup-
ply and progression is not straightforward. For instance, al-
though it is tempting to increase the dose of angiosuppres-
sive drugs, doing so might transform the cancer capillaries to 
the point where cytotoxic drug perfusion is impaired. Exam-
ples of this can be seen in a phase II trial that tested the com-
bination of leucovorin and 5-fluorouracil with two different 
doses of bevacizumab in metastatic colorectal cancer patients 
[110] and in a phase II study of vandetanib (100 or 300 
mg/day) plus docetaxel in previously treated NSCLC [61]. In 
these two studies, the lower doses of antiangiogenic agents 
were more effective than the higher doses. 
In the context of the above discussed vessel normaliza-
tion theory, the combination strategy of multitargeted TKIs 
and chemotherapy could also be challenging in the clinical 
practice. It has been hypothesized that because PDGF recep-
tors expressed by pericytes have an important role in the 
normalization process, blocking perivascular cell recruitment 
with TKIs might impede vessel normalization and conse-
quently reduce the efficacy of simultaneous chemotherapy 
[111, 112]. This hypothesis may provide explanation for the 
clinical failure of certain multitargeted TKIs to augment the 
efficacy of chemotherapy. However, the advantages and dis-
advantages of targeting pericytes in addition to ECs with 
TKIs during chemotherapy remain to be elucidated. 
A further problem is that VEGF is not the only angio-
genic factor produced by human cancers; in contrast, during 
progression, tumors secrete concurrently many angiogenic 
factors: bFGF, TGF-ß1, PIGF, PDGF, and pleiotrophin 
[113]. Therefore, antiangiogenic therapy should be tailored 
depending on the angiogenic phenotype and expression of 
endothelial growth factors in each single tumor. In line with 
that, combinations of different antivascular agents to target 
multiple pathways simultaneously may lead to additional 
survival benefit for patients with progressive tumors with 
alternating angiogenic profiles. However, chances are the 
simultaneous inhibition of all key angiogenic pathways 
might interfere with the "vessel normalization" process (i.e. 
the activity of chemoradiotherapy), just as an overdose of an 
antiangiogenic agent with a single target results in the exces-
sive pruning of the vessel network and thus impedes the de-
livery and efficacy of cytotoxic treatment. 
Another important issue is how to cope with the problem 
of nonangiogenic NSCLC growth. Because, as discussed 
above, nonangiogenic tumors can obtain sufficient blood 
supply from pre-existing alveolar vasculature to grow with-
out angiogenesis (i.e. endothelial proliferation) [21-23], this 
subtype of NSCLCs will probably be refractory to therapy 
with antiangiogenic drugs (angiosuppressive agents). 
Moreover, it can be speculated that this resistance will arise 
irrespective of the proportion of nonangiogenic parts in the 
tumor: nonangiogenic cell clones might be selected by an-
giosuppressive drugs. Therefore, when nonangiogenic 
growth plays a role in NSCLC progression, the use of VDAs 
against ECs of the pre-existing intratumoral vasculature 
seems to be an appropriate strategy. 
SUMMARY 
There are a number of antivascular agents progressing 
through clinical trial evaluation for the treatment of ad-
vanced NSCLC. However, clinical experience in this field is 
still limited and several questions remain to be answered. 
Most important are the problems of the optimal biologic 
dose and the best possible combination treatment strategy 
with chemotherapy. A further relevant clinical problem is to 
find the best techniques for determining efficacy of antivas-
cular agents. In line with that, biomarkers including imaging 
techniques, peripheral blood counts of EPCs and plasma 
levels of different angiogenic cytokines have been tested 
preclinically and in clinical trials as markers of activity for 
these agents. Establishing the toxicity profile of novel anti-
vascular drugs over long-term periods will also be essential. 
Like bevacizumab, many agents display the on-target effect 
of hypertension in their toxicity profile, although this is usu-
ally manageable with a standard management algorithm. 
However, unlike bevacizumab, the majority of these agents 
are orally available, and therefore more convenient, less 
likely to cause significant hemorrhage, and thus far have not 
been shown to be more hazardous in those with squamous 
histology NSCLC.  
All in all, although a large body of preclinical evidence 
has confirmed angiogenesis as a key process of NSCLC pro-
gression and the results of ongoing trials of antivascular 
agents in NSCLC are eagerly awaited, it will likely be sev-
eral years before their precise role is clarified in pulmonary 
oncology. 
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ABBREVIATIONS 
BM = bone marrow 
CA4P = combrestatin A4 phosphate 
CEC = circulating endothelial cell 
CRP = C-reactive protein 
CT = computed tomography 
CTCAE = common terminology criteria for adverse 
events 
DMXAA = 5,6 dimethylxanthenone-4-acetic acid 
EC = endothelial cell 
ECOG = Eastern Cooperative Oncology Group 
EGFR = epidermal growth factor receptor 
EPC = endothelial progenitor cell 
FDA = Food and Drug Administration 
HGF = hepatocyte growth factor 
IL-8 = interleukin-8 
MMPI = matrix metalloproteinase inhibitor 
MMP = matrix metalloproteinases 
MRI = magnetic resonance imaging 
NO = nitric oxide 
NSCLC = Non-small cell lung cancer 
PDGFR = platelet derived growth factor receptor 
PET = positron emission tomography 
PFS = progression-free survival 
PlGF = placental growth factor 
SPECT = singlephoton emission computed tomogra-
phy 
TGF-ß1 = transforming growth factor beta-1 
TKI = Tyrosine kinase inhibitor 
TNF- = tumor necrosis factor-alpha 
VDA = vascular-disrupting agent 
VEGF = vascular endothelial growth factor 
VEGFR = vascular endothelial growth factor receptor 
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